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ABSTRACT 
Klara Rachel Klein: Adrenomedullin, Chemokine Receptors, and Receptor Activity Modifying 
Proteins in Lymphangiogenesis 
(Under the direction of Kathleen Caron) 
Over the past decade, we have begun to appreciate that the lymphatic vascular 
system does more than simply return plasma back into the circulatory system and, in fact, 
contributes to a wide variety of normal and disease states. For this reason, much research 
has been devoted to understanding how lymphatic vessels form and function, with a 
particular interest in which molecules contribute to lymphatic vessel growth and 
maintenance. Here, we have focused on a potent lymphangiogenic factor, adrenomedullin, 
and its known roles in lymphangiogenesis, lymphatic function, and lymphatic disease.  
In the course of our studies, we have discovered that the decoy receptor CXCR7 is 
required as a molecular rheostat for controlling the concentration of AM ligand during 
cardiac and lymphatic vascular development. Loss of mammalian CXCR7 results in 
postnatal lethality due to aberrant cardiac development and myocyte hyperplasia. In Part I, 
we provide the molecular underpinning for this proliferative phenotype by demonstrating that 
the dosage and signaling of adrenomedullin is tightly controlled by CXCR7. To this end, 
Cxcr7-/- mice exhibit gain-of-function cardiac and lymphatic vascular phenotypes which can 
be reversed upon genetic depletion of adrenomedullin ligand. In addition to identifying a 
biological ligand accountable for the phenotypes of Cxcr7-/- mice, these results reveal a 
previously underappreciated role for decoy receptors as molecular rheostats in controlling 
the timing and extent of GPCR-mediated cardiovascular development.  
 iv
In Part II, we investigated whether CXCR7 and related chemokine receptors (CKRs), 
CXCR4 and CCR5, form protein-protein interactions with one component of the AM 
signaling system, Receptor Activity Modifying Proteins (RAMPs). BRET studies, confocal 
microscopy, and fluorogen-activating protein assays indicate CKRs associate with RAMP2 
and RAMP3 in vitro, suggesting that a broader group of GPCRs interact with RAMPs than 
previously thought. Future studies will allow us to characterize the breadth of RAMP 
interactions, facilitating a shift in the focus of RAMP research to the design of functional 
assays that help determine whether a given GPCR-RAMP association affects biological 
activity. A thorough understanding of RAMP effects on biology has the potential to have 
significant clinical impact, as targeting of the RAMP-GPCR interface could yield specific, 
high affinity drugs.  
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Chapter 1: Adrenomedullin in Lymphangiogenesis - From Development to Disease1,2 
 
Overview 
Over the past decade, we have begun to appreciate that the lymphatic vascular 
system does more than simply return plasma back into the circulatory system and, in fact, 
contributes to a wide variety of normal and disease states. For this reason, much research 
has been devoted to understanding how lymphatic vessels form and function, with a 
particular interest in which molecules contribute to lymphatic vessel growth and 
maintenance. In the following review, we focus on a potent lymphangiogenic factor, 
adrenomedullin, and its known roles in lymphangiogenesis, lymphatic function, and human 
lymphatic disease.  As one of the first, pharmacologically-tractable G protein-coupled 
receptor pathways characterized in lymphatic endothelial cells, the continued study of 
adrenomedullin effects on the lymphatic system may open new avenues for the modulation 
of lymphatic growth and function in a variety of lymphatic-related diseases that currently 
have few treatments. 
 
 
 
 
                                               
1 Authors: Klein, K.R. and Caron, K.M.  
2 Reprinted with permission from: Klein K, Caron K (2015) Adrenomedullin in lymphangiogenesis: 
from development to disease. Cellular and Molecular Life Sciences: 1-12. 
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Introduction 
The lymphatic system is a vascular network in parallel with blood vessels that 
penetrates every tissue in the body, with the exception of bone marrow and the central 
nervous system [1]. Over the past dozen years, our understanding of how the lymphatic 
system develops, functions, and contributes to disease has markedly improved [2]. It has 
become apparent that this complex system is more than just a simple conduit for returning 
interstitial fluid to blood. The lymphatic system not only participates in maintaining fluid 
homeostasis, but also mediates fat absorption and provides a highway for immune cell 
trafficking to distant sites. In fact, the lymphatic system has now been recognized for its 
contribution to a wide variety of normal and pathophysiological states [3,4].  
Lymphedema, the most common and poorly treated lymphatic disease, affects 140-
250 million people worldwide. Characterized by debilitating swelling of one or more limbs, 
lymphedema is a lifelong condition that can lead to inflammation, fibrosis, infection, 
subcutaneous fat accumulation, and decreased mobility and function [1,5]. Despite its 
prevalence and morbidity, no pharmacological agents exist for the management of 
lymphedema.  
A multitude of studies in genetic mouse models have also implicated lymphatics in 
other common diseases. For example, disruption of neolymphangiogenesis in the skin 
induces salt-sensitive hypertension in mice [6]. This model demonstrates that dermal 
lymphangiogenesis is required to maintain electrolyte balance and subsequently blood 
pressure homeostasis [6]. Further, haploinsufficiency of the essential transcription factor 
Prox1 leads to adult onset obesity due to abnormal fluid leakage from disrupted lymphatic 
vessels [7]. Examples like these suggest that novel therapeutics designed to modulate the 
lymphatic vasculature could offer treatment for prevalent diseases like lymphedema, 
essential hypertension, and obesity.  
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To this end, a great deal of effort has recently been devoted to identifying factors that 
participate in lymphangiogenesis and control lymphatic vascular function in adults. The 
following review will focus on one such factor, adrenomedullin (AM = peptide, Adm = gene), 
and will address what is currently known about its role in the lymphatic vascular system, and 
its potential as a novel therapeutic for the treatment of diseases linked to lymphatic 
dysfunction.  
The Adrenomedullin Peptide Family and Its Receptors 
AM, a 52-amino acid peptide hormone, is classified as a member of the calcitonin 
gene related peptide (CGRP) family due to its shared secondary structure and overlapping 
biological activity with other peptide family members [8,9]. The four peptides of this family 
besides AM include amylin, calcitonin, intermedin, and CGRP. Each of these peptides has 
essential roles in normal physiology [10]. Similarities in their secondary structure allow for 
overlap in the pharmacology of the binding sites of the CGRP family and, consequently, 
cross-reactivity between their receptors [8,11]. Therefore, discerning which biological 
activities are distinct to AM proved to be challenging until the discovery of a class of single-
pass transmembrane proteins called receptor activity modifying proteins (RAMPs) [12]. 
These proteins bind to and confer ligand specificity for G protein-coupled receptors (GPCRs) 
and allow cells to distinguish between members of the CGRP family. 
When bound to a GPCR, RAMPs dictate ligand specificity, downstream signaling, 
and receptor recycling [9,12,13]. The three identified RAMPs, RAMP1, -2, and -3 share 30% 
sequence identity, with their nonhomologous domains modulating specificity [8]. For 
example, when calcitonin receptor-like receptor (CLR) associates with RAMP2 or RAMP3, 
the receptor binds AM with high affinity. When complexed with RAMP1, on the other hand, 
CLR performs as a high affinity CGRP receptor. Thus, specific tissue and temporal 
expression of the RAMPs determines whether a cell will respond to AM or CGRP [13]. As 
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will be discussed below, recognition of the role of RAMPs in the responsiveness of AM 
allowed for the design of gene-targeted mouse knockout models that helped determine the 
physiological role of AM. The participation of RAMP2 with CLR was found to be absolutely 
necessary for AM response during development, as genetic deletion of Ramp2 phenocopied 
Adm knockout models [14]. This unusual signaling offers a unique opportunity for specific 
targeting without interrupting the activity of other, closely related ligand-receptor pathways.  
Prior to the discovery of RAMPs, there were two additional putative AM receptors 
reported in the literature [15]. In 1995, Kapas and Clark suggested that two orphan GPCRs, 
RDC-1 and L1, served as AM receptors [16,17]. An inability to reproduce these findings led 
to significant controversy regarding their ability to bind AM. While L1, now known as 
GPR182, remains an orphan receptor, RDC-1 has been identified as an atypical chemokine 
receptor, a promiscuous receptor that binds several ligands including SDF-1/CXCL12 [18], 
CXCL11 [19], and intermediate opioid peptide [20]. RDC-1 has since been renamed CXCR7 
or atypical chemokine receptor 3 (ACKR3). The role of CXCR7 in AM signaling continues to 
evolve. Mounting evidence in the literature over the past decade suggests that RDC-
1/CXCR7/ACKR3 does indeed associate with adrenomedullin [15,21-24]. Although the 
discovery of RAMP-guided CLR responsiveness to AM overshadowed the role of these 
other receptors in AM biology, as will be discussed later in this review, recent studies 
demonstrate that AM-mediated downstream signal is indeed modulated through CXCR7 
[25,26]. The identification of a second AM receptor is especially exciting, as it offers another 
avenue for drug discovery for the treatment of AM-mediated pathologies. 
AM has been shown to be involved in a wide variety of human diseases, including 
sepsis, myocardial infarction, and preeclampsia [13,27,28]. In particular, as a potent 
vasodilator, the AM signaling system has garnered interest as a potential biomarker and 
therapeutic target for cardiovascular diseases [29,30]. Preliminary studies suggest that, 
when used as an adjunct therapy, intravenous AM can improve cardiovascular outcomes 
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such as wall motion and infarct size [31]. Modulation of the AM signaling system, therefore, 
could prove to be a viable and safe treatment option not only for cardiovascular diseases, 
but also for other diseases in which AM plays a role. In particular, genetic models have 
uncovered an additional role for AM in the development and regulation of the lymphatic 
vascular system.  
Adrenomedullin During Lymphatic Vascular Development 
Initial lymphatic vessel formation begins between e9.5-10.5 with the commitment of 
endothelial cells of the cardinal vein (CV) to a lymphatic fate (Figure 1-1A) [1]. After 
polarization of lymphatic progenitor cells in the jugular vein at e11.5-12.5, lymphatic 
endothelial cells (LECs) begin to migrate away and form a premature lymphatic vessel. 
Historically, this vessel has been referred to as the lymph sac. Recently however, 
ultramicroscopy of whole mount mouse embryos has revealed that the lymph sac is 
comprised of two separate lymphatic structures, a peripheral longitudinal lymphatic vessel 
and a primordial thoracic duct [32]. These structures are formed by migrating LECs that 
originate from both the CV and additional venous sources [32]. Failure of these ECs to 
establish LEC fate, migrate, or proliferate results in severe edema and embryonic lethality. 
For example, genetic deletion of Prox1 prevents EC differentiation to lymphatic fate. Prox1-
null animals are devoid of lymphatic vasculature and die by e14.5 [33-35]. Similarly, though 
ECs of VEGF-C-null mice can establish LEC fate, LECs fail to migrate away from the CV, 
lymphangiogenesis is arrested and embryonic edema ensues, demonstrating that VEGF-C 
is an essential lymphangiogenic factor [36-38]. The severity and timing of the edema and 
subsequent embryonic lethality in these mouse models provided an essential clue for 
determining the role of AM in lymphangiogenesis.  
 In the early 2000s, an elegant series of gene-targeted knockout mouse models 
identified AM as an essential factor for proper lymphatic vascular development [13,14,39]. 
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Several labs observed that mice globally lacking Adm exhibited profound edema, known as 
hydrops fetalis [40-42]. Similarly, knockouts of Calcrl, the gene for CLR, [39], or Ramp2 
[14,43,44], which make up the canonical receptor for AM, have the same lethal phenotype. 
Furthermore, peptidylglycine alpha-amidating monooxygenase (PAM) knockout mice [45], 
an enzyme required for the amidation and function of AM, are also embryonic lethal due to 
extreme edema [27]. These models clearly demonstrate that AM is essential for life; 
however, the root cause of this edema was not understood.  
 Consistent with what was known about AM at the time and with the nascent 
lymphatic vascular field, early studies of these mouse models focused on AM in cardiac and 
blood vascular development rather than lymphangiogenesis. Indeed, AM was found to have 
a significant proliferative effect during cardiac development. Adm-/-, Calcrl-/-, and Ramp2-/- 
mice share a phenotype of small, hypoplastic hearts [14,39,40]. All three genes were also 
found to be highly expressed in the heart and the vascular endothelium, confounding 
whether the observed edema could be attributed to cardiac defects or vascular dysfunction. 
To solve this problem, Fritz-Six et al. utilized mice expressing an endothelial cell-specific Cre 
recombinase via expression of a Tie2-Cre transgene [46]. Though Tie2-Cre expression has 
only been observed in restricted regions of adult lymphatic vessels, Tie2-Cre is expressed in 
the venous progenitors of lymphatic endothelial cells.  Thus, prior to the development of 
lymphatic-specific Cre drivers, Tie2-Cre mice were widely used to excise genes from venous 
lymphatic progenitors during embryonic lymphangiogenesis [47-51].  
 Using this Tie2-Cre model, Fritz-Six et al. found that specific deletion of Calcrl in the 
venous lymphatic progenitors results in extreme hydrops fetalis, suggesting that AM-
mediated effects in endothelium, not the heart, were responsible for the edema [14]. 
Because Tie2-Cre is expressed in progenitors that lead to both blood and lymphatic 
endothelial lineages [27], this model could not definitively distinguish whether blood or 
lymphatic vessel dysfunction led to the hydrops fetalis. However, as mentioned above, the 
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onset of edema in the AM signaling-disrupted mice between e12.5-e14.5 coincides with the 
separation of the lymphatic sac from the jugular vein and the beginning of lymphatic flow, 
suggesting that the edema could be lymphatic in origin. 
  Fritz-Six et al. surveyed the AM system effects on developmental lymphangiogenesis 
by deleting Adm, Calcrl, and Ramp2 [14]. Each gene-targeted knockout model exhibited the 
same edematous phenotype, while no problems with blood vascular leakage were observed 
[14]. Quantitative PCR of both lymphatic and blood endothelial cells further revealed that 
CALCRL and RAMP2 were enriched in the lymphatic endothelium compared to the blood 
endothelium, a finding that has since been confirmed by other groups [14,52]. Additionally, 
transfection of cultured LECs with a PROX1 expression plasmid led to a three-fold increase 
in endogenous CALCRL expression, demonstrating that the genes required for AM signaling 
are inducible by this master lymphatic fate regulator [14]. Later studies have also shown that 
AM-treatment of LECs causes an upregulation of PROX1 [53], demonstrating that not only 
are the genes required for AM signaling upregulated in LECs leading to preferential AM 
action, but that AM activity in LECs feeds back positively on PROX1 expression. Consistent 
with this notion, Fritz-Six et al. found that prior to embryonic lethality, the lymphatic sacs of 
AM-signaling null mice were significantly smaller when compared to those of wild-type 
littermates [14]. Careful study of proliferation in LECs revealed that loss of AM signaling 
results in hypoplasia of the lymphatic sacs. These hypoplastic lymphatic sacs failed to 
collect extravasated fluid and resulted in aberrant accumulation of interstitial fluid in mutant 
embryos. This finding was consistently observed in Adm-/-, Calcrl-/-, and Ramp2-/- embryos. 
  Furthermore, the lymphatic vessels of AM signaling-null mice are hyperpermeable, 
thus perpetuating and contributing to edema formation. Previous work has shown that 
vascular endothelial growth factor A (VEGF-A) treatment of cultured blood endothelial cells 
(BECs) and LECs increases permeability to trypan blue-labeled albumin [54,55]. However, 
co-treatment with AM and VEGF-A dose-dependently prevents VEGF-A-induced 
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permeability [54]. This reduction of permeability is caused by a reorganization of the cell-cell 
junctions. VEGF-A treatment of LECs disrupts the junctional proteins Zonulus Occludin-1 
(ZO-1) and vascular endothelial cadherin (VE-cadherin), thereby creating characteristic gaps 
and a zipper-like staining pattern [54]. AM treatment stabilizes ZO-1 and VE-cadherin 
(Figure 1-1B) and abrogates VEGF-A-induced disruption, decreasing lymphatic permeability 
[54]. Fluorescent microlymphography of adult mice confirms this finding. AM-treated mice 
have significantly decreased uptake of FITC-dextran when compared to control mice, 
demonstrating that AM stabilizes the lymphatic endothelial barrier in vivo [54]. Therefore, it 
follows that mice lacking Adm, Calcrl, or Ramp2 may also have increased lymphatic 
permeability that exacerbates the edema. Taken together, the evidence strongly suggests 
that in the absence of AM signaling, edema is caused by aberrant lymph sac formation, 
failed lymphangiogenesis, and abnormally permeable lymphatic vessels.  
  Ichikawa-Shindo and colleagues observed similar edematous phenotypes in Ramp2 
knockout mice [43]. However, while Fritz-Six et al. concluded the edema was predominantly 
lymphatic in origin, Ichikawa-Shindo et al. reported that Ramp2 deficient mice also exhibit 
significant vascular endothelial cell dysfunction and increased blood vascular permeability 
due to decreased expression of VE-Cadherin, claudin 5, and type-IV collagen [43,56]. 
Disruption of these proteins, which make up tight and adherens junctions and the basement 
membrane of endothelial cells, results in increased pericellular leakage and edema [43]. 
While these studies did not examine lymphatic vascular development or function, the effects 
of loss of RAMP2 on the blood endothelium are consistent with the known role of AM to 
modulate the development and regulate the function of the blood vasculature [41,57,58].  
Thus, leaky blood vessels coupled with arrested lymphangiogenesis and poor lymphatic 
uptake of interstitial fluid likely account for the severity of the edematous phenotype.  
  Moreover, the lymphatic and blood endothelium are interdependent. Lymphatic 
vessels develop directly from the venous vasculature and then parallel the blood vascular 
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system throughout the body. These two vascular systems may only physically connect on 
either side of the body near the jugulo-subclavian junction where lymph is returned to the 
blood, however these systems are developmentally, genetically, and molecularly connected 
in many complex ways [56]. The lymphatic vasculature has effects on the blood vasculature 
throughout development and beyond, and vice versa. Therefore, although aberrant 
lymphangiogenesis is the primary cause of AM-associated edema, the effects of AM on the 
blood vasculature should not be disregarded.  
  Likewise, it has become clear that spatial and temporal expression of receptors and 
their ligands in a microenvironment can affect development of surrounding tissue [59,60]. 
Because of the close proximity of and complex connections between the lymphatic and 
blood vasculatures, it is possible that expression of Adm, Calcrl, and Ramp2 by both BECs 
and LECs has effects not only in their own microenvironments, but also in the adjacent 
vascular tissue. Recent studies from our lab have substantiated this hypothesis, definitively 
identifying CXCR7 as a potent modulator of AM signaling and AM-mediated 
lymphangiogenesis [25]. 
  As discussed in the previous section of this review, whether CXCR7, a known non-
signaling decoy receptor, acts as an AM receptor has remained unclear for over a decade. 
The promiscuity of the decoy receptor has also made it challenging to discern which ligand 
is responsible for a given phenotype. This difficulty was particularly apparent in Cxcr7-null 
mice, which exhibited cardiac enlargement and hyperplasia, a phenotype that was not 
observed in mutant mice of the canonical ligands, SDF-1 and CXCL11 [21,61,62]. However, 
the cardiac phenotypes closely phenocopied a genetic model of AM overexpression (known 
as Admhi/hi mice) which results in gross cardiac hyperplasia during embryogenesis [25,63]. 
The similarity in cardiac phenotypes and the historical association of AM and CXCR7 
sparked curiosity about whether CXCR7 could behave as a decoy receptor for AM. In this 
way, loss of the AM decoy receptor would result in a surplus of AM, excessive AM-mediated 
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signal, and a phenocopy of the Admhi/hi mice. Our lab hypothesized that if CXCR7 does 
behave as an AM decoy receptor, loss of CXCR7 would also lead to lymphatic vascular 
defects. Because loss of AM signaling results in small, hypoplastic hearts and lymph sacs 
[14,39,40], and AM overexpression results in enlarged, hyperplastic hearts, we predicted 
that loss of Cxcr7 would result in enlarged, hyperplastic lymphatic vessels.  
  Indeed, as discussed extensively in Chapter 2, consistent with the notion that 
CXCR7 sequesters AM, Cxcr7-/- mice exhibited enlarged, blood filled lymph sacs. Careful 
examination of the number of proliferating LECs in the lymph sac demonstrated that the 
enlarged lymph sacs were hyperplastic (Figure 1-2A). These data suggest that, in the 
absence of the decoy receptor, an excess of AM leads to hyperproliferation of LECs and 
subsequently enlarged, poorly formed lymph sacs [25].  Further examination of LECs in vitro 
and lymphatic beds in vivo confirmed the ability of CXCR7 to affect the lymphatic 
endothelium. When treated with AM, cultured CXCR7 knockdown LECs proliferated more 
than wildtype LECs [25]. Moreover, dermal and cardiac lymphatic beds were disrupted in 
Cxcr7-null mice and displayed dysmorphic vasculature consistent with hyperplasia [25].  
  To definitively show that these phenotypes were caused by excessive AM signaling, 
we genetically titrated AM ligand onto Cxcr7-/- mice. Both genetic increase and reduction of 
AM peptide on the Cxcr7 null background resulted in striking effects on the lymphatic 
phenotypes. Genetic reduction of Adm in Cxcr7-/- mice restored the lymphatic and cardiac 
hyperplasia to wildtype levels, indicating that the hyperplasia observed in Cxcr7-/- mice 
resulted from excessive AM signaling [25]. Moreover, intercross of Cxcr7 mutant mice with 
Admhi/hi mice resulted in an exacerbation of the lymphatic enlargement and increased 
embryonic lethality to the point that it was difficult to maintain a Cxcr7+/-; Admhi/+ mouse 
colony due to embryonic and early post-natal loss [25]. Taken together, these data 
demonstrate that the dosage of AM is critical for maintaining proper cardiovascular 
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development and that, without tight control of AM-mediated signaling, proliferation of both 
myocardial and lymphatic endothelial cells is disrupted (Figure 1-2A). 
  Interestingly, while the lymphatic endothelium dynamically expresses Cxcr7, we 
observed that the blood endothelium directly adjacent to the lymphatic endothelium 
persistently expressed Cxcr7. Cxcr7 was infrequently observed in the dermal lymphatics 
where Cxcr7-/- mice exhibited phenotypes consistent with dermal lymphatic hyperplasia but 
was regularly observed in the dermal blood vessels [25]. Consistent with previously 
published papers, therefore, we concluded that the presence of the scavenging receptor in 
the adjacent blood endothelium impacts development of the surrounding tissue [25]. These 
findings again highlight the importance that expression of the ligand and its receptors in 
proximity (but not necessarily directly within) the lymphatic endothelium has the ability to 
impact lymphangiogenesis. Taken together, these data demonstrate that Cxcr7 modulates 
AM signal and identifies a new paradigm of 7-transmembrane decoy receptors as regulators 
of lymphatic vascular development. 
Adrenomedullin Signaling During Adulthood 
 Mid-gestational embryonic lethality due to global knockout of the AM signaling 
system has made elucidation of the signaling effects of AM on the lymphatic system in 
adulthood difficult. The recent design of an inducible knockout model, however, has 
confirmed an important role for AM in lymphatic maintenance and function following normal 
lymphangiogenesis. Global reduction of Calcrl in Calcrlfl/fl animals using a ubiquitously 
expressed, tamoxifen-inducible Cre transgenic line (CAGGCre-ERTM) resulted in acute and 
chronic lymphatic dysfunction, leading to ocular inflammation, disrupted fat absorption, and 
delayed wound healing due to persistent edema [64]. Seven to 10 days following tamoxifen 
induction of Cre, two thirds of Calcrlfl/flCAGGCre-ERTM mice developed overt ocular 
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opaqueness [64]. After ruling out glaucoma, Hoopes et. al reported that Calcrl-deficient mice 
exhibit corneal edema, inflammation, and dilated corneoscleral lymphatic vessels.  
 While healthy cornea is largely avascular, lymphangiogenesis occurs in response to 
inflammation and can ultimately lead to blindness [65]. Though no corneal 
lymphangiogenesis was reported in Calcrlfl/flCAGGCre-ERTM mice, these mice were only 
evaluated after one week, which may not allow enough time for neolymphangiogenesis. 
Given more time, the inflammation in Calcrlfl/flCAGGCre-ERTM may lead to corneal 
lymphangiogenesis. It is also possible that the absence of the AM receptor would prevent 
new lymphatic vessels from forming. Regardless, these findings highlight the importance of 
proper lymphatic function in maintenance of fluid homeostasis in and around the eye. 
Indeed, recent studies have demonstrated that the endothelial cells lining Schlemm’s canal 
express several lymphatic marker genes, are responsive to VEGFC and thereby control the 
aqueous humor with the anterior chamber of the eye. [66-68].  Thus, modulation of these 
vessels may allow for either increased hydration or drainage of the eye, allowing for a novel 
treatment of dry eyes, ocular edema, and glaucoma.  
 In addition to the ophthalmic pathology, Calcrlfl/flCAGGCre-ERTM mice also failed to 
match weight gain of their wild-type littermates. Examination of the mesenteric vessels of 
experimental mice showed dilated lymphatic vessels filled with chyle when fed a high-fat 
meal. These data suggest that AM signaling is critical for absorption of fat from mesenteric 
lymphatic vessels. Close examination of the mesenteric lymphatic vessels following high-fat 
diet revealed disrupted lymphatic junctions, a finding that was consistent with previously 
published work demonstrating that AM stabilizes the lymphatic endothelial barrier and 
increases vascular permeability [54]. Indeed, further examination of the lymphatic 
endothelium revealed disrupted lymphatic permeability. Intradermal injection of Evans blue 
dye into the ear revealed rapid lymphatic uptake in both experimental and control mice. At 
five minutes, however, mice lacking Calcrl showed increased leakage and diffuse spreading 
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of the dye [64]. Importantly, no difference in blood vascular permeability was observed, 
reinforcing that AM loss affects primarily the lymphatic vasculature [64].  
 To induce edema, complete Freund’s adjuvant (CFA) was injected into the paw of 
the hindlimb. In contrast to tamoxifen-injected controls, Calcrlfl/flCAGGCre-ERTM mice had 
prolonged edema [64], suggesting that AM is required for proper reabsorption of interstitial 
fluid and resolution of edema. As discussed above, previous studies demonstrate that AM 
treatment stabilizes the lymphatic endothelial barrier (Figure 1-1B) [54]. Therefore, similar to 
the mesenteric lymphatics, it follows that loss of Calcrl destabilizes the lymphatic 
endothelium in the peripheral lymphatics, increases vascular permeability, allows for 
lymphatic fluid leakage back into the interstitium, and prevents proper edema resolution.  
 These findings (summarized in Figure 1-3) are particularly intriguing because they 
demonstrate that appropriate AM dosage following development is required for proper 
lymphatic maintenance and function. Loss of AM signaling results in leaky vessels, failure to 
resolve edema, and alterations in fat absorption. All of these data suggest that AM may be a 
reasonable target for the treatment of a variety of diseases for which we currently have 
limited therapies. Pharmaceuticals that modulate fat absorption could be a useful tool to 
help prevent or reduce the extent of obesity. Additionally, use of AM agonists could 
decrease lymphatic vessel leakiness and increase uptake of interstitial fluid, allowing for the 
partial or complete resolution of lymphatic associated edema. 
Adrenomedullin and Lymphedema 
 As mentioned above, lymphedema is the most common lymphatic disease, affecting 
hundreds of millions of people worldwide. Lymphedema is categorized as primary or 
secondary. Primary lymphedema often results from congenital abnormalities. Mutations in 
nineteen genes have been associated with primary lymphedema, which have been 
extensively reviewed recently by Brouillard and colleagues [69]. Many of these mutations 
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disrupt genes critical for downstream signaling in LECs, including mutations in the genes 
encoding VEGFR3, VEGFC, and CCBE1 [69]. Additionally, disruption in several 
transcription factors required for LEC differentiation and specification (for example, GATA2, 
FOXC2, and SOX18) result in syndromic forms of primary lymphedema [1,69]. Although no 
mutations in the AM signaling cascade have yet been identified in human primary 
lymphedema, as whole exome sequencing studies continue, it is possible that AM will be 
found to associate with primary lymphedema. Secondary lymphedema, on the other hand, 
stems from disruption of the normal lymphatic vasculature by infection or iatrogenic 
intervention [5]. Despite its prevalence and significant effect on quality of life, currently no 
cure exists for lymphedema. Additionally, it is not well understood why some individuals are 
predisposed to developing lymphedema. 
  Recently, AM was implicated as a molecule that might contribute to the onset of 
secondary lymphedema. Adm haploinsufficiency predisposed mice to developing secondary 
lymphedema following hind limb injury compared to wildtype mice [52]. Further, systemic 
injection of AM to Adm+/- mice restored proper wound healing, thereby preventing the onset 
of lymphedema [52]. Here, these data demonstrate the importance of AM dosage in the 
resolution of edema.  
 Though lymphedema has yet to be associated with mutations in the AM signaling 
system in humans, these studies suggest that AM administration has potential as a novel 
therapeutic for the treatment of secondary lymphedema. The primary cause of secondary 
lymphedema in western countries is radical axillary lymph node dissection, with 20-30% of 
patients developing severe lymphedema following surgery [70-72].  The most promising 
treatment is the generation of new lymphatic vessels [70]. Jin and colleagues demonstrate 
that AM administration increases lymphatic flow, promotes angiogenesis and 
lymphangiogenesis, and ultimately decreases tail lymphedema in vivo [73]. The cause of 
this accelerated healing is likely due to a combination of new blood and lymph vessel 
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formation, as both angiogenesis and lymphangiogenesis are required for wound healing [73-
75]. However, the preferential effect of AM on lymphatic endothelial cells indicates that the 
primary cause for increased healing is neolymphangiogenesis. Therefore, AM administration 
following surgical resection of lymph nodes may not only promote wound healing, but also 
prevent the onset of lymphedema. While there are no current studies using AM infusion to 
treat lymphedema in humans, the potential of AM to act as a novel therapy for lymphedema 
is promising. 
Adrenomedullin in Cancer 
 Originally isolated from pheochromocytoma, a rare neuroendocrine tumor, elevated 
AM has been associated with neoplasms [76,77].  Many cancer subtypes overexpress Adm 
[15], and plasma AM levels often correlate with metastasis, invasion, and poor survival 
[78,79]. How AM modulates cancer progression is not well understood. Many experts have 
speculated that AM contributes to tumor survival and progression by increasing blood flow to 
a hypoxic tumor environment [15,76,80]. However, the importance of lymphangiogenesis 
and lymphatic vessel remodeling to cancer biology [81,82] has also delineated a role for 
AM-mediated lymphangiogenesis in promoting distant metastasis. 
 Using a Lewis lung carcinoma (LLC) cell line, Karpinich et al. generated a series of 
tumor cells that stably over- or under-expressed Adm and demonstrated a regulatory role for 
AM in tumor lymphangiogenesis [83]. The LLC model was particularly attractive because 
LLCs do not express the canonical AM receptor, Calcrl and Ramp2. Consequently, 
alterations in Adm expression did not affect tumor cell proliferation [83]. Therefore, following 
injection into mice, AM-mediated increases in tumor size would not confound differences in 
tumor metastasis. 
 Interestingly, alterations in tumor Adm expression robustly impacted tumor lymphatic 
vessels. While Adm overexpression had little effect on blood vessel density or BEC 
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proliferation, Adm overexpression resulted in a 3-fold elevation of LECs in both tumors and 
sentinel lymph nodes compared to tumors with reduced Adm expression (Figure 1-2B) [83]. 
Lymphatic vessels of Adm overexpressing tumors were also significantly dilated. Careful 
evaluation of tumor metastasis revealed that Adm overexpression increased tumor 
dissemination [83]. These data recapitulate what has been observed in human tumors and 
suggest that Adm expression can promote metastasis via lymphangiogenesis.  
 Importantly, these findings extend beyond the LLC model. Studies in cervical cancer 
have also found associations between AM-mediated lymphangiogenesis and severity of 
disease. Huang et al. report that loss in the tumor stromal endothelium of miR-126, a 
microRNA that maintains vessel integrity during development, results in significant 
upregulation of Adm and strongly associates with invasive carcinomas [84]. Upregulation of 
AM peptide also coupled with increases in CD31-positive endothelium (5.3% in tumors with 
high levels of miR-126 expression vs. 71% in invasive tumors with low miR-126 expression), 
suggesting that AM may promote disease progression through angiogenesis [84]. However, 
because lymphatic and blood vessels both stain CD31-positive, it is unclear whether this 
increase in vessel density is due AM-mediated effects on the blood or lymphatic 
endothelium. Taken together with previous in vivo and in vitro studies that demonstrate that 
AM has preferential effects on the lymphatic endothelium, it is expected that much of the 
increase in vessel density is due to AM-mediated lymphangiogenesis. Consistently, the 
authors found significant co-localization of AM peptide with LYVE1-positive vessels [84].  
 These findings make a compelling argument for an association between increased 
Adm expression and tumor invasion. As such, modulation of Adm expression via AM 
inhibitors may prove to be an exciting chemotherapeutic target. VEGF inhibitors, which 
target tumor angiogenesis, are being utilized in the clinic at present and have been found to 
increase patient survival in certain cancer types [85,86]. However, the survival increase is 
modest, often measured only in months rather than years [86]. The benefit of VEGF 
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inhibitors could be strengthened by co-administration with AM inhibitors [87]. This 
hypothesis has already been tested in mouse models of prostate cancer, where anti-AM 
antibodies were found to disrupt tumor vasculature, decrease lymphatic vessel density, 
increase LEC death, and suppress tumor growth [88]. Though this anti-AM antibody has not 
been fully characterized or utilized in other studies, this finding supports the hypothesis that 
AM inhibition may improve cancer-related outcomes.  
Adrenomedullin-induced Lymphangiogenesis in the Reproductive System 
 Perhaps the most exciting and novel aspect of AM-mediated lymphangiogenesis is 
its involvement in the lymphatic vasculature of the reproductive system. Our lab and others 
have shown that AM is critical in healthy pregnancy [9]. In a normal human pregnancy, AM 
increases 3-5 fold [89]. Dysregulation of this physiologic increase in both humans and 
mouse models has been associated with significant complications, most notably 
preeclampsia [90-92]. Additionally, haploinsufficiency of Adm in female mice results in 
reduced fertility due to implantation defects [93]. The essential role of AM in the normal 
reproductive system has therefore become increasingly apparent and clinically relevant over 
the past two decades. As such, there has been a rapidly growing interest in the role of AM-
mediated angiogenesis and lymphangiogenesis in the reproductive system. 
 Consistent with the finding that AM promotes tumor progression, several studies 
report increased lymphangiogenesis and metastasis in pregnant women with melanoma 
when compared with non-pregnant melanoma patients [94,95]. The direct cause of the 
increased lymphangiogenesis remains unknown. However, it stands to reason that the 
significant increase in Adm during pregnancy may be responsible. The physiologically 
higher levels of AM during pregnancy may interact with the tumor endothelium, thereby 
promoting LEC proliferation and lymphangiogenesis. This hypothesis differs from previous 
reports suggesting that AM originates from the tumor cell. Here, increased plasma 
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concentration of AM originates from the host and impacts the tumor environment. It will be 
interesting to tease out whether levels of AM originating outside of the tumor impact cancer 
progression via lymphangiogenesis. Adm overexpression models may prove useful in 
determining host AM status on tumor progression [63].  
 Despite the focus on AM as a tumor-promoting peptide, increased Adm expression 
also plays important roles during the normal reproductive cycle. Recent studies have 
suggested that endometrial lymphangiogenesis is required for normal menstrual cycling and 
repair of damaged blood vessels during menstruation [96]. Examination of Adm during 
various stages of the menstrual cycle reveals that Adm expression is elevated during stages 
of endometrial repair [97]. Also, AM treatment results in increased lymphatic endometrial 
endothelial cell growth [97,98]. Taken together, these findings suggest that AM-mediated 
lymphangiogenesis facilitates endometrial repair and allows progression through the 
menstrual cycle. Dysregulation of endometrial Adm expression may lead to improper repair 
of damaged blood vessels and prolonged or heavy menstrual bleeding [97]. These findings 
again suggest that modulation of the AM signaling system could be utilized clinically for the 
treatment of common diseases that significantly affect quality of life. 
Concluding remarks 
 The essential role for AM in the development, maintenance, and function of the 
lymphatic vasculature has been clearly demonstrated over the past decade. Genetic models 
have greatly contributed to our understanding of how AM modulates lymphangiogenesis and 
underscored the importance of proper AM dosage: Complete loss of AM is incompatible with 
life. Adm haploinsufficiency may predispose individuals to lymphedema, and overexpression 
of AM in cancer models correlates with severity of disease. Clearly, aberrant AM expression 
has the potential to lead to significant lymphatic associated pathologies, and tight control of 
AM dosage from development through adulthood is critical for proper lymphatic function. 
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Future studies will continue to elucidate the mechanisms of AM signaling. Whether the AM 
system interacts with other signaling cascades during lymphangiogenesis, such as Notch 
and VEGFR3, will be of particular interest, as previously published work has shown AM is 
capable of activating Notch and transactivating VEGFR2 [57,99,100].  These studies will 
expand our understanding of how AM impacts lymphatic physiology and offer the potential 
of identifying a G protein-coupled receptor target for the pharmacological modulation of the 
lymphatic vasculature in human disease.  
 20
FIGURES 
  
Figure 1-1. Early development of the lymphatic system and the effects of AM on LECs. 
(A) Development of the lymphatic system begins between e10.5-11.5 when the master 
regulators of lymphatic fate, Prox1 and Sox18, turn on. By e13.5, the lymph sac is fully 
separated from the jugular vein and activation of the AM system allows LEC proliferation. (B) 
Additionally, AM acts to stabilize the lymphatic endothelial barrier by reorganizing the tight 
junction protein, ZO-1, and the adherens junction protein, VE-cadherin, thereby decreasing 
lymphatic vessel permeability. (AM = adrenomedullin; BEC = blood endothelial cell; LEC = 
lymphatic endothelial cell) 
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Figure 1-2. Proper AM dosage is required for normal lymphangiogenesis during 
development and in tumor biology. (A) Precise AM concentration is required during 
development to regulate LEC proliferation. Absent AM signaling results in small, hypoplastic 
lymph sacs. Conversely, loss of the decoy receptor, CXCR7, results in excessive AM 
signaling and enlarged, hyperplasic lymph sacs. (B) Similarly, overexpression of Adm in 
tumor models results in enhanced proliferation of LECs, dilated lymphatic vessels, and 
increased tumor metastasis. 
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Figure 1-3. Loss of AM signaling in adulthood results in disruption of many lymphatic 
beds. Here, we provide a summary of the findings when AM signaling is disrupted following 
embryonic development. Conditional knockdown of Calcrl in adult mice results in significant 
alterations in the ocular, intestinal, dermal, and peripheral lymphatic vessels. Additional 
studies that suggest AM is critical for lymphangiogenesis during adulthood are highlighted in 
purple.  
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Chapter 2: Decoy Receptor CXCR7 Modulates Adrenomedullin-Mediated Cardiac and 
Lymphatic Vascular Development1,2 
 
Overview  
Atypical 7-transmembrane receptors, often called decoy receptors, act 
promiscuously as molecular sinks to regulate ligand bioavailability and consequently temper 
the signaling of canonical G protein-coupled receptor (GPCR) pathways. Loss of 
mammalian CXCR7, the most recently described decoy receptor, results in postnatal 
lethality due to aberrant cardiac development and myocyte hyperplasia. Here, we provide 
the molecular underpinning for this proliferative phenotype by demonstrating that the dosage 
and signaling of adrenomedullin (Adm = gene, AM = protein)—a mitogenic peptide-hormone 
required for normal cardiovascular development—is tightly controlled by CXCR7.  To this 
end, Cxcr7-/- mice exhibit gain-of-function cardiac and lymphatic vascular phenotypes which 
can be reversed upon genetic depletion of adrenomedullin ligand.  In addition to identifying a 
biological ligand accountable for the phenotypes of Cxcr7-/- mice, these results reveal a 
previously underappreciated role for decoy receptors as molecular rheostats in controlling 
the timing and extent of GPCR-mediated cardiac and vascular development. A graphical 
abstract is included in Figure 2-A1.  
                                               
1 Authors: Klara R. Klein, Natalie O. Karpinich Ph.D, Scott T. Espenschied, Helen H. Willcockson, 
William P. Dunworth Ph.D, Samantha L. Hoopes, Ph.D, Erich J. Kushner Ph.D., Victoria L. Bautch 
Ph.D,  Kathleen M. Caron, Ph.D. 
 
2 Reprinted with permission from 1. Klein KR, Karpinich NO, Espenschied ST, Willcockson HH, 
Dunworth WP, et al. (2014) Decoy Receptor CXCR7 Modulates Adrenomedullin-Mediated Cardiac 
and Lymphatic Vascular Development. Dev Cell 30: 528-540. 
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Introduction 
The precise spatiotemporal dosage of mitogenic and chemotactic factors is critical 
for the proper organization and development of organ systems.  While the concentration of 
ligands often differs between tissues and developmental stages, the bioavailability of ligands 
within local microenvironments must also be controlled at a cellular level.  Thus, cells can 
express molecular sink receptors, which in an autocrine or paracrine manner, sequester 
ligand away from canonical signaling receptors, thereby driving important developmental 
processes like neurogenesis, angiogenesis, chemotaxis and cellular proliferation [2,3]. 
Molecular sink receptors include atypical chemokine receptors, also known as decoy 
receptors, which belong to the larger family of 7-transmembrane receptors. Decoy receptors 
act as molecular sinks by binding, internalizing, and degrading a wide range of ligands 
independent of G-protein coupling (Graham, 2012).  CXCR7 is the most recently described 
decoy receptor and has been extensively studied for its role as a CXCL12/SDF-1 receptor 
[4-6], particularly in tumor cell migration and cancer progression [7,8].  
However, prominent roles for CXCR7 during normal development and physiology 
have also been recently appreciated.  In zebrafish, the expression and molecular sink 
functions of CXCR7 in trailing cells of the posterior lateral line primordium allows for a 
CXCL12 chemotactic gradient to be established and sensed by the leading primoridal germ 
cells which express CXCR4, the canonical SDF-1/CXCL12 receptor [9-12]. In this instance, 
CXCR7 exerts its decoy activities over a wide region to help coordinate and guide the 
migration of multicellular tissue structures.  
However, the decoy activities of CXCR7 can also occur in a cell-autonomous 
fashion.  For example, the co-expression of CXCR7 within migrating cortical neurons allows 
for the continued sensitization and chemotactic signaling of CXCR4--rather than receptor 
desensitization and downregulation that would typically occur within an environment of high 
CXCL12 ligand [13,14]. Recently, CXCR7 expression in endothelial cells has also been 
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shown to regulate circulating levels of ligands, suggesting that CXCR7 expression in vessels 
may not only affect signaling events in a microenvironment, but systemically as well [15]. 
Due to these well-described roles in the CXCL12/CXCR4 signaling axis, Cxcr7-/- 
mice were expected to exhibit phenotypes that might resemble gain-of-function mutations 
for the CXCL12/CXCR4 signaling axis. However, Cxcr7-/- mice have unexpected phenotypes 
including cardiomyocyte hyperplasia and postnatal lethality associated with gross cardiac 
enlargement and cardiac valve defects [16-18]. Because decoy receptors typically bind and 
sequester multiple ligands, it has been difficult to discern which ligand may be causally 
related to the developmental cardiac defects of Cxcr7-/- mice.  In this regard, we appreciated 
that CXCR7 was originally identified as RDC1--a putative receptor for adrenomedullin (Adm 
= gene, AM = protein), a 52 amino acid mitogenic peptide hormone critical for cardiac and 
lymphatic vascular development [19-22]. AM binds RDC1/CXCR7 with a Kd of 1.9 x10-7 M, 
similar to CLR when associated with RAMPs [23].  Importantly, we have recently shown that 
genetic overexpression of AM ligand in Admhi/hi mice results in gross cardiac enlargement 
due to cardiac hyperplasia during embryogenesis [24], which closely phenocopies the 
dysmorphic cardiac hyperplasia of Cxcr7-/- mice.  
We therefore sought to address whether a principal function of CXCR7 may involve 
controlling the dosage of AM ligand during development, first focusing our attention on the 
cardiac hyperplasia. In the course of our studies, we also discovered lymphatic vascular 
defects in Cxcr7-/- mice, which are consistent with the prominent role that AM signaling plays 
in driving normal lymphangiogenesis [19,20,25,26]. In addition to identifying a biological 
ligand that is causally associated with the Cxcr7-/- phenotypes, the results described here 
elucidate a role for decoy receptors as molecular rheostats that control normal cardiac and 
lymphatic vascular development. 
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Results 
Gene expression of Cxcr7 and Adm are coupled in the heart and lymphatic endothelium 
Historical ligand binding data [23] and more recent findings showing a down-
regulation of Adm gene expression in Cxcr7-/- mice [17], strongly support the existence of 
this ligand-receptor pair.  Considering the well-established function of CXCR7 as a decoy 
receptor, we predicted that expression levels of Cxcr7 may homeostatically increase under 
conditions of increased AM peptide.  To further evaluate whether this interaction exists, we 
measured the expression of Cxcr7 in hearts of Admhi/hi  mice which have a genetically 
engineered, 3-fold increase in Adm gene expression [24].  Indeed, utilizing qRT-PCR, we 
identified a potent 2.5-fold upregulation of Cxcr7 gene expression in Admhi/hi cardiac tissue 
compared to that of wildtype littermates (Figure 2-1A). Conversely, loss of Adm expression 
in isolated endothelial cells resulted in a nearly 5-fold reduction in Cxcr7 expression (Figure 
2-1A). 
We also found that Cxcr7 is expressed at high levels in isolated, adult lymphatic 
vessels—a tissue where AM peptide plays important roles (Figure 2-S1A).  Consistently, 
microarray analysis of cultured, human lymphatic endothelial cells (LECs) showed that 
expression of the human CXCR7 gene (aka ACKR3 or CMKOR1) was one of the ten most 
significantly induced genes within 1 hour of 10nM AM treatment (p=2.5E-07) (Figure 2-1B 
and Table 2-S1).  This finding was further confirmed by qRT-PCR, revealing a 4-fold 
increase in CXCR7 gene expression following 1- and 24- hours of AM treatment (Figure 2-
1C). Pretreatment with AM22-52, a CLR/R2 antagonist, significantly reduced this AM-
mediated increase (Figure 2-1C), demonstrating that the upregulation of CXCR7 gene 
expression is modulated through the canonical AM receptor. Collectively, these data 
indicate that CXCR7 and ADM gene expression levels are coupled within tissues where AM 
peptide plays important developmental and physiological roles. Since excess AM, either by 
genetic overexpression in vivo or exogenous treatment in vitro, triggered an increase in 
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CXCR7 expression, we next tested directly the hypothesis that CXCR7 serves as a decoy 
receptor to modify AM concentration. 
CXCR7 scavenges AM peptide and dampens canonical AM signaling 
Using a classical scavenger assay, CXCR7-expressing HEK293T cells were treated 
with biotinylated-AM1-52, and aliquots of media were collected over time to determine the 
remaining levels of AM peptide within the media. While the levels of biotinylated-AM1-52 in 
the media of vector-transfected control cells remained unchanged, CXCR7-expressing cells 
rapidly and steadily depleted AM peptide from the media to levels that were statistically 
lower than control cells by the conclusion of the time course (Figure 2-1D, E). These data 
demonstrate the ability of CXCR7 to modulate AM ligand concentrations exogenously in a 
controlled in vitro system. 
To determine whether this scavenging of AM peptide by CXCR7 was conserved in 
vivo, we compared AM staining in cardiac tissue of wildtype mice and Cxcr7-/- mice, which 
harbor an insertional GFP reporter within the targeted allele.  Firstly, we noted that 
expression of the GFP reporter was enriched within the epicardium and the endocardium 
surrounding the trabeculae and weakly expressed in the compact zone (Figure 2-1F). 
Secondly, the staining pattern of receptor expression was spatially juxtaposed and/or 
overlapping with the most prominent sites of AM peptide expression, including the 
epicardium and trabeculae (Figure 2-1G and [24]).  Remarkably, we found a significant 30% 
increase in the relative staining intensities of AM peptide in the epicardium and trabeculae of 
Cxcr7-/- mice compared to wildtype littermates (Figure 2-1H-K), but no changes within the 
compact zone where levels of Cxcr7 reporter expression were modest (Figure 2-1L). These 
findings indicate that spatially juxtaposed and/or overlapping expression of CXCR7 and AM 
during cardiac development is essential for scavenging AM peptide in cardiac tissue in vivo.   
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 Activation of the canonical AM-receptor complex, CLR and receptor activity 
modifying protein 2 (RAMP2), elicits an increase in cAMP and subsequent downstream 
activation and phosphorylation of ERK [19]. Utilizing a highly-sensitive bioluminescence 
resonance energy transfer (BRET) reporter system [27,28], we found that HEK293 cells that 
overexpress CXCR7 failed to accumulate cAMP upon AM stimulation—a finding consistent 
with the lack of G-protein coupling by decoy receptors (Figure 2-S1B).  As expected, AM 
treatment of CLR/RAMP2-expressing cells resulted in a potent accumulation of cAMP 
(Figure 2-S1B) and pERK:tERK upregulation (Figure 2-1M, N and Figure S1C).  
Importantly, while AM did not elicit a pERK:tERK upregulation in cells transfected with 
CXCR7 alone, the CLR-RAMP2 mediated activation of pERK:tERK was markedly abrogated 
when cells were co-transfected with CXCR7 (Figure 2-1M, N).  These in vitro signaling 
assays demonstrate that CXCR7 can act as a cell-autonomous molecular rheostat to 
dampen canonical AM pERK:tERK signaling. 
The effects of CXCR7 on dampening pERK:tERK signaling were also confirmed in 
vivo, where we noted significant accumulation of pERK staining in dermal lymphatic vessels 
of postnatal day 1  Cxcr7-/- tail skin compared to wildtype littermates (Figure 2-S2A-D). 
Furthermore, we also observed a significant increase in the pERK staining in the lymph sac 
of e13.5 Cxcr7-/- embryos compared to wildtype animals (Figure 2-S2E-J). These in vivo 
data from a genetic loss-of-function model aptly reciprocate the findings from the in vitro 
gain-of-function experiments and furthermore demonstrate that loss of Cxcr7 expression 
influences ERK phosphorylation on a tissue level. 
CXCR7 is dynamically expressed in lymphatic endothelium during development 
Previous studies have reported that nearly one third of adult dermal lymphatic 
vessels express CXCR7 [29], but the spatiotemporal expression of CXCR7 during 
developmental lymphangiogenesis has yet to be described.  Using the GFP-targeted 
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Cxcr7+/- reporter allele, we found Cxcr7 expression co-localized with the lymphatic makers 
LYVE1 (Figure 2-2A-C), Prox1 (Figure 2-2G-I) and podoplanin (Figure 2-2I-L).  At e11.5, 
lymphatic progenitor cells are arranged in a stereotypically-polarized fashion within the 
jugular vein (JV) and express Cxcr7 (Figure 2-2D-F, white arrows, Figure 2-2G, H). 
Interestingly, we often noted that Cxcr7 expression is temporarily reduced as the lymphatic 
progenitors begin to migrate away from the JV (Figure 2-2F, I asterisks)− underscoring the 
dynamic expression of the decoy receptor in areas of active cell migration. As lymphatic 
cells coalesce to form the lymph sacs (LS) between e11.5-e13.5, Cxcr7 was again 
expressed in some lymphatics, which were identified by LYVE1 and podoplanin co-labeling 
(Figure 2-2J-O). Cxcr7 was also persistently expressed in the JV cells directly adjacent to 
the LS (Figure 2-2P-R, white arrowheads), consistent with recently published studies 
demonstrating a paracrine function for decoy receptors [12,30]. In summary, Cxcr7 is highly 
and dynamically expressed within lymphatic progenitors and early lymphatic vessels at the 
time of nascent lymphangiogenesis, which also spatiotemporally correlates with the 
proliferative effects of AM during lymphatic development.  
Cxcr7-/- mice have enlarged, blood filled lymphatic sacs 
We have previously established that AM signaling is required for normal LEC 
proliferation at e13.5 [19]. Thus, we investigated whether loss of Cxcr7, which we 
hypothesize to be a molecular rheostat for AM, disrupts lymphangiogenesis at this point 
during embryogenesis. Indeed, approximately 10% of Cxcr7-/- mice exhibited visible 
interstitial edema upon dissection at mid-gestation (Figure 2-3A, white arrows, Figure 2-3B, 
C, black arrows). Histological evaluation further revealed that approximately 10-15% of 
Cxcr7-/- mice displayed interstitial edema, particularly within the thoracic regions surrounding 
the developing jugular lymphatics. Additionally, we noticed abnormal LS morphology, 
including markedly enlarged and dysmorphic LS in Cxcr7-/- embryos compared to wildtype 
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littermate embryos (Figure 2-3D-F). Utilizing computerized morphometry to calculate LS and 
JV area, we found that the LS:JV ratio of null mice was increased 4-fold compared to 
Cxcr7+/+ mice (Figure 2-3G). Some sections revealed failure of the LS to separate from the 
JV, with prominent platelet thrombi (Figure 2-3F, black arrows). Moreover, Cxcr7-/- lymphatic 
vessels exhibited remarkable blood (Figure 2-3E, asterisks) and proteinaceous deposits 
(Figure 2-3E, arrowheads), which are phenotypes commonly ascribed to pathologic 
lymphangiogenesis and lymph stasis in several mouse models [31,32]. A scoring rubric to 
assess the severity of lymphatic defects showed that LS of Cxcr7-/- embryos had significantly 
more blood and protein accumulation compared to control mice (Figure 2-3H, I).  Taken 
together these results demonstrate that loss of Cxcr7 during embryonic development results 
in aberrant LS formation. 
To determine whether the blood accumulation in the LS was due to improper 
development or structure of the lymphovenous valves, we stained frontally sectioned 
embryos with the lymphatic markers Prox1 and podoplanin. We observed no structural 
differences between Cxcr7+/+ and Cxcr7-/- lymphovenous valves (Figure 2-S3A, B), with both 
wildtype and mutant animals exhibiting characteristic high-Prox1 staining on the valve 
leaflet.  We next considered whether the blood accumulation in Cxcr7-/- lymph sacs might be 
associated with precocious development of the lymphatic sac. As expected, e11.5 wildtype 
embryos exhibited polarization of LYVE1+ lymphatic progenitors within the jugular vein. 
However, some Cxcr7-/- littermate embryos exhibited premature migration of LECs from the 
jugular vein and precocious formation of enlarged, blood-filled lymph sacs (Figure 2-S3C, 
D)—a process that typically occurs 1-2 days later in development. Thus, we reasoned that 
the likely cause of blood accumulation in the Cxcr7-/- mutants is precocious lymph sac 
formation prior to proper separation of the blood and lymphatic vascular systems.  
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Loss of CXCR7 enhances LEC migration in vivo and in vitro  
We next sought to determine whether loss of Cxcr7 affected lymphangiogenesis in 
other lymphatic vascular beds. At e18.5, staining of Cxcr7-/- cardiac tissue revealed 
increased LYVE1+ vessels on the surface of the heart (Figure 2-4A). This increase might 
be expected due to the cardiac hyperplasia in Cxcr7-/- embryos. Nevertheless, when 
normalized to total surface area of the heart, null animals exhibited a 20% increase in 
cardiac lymphatic vessels on the ventral surface of the heart (Figure 2-4B). Higher power 
examination of the cardiac lymphatic vessels of Cxcr7-/- animals revealed a disruption of 
branching complexity and lacunae number (Figure 2-S4A-F), as well as an extensive 
network of lymphatic vessels in the curvature of the outflow tract on cardiac dorsal-surface 
(Figure 2-S4C, arrows) which were not present in wildtype mice. Additionally, these 
LYVE1+ vessels tended to extend farther down the apex of the heart in Cxcr7-/- embryos, 
suggesting that Cxcr7 also affects LEC migration (Figure 2-4A, C).   
To elucidate whether loss of CXCR7 is directly involved in enhancing AM-mediated 
downstream signaling pathways and cellular migration, we utilized shRNA lentiviral vectors 
to achieve 80% knockdown of CXCR7 in human neonatal-LECs (Figure 2-4D). We first 
used a scavenger assay to confirm that CXCR7 shRNA-infected LECs scavenged less AM 
than control cells, resulting in increased AM available to interact with the signaling receptor, 
CLR/R2 (Figure 2-S5A, B).  Next, we showed that knockdown of endogenous CXCR7 in 
LECs results in an increase in AM-mediated ERK phosphorylation, with CXCR7 shRNA-
infected LECs exhibiting a potent upregulation in pERK:tERK ratios in response to AM 
treatment, whereas control cells did not (Figure 2-S5C). 
These CXCR7 knockdown cells were then used to evaluate whether loss of CXCR7 
enhances AM-mediated LEC migration.  Using an in vitro scratch assay, we showed that AM 
promotes LEC migration, since AM-treated control cells migrated 41% more than vehicle-
treated cells (Figure 2-4E, G). On the other hand, AM treatment of CXCR7 knockdown cells 
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caused the cells to migrate into the scratch 66% more than vehicle-treated cells (Figure 2-
4F, H). Moreover, percent migration of AM-treated CXCR7 knockdown LECs was 
significantly increased above all other conditions (Figure 2-4I). These scratch assay findings 
were fully recapitulated using a transwell migration assay (Figure 2-4J). Finally, the effect of 
CXCR7 on AM-mediated cell migration was corroborated using an overexpression model.  
As expected, AM treatment of CLR/RAMP2-expressing HEK293T cells resulted in increased 
migration across a transwell.  However, this migration was abrogated when cells were co-
transfected with a CXCR7 expression plasmid (Figure 2-4K).  Collectively, these data show 
that CXCR7 expression modulates AM-mediated downstream signaling activity, with 
knockdown of endogenous CXCR7 increasing and overexpression of CXCR7 reducing AM-
mediated cellular migration. 
Dermal lymphatic vessels of Cxcr7-/- animals are enlarged, with less branching complexity 
We also observed morphological changes in the dermal lymphatic vessels of Cxcr7-/- 
mice. Interestingly, although there was stochastic expression of Cxcr7 in dermal lymphatic 
vessels (Figure 2-S6), we consistently observed Cxcr7 expression in blood vessels, again 
suggesting that non-cell autonomous expression of Cxcr7 can affect lymphangiogenesis. 
While the dermal lymphatics of wildtype animals formed a highly-structured lattice network, 
those of Cxcr7-/- embryos failed to extend and connect to neighboring vessels, resulting in 
fewer ring-like structures or lacunae (Figure 2-5A, B asterisks). For example, control 
lymphatic capillary networks comprised between 6-8 lacunae per image, but the lymphatic 
network of Cxcr7-/- skin consisted of only 4-5 lacunae per image (Figure 2-5C). Quantitation 
of the number of branch points also revealed a significant reduction in branching complexity, 
from 23.2 to 16.3 per image, between control and Cxcr7-/- dermal lymphatics (Figure 2-5D). 
(Image area measured 132800 µm2.) Additionally, Cxcr7-/- dermal lymphatic vessels were 
enlarged compared to littermate controls (Figure 2-5E-I, yellow dashed line). The junctional 
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area where vessels coalesce to form a branch point was also increased (Figure 2-5G, H, J 
yellow solid line). 
Previously published studies demonstrate that this type of increase in vessel 
diameter and decreased branching complexity is consistent with a hyperplastic phenotype 
[33,34], suggesting that loss of CXCR7 results in hyperproliferation of LECs. We therefore 
sought to determine if this hyperplastic phenotype of Cxcr7-/- dermal lymphatics could be 
attributed to increased AM-mediated LEC proliferation—a biological effect of AM which has 
been demonstrated by our group and others [19,35,36].   Using CXCR7 knockdown LECs, 
we observed a 50% increase in proliferation in AM-treated CXCR7 knockdown LECs 
compared to AM-treated control cells (Figure 2-5K). Collectively, these data demonstrate 
that loss of CXCR7 promotes AM-mediated LEC lymphangiogenesis by enhancing both 
migration and proliferation in vivo and in vitro.  
Genetic titration of Adm changes Cxcr7-/- survival 
We next sought to determine whether the phenotypes of Cxcr7-/- embryos could be 
causally associated with AM ligand concentration in vivo.  To test this, we employed a 
genetic approach, depicted in Figure 2-6A, C, which allowed for the generation of Cxcr7 
gene-targeted mice on a titrated background of AM ligand that ranges from 50% to 300% 
wildtype levels.  Adm+/- mice express 50% of wildtype levels of Adm mRNA and peptide and 
exhibit exacerbated cardiovascular damage, reduced female fertility, and defective 
lymphatic function [22,37,38].  Admhi/hi animals survive to adulthood, but exhibit profound 
cardiac hyperplasia during development [24]. Therefore, we were confident that the effective 
dosage of AM peptide achieved with the AM “gene titration” mice was within a range that 
would have significant biological impact on lymphatic and cardiac development. 
First, because we noted some embryonic lethality in Cxcr7-/- animals in the genetic 
reduction experiment, we asked whether Adm haploinsufficiency might improve Cxcr7-/- 
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embryo survival during mid-gestation. At e13.5 we observed equivalent numbers of Cxcr7-/-
;Adm+/+ and Cxcr7-/-;Adm+/- animals from compound heterozygous intercrosses (Figure 2-
6B, e13.5).  However, at e14.5 the expected 1:1 ratio of Cxcr7-/-; Adm+/+:Cxcr7-/-; Adm+/- mice 
was significantly skewed, with less than 50% of the expected Cxcr7-/-; Adm+/+ genotype 
being offset by a disproportionate survival of Cxcr7-/-;Adm+/- embryos (Figure 2-6B, e14.5).  
Thus, haploinsufficiency of Adm improves Cxcr7-/- embryo survival during mid-gestation. It is 
also noteworthy that embryonic lethality was significantly increased in the Cxcr7+/-;Adm+/- 
cross, which is likely due to the critical role of AM in female reproductive physiology [37,39-
42]. This finding suggests that disruption of the parental CXCR7-AM axis likely contributes 
to the severity of the phenotypes. 
Next, we bred Cxcr7+/- mice to Admhi/hi animals in order to evaluate whether AM 
overexpression might exacerbate Cxcr7-/- gestational loss or influence survival. Interestingly, 
we found that postnatal survival of compound heterozygous pups was poor, with nearly 30% 
postnatal lethality, making maintenance of the Cxcr7+/-;Admhi/+ mouse colony very 
challenging. Whereas we had not previously observed Cxcr7+/- pup lethality in other genetic 
crosses, Cxcr7+/- animals that expressed a single Admhi allele were more susceptible to 
death. Moreover, homozygosity for the Admhi allele resulted in a striking 65% lethality of 
Cxcr7+/-;Admhi/hi mice (Figure 6D). Collectively, these data demonstrate that titration of the 
endogenous AM ligand is causally associated with profound changes in the survival of 
Cxcr7 gene targeted animals.  
Haploinsufficiency of AM normalizes lymphatic and cardiac hyperproliferation of Cxcr7-/- mice 
Based on the improved embryonic survival of Cxcr7-/-;Adm+/- embryos, we next 
performed phenotypic characterization of lymphatic and cardiac development in these 
animals, with the expectation that haploinsufficiency for AM ligand might normalize the 
hypertrophic cardiovascular phenotypes of Cxcr7 null embryos. Importantly, 
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haploinsufficiency of AM had no effect on the LS:JV ratio in Cxcr7+/+ animals (Figure 2-6E, 
F). Consistent with Figures 3E-G, the podoplanin-positive lymph sacs of e13.5 Cxcr7-/-
;Adm+/+ embryos showed a significant 4-fold enlarged LS:JV ratio compared to wildtype 
littermates (Figure 2-6G, I).  However, this lymph sac enlargement was normalized in Cxcr7-
/-;Adm+/- mice, resulting in LS:JV ratios that were statistically indistinguishable from wildtype 
animals (Figure 2-6H, I).  Additionally, we used Ki67 staining to quantitate the number of 
proliferating LECs and found a direct correlation between the proliferation of LECs and the 
LS:JV ratios and genotypes.  While Cxcr7-/-;Adm+/+ mice had significantly more proliferating 
cells in the LS compared to wildtype animals (Figure 2-6G, J), haploinsufficiency for AM 
(Cxcr7-/-;Adm+/-) allowed this hyperproliferation to revert to levels that were equivalent to 
those observed in wildtype animals (Figure 2-6H, J).  Taken together, these findings 
demonstrate that the increase in LS:JV ratio in CXCR7 null mice is due to an increase in 
LEC proliferation which can be reversed by genetic reduction of AM ligand.  
Similar effects were observed in the developing heart.  Using BrdU incorporation 
assays, we quantitated the amount of proliferating cells in e11.5 cardiac tissue from the AM 
genetic titration animals. Percent proliferation of cardiac cells in Cxcr7+/+;Adm+/- animals was 
equivalent to wildtype animals, demonstrating that Adm haploinsufficiency alone does not 
affect heart size (Figure 2-7A-D). Consistent with other studies [18], we noted a statistically 
significant increase in proliferation of Cxcr7-/- cardiac tissue compared to wildtype (Figure 2-
7E, F, I).  Importantly, this aberrant cardiac hyperproliferation was normalized to wildtype 
levels in Cxcr7-/-;Adm+/- embryos (Figure 2-7G, H, I). We noted increased proliferation 
particularly within the epicardium and trabeculae (Figure 2-7F-H, arrows and arrowheads 
respectively)--regions of the heart where CXCR7 is highly expressed (see Figure 2-1F). 
Furthermore, 2 days after the AM-mediated peak in myocyte proliferation, many of the 
hearts of Cxcr7-/-;Adm+/- embryos appeared phenotypically normal and similar in size to 
wildtype animals (Figure 2-7J-L). We therefore conclude that genetic reduction of AM 
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peptide alleviates the pathological cardiac hyperproliferation of Cxcr7 null animals and 
ultimately impacts cardiac size during development. 
Though difficulty maintaining the line precluded extensive timed matings, we 
observed even more precocious development of the LS of Cxcr7-/-;Admhi/hi embryos. At 
e11.5, Cxcr7-/-;Admhi/hi embryos often had fully formed lymph sacs that were dramatically 
enlarged, and blood filled (Figure 2-S3E). This further exacerbated lymphatic development 
confirmed our hypothesis that Cxcr7-/- LS develop precociously. Hearts of Cxcr7-/- on the 
Admhi/hi background also tended to be enlarged with thickened compact zones and 
significant blood accumulation in the ventricles and atria (data not shown). 
Discussion 
The pleiotropic consequences of CXCR7 loss have made it difficult to discern which 
ligand(s) are responsible for a given phenotype. In this study, using both loss-of-function 
and gain-of-function animal models, we demonstrate that several of the essential functions 
of CXCR7 during cardiovascular development can be attributed to its decoy activities for the 
ligand, AM.  Haploinsufficiency of AM in a Cxcr7-/- animal effectively reversed cardiac and 
lymphatic hyperproliferation, demonstrating that CXCR7 is required as a molecular rheostat 
for controlling AM ligand availability during development.  While other atypical chemokine 
receptors are known to bind multiple ligands, only recently has the repertoire of CXCR7 
ligands been expanded beyond the chemokines CXCL12 and CXCL11.  For example, a 
very recent study has elegantly demonstrated that proteolytic peptide fragments of the 
adrenal neuropeptide proenkaphalin A interact with CXCR7 and thereby mediate responses 
to glucocorticoid secretion and anxiety behaviors in mice [43].  Structure-function studies of 
the proenkaphalin A-derived peptides, along with our current findings on the AM peptide, 
further highlight the ability of CXCR7 to bind to several classes of small peptidergic ligands, 
which also happen to be particularly enriched in the adrenal gland.  Whether 
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adrenomedullin—which as it name implies, is also highly expressed in the adrenal gland—is 
also implicated in the CXCR7-mediated glucocorticoid secretion and anxiety behaviors has 
yet to be determined.   
Likewise, our study does not formally rule out the involvement of CXCL12 in the 
described cardiovascular hyperplasia phenotypes of Cxcr7-/- mice. Genetic deletion of either 
CXCR4 or CXCL12 has been associated with defective ventricular septum formation 
[44,45]. However, only recently have studies in chick embryos demonstrated a gain-of-
function phenotype for CXCL12 overexpression in neural crest cell migration related to 
cardiac development [46].  While the effects of CXCL12 overexpression might be anticipated 
to more closely parallel the effects of CXCR7 loss-of-function, the cardiac phenotypes of 
these two models are markedly different.  CXCL12 mis-expression in chick embryos diverts 
neural crest cell migration to the heart, while CXCR7 deficiency promotes cardiac myocyte 
hyperplasia and septal defects.  Our current study does not preclude the functional 
deregulation of CXCL12, however it does definitively demonstrate that genetic reduction in 
AM ligand is fully sufficient to rescue the Cxcr7-/- cardiac hyperplasia.  Therefore, although 
we cannot exclude potential effects of CXCL12 on the Cxcr7-/- cardiac phenotypes, we have 
identified AM as the critical ligand for mediating the cardiac hyperproliferation. 
With respect to lymphangiogenesis, genetic studies in zebrafish have also 
established a central role for CXCL12(SDF-1)/CXCR4 signaling during the stepwise 
assembly of the lymphatic trunk network [47].  Interestingly, the requirement for CXCL12 in 
guiding zebrafish LEC migration occurs at developmental time points that are subsequent to 
LEC sprouting from the posterior cardinal vein.  However, our expression studies in mice 
revealed little expression of CXCR7 in LECs that have migrated away from the jugular vein, 
and we failed to observe prominent defects in the migration and assembly of lymphatic sacs 
in Cxcr7-/- mice.  Although these spatiotemporal differences in receptor-ligand expression 
patterns may simply be attributed to differences between species, a more compelling 
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implication of these studies is that dynamic changes in the expression of CXCR4 and 
CXCR7 may be critical for orchestrating the extent and time frame to which nascent LECs 
sense and respond to different lymphangiogenic growth factors.  Moreover, the dynamic 
spatiotemporal expression of signaling and decoy receptors likely provides a mechanism for 
individual LECs and their adjacent tissues to create a localized microgradient of chemotactic 
or proliferative factors [11,12] to promote the stepwise growth of lymphatic vessels.  
Although our current study has focused on the effects of CXCR7 on AM-mediated 
cardiac and lymphatic development, it is important to recognize that the interaction of 
CXCR7 with AM may initiate downstream signaling and active processes in other cell types 
or tissues. For example, several studies have pointed to potential non-decoy functions of 
CXCR7, such as signaling through ß-arrestin, heterodimerizing with other GPCRs in certain 
tissues, and coupling with G-proteins in astrocytes [23,48,49]. Therefore, while we have 
currently established CXCR7 as a molecular rheostat for AM signaling during cardiovascular 
development, future studies may identify potential CXCR7-GPCR complexes that allow for 
functional AM signaling in other cell types or tissues. 
Our findings of increased ERK phosphorylation in dermal lymphatics of Cxcr7-/-  mice 
are consistent with several previously described models with aberrant lymphangiogenesis 
associated with increased ERK signaling. For example, ex vivo expression of Spred-1/2, 
negative regulators of ERK activation, suppresses LEC proliferation while double knockout 
mice exhibit dilated, blood-filled lymphatics—similar to the Cxcr7-/- phenotype described here 
[50]. Likewise, mice lacking apoptosis stimulating protein of p53 (Aspp1) have increased 
ERK activation and exhibit similar transient subcutaneous edema with dilated and 
dysmorphic lymphatics and increases in cardiac LYVE1+ staining [51]. Most recently, a fine-
tuned balance between ERK and Akt signaling pathways has been recognized as an 
essential component for establishing LEC fate determination and differentiation [52,53].  
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Collectively, these studies identify ERK signaling as a critical regulator of 
lymphangiogenesis and either loss or excessive ERK signal as a cause of aberrant 
lymphangiogenesis.  Results of this study identify a mechanism, whereby the positioning of 
a decoy receptor at the junction of lymphatic sprouting and migration serves as a biological 
rheostat for regulating the migratory and mitogenic effects of lymphangiogenic growth 
factors that are upstream of ERK activation.  Additional studies to determine whether and 
how other atypical chemokine receptors may influence cardiac and lymphatic development 
are warranted and may lead to conceptual paradigms about how growth factor gradients 
and their downstream signaling pathways can be precisely controlled by 7-transmembrane 
decoy receptors during cardiovascular development.   
Experimental Procedures 
Mice  
 Mice that contain a GFP reporter knocked into the Cxcr7 gene were purchased 
(C57BL/6-Ackr3tm1Litt/J, The Jackson Laboratory). Generation of Adm+/- and Admhi/hi mice 
with a targeted, deletion and overexpression of Adm, respectively, has been previously 
described. [21,22,40].  For timed pregnancies, Cxcr7+/- animals were intercrossed with 
Cxcr7+/- or Cxcr7+/-;Adm+/- animals. Dams were monitored for vaginal plugs, and the day 
when the vaginal plug was detected was considered E0.5. Cxcr7+/-;Admhi/+ animals were 
also intercrossed to establish survival. For BrdU incorporation assays, pregnant females 
were injected with BrdU (0.1 mg/g of BW, Sigma-Aldrich) via intraperitoneal injection two 
hours prior to dissection. All experiments involving mice were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill.  
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Cell culture and RNAi 
 Human adult (HMVECdLyAd-Der) and neonatal (HMVEC-d Neo) dermal lymphatic 
endothelial cells (Lonza) were cultured in EGM-2MV media. HEK293T cells were maintained 
in DMEM with 10% fetal bovine serum and 1% penicillin streptomycin or gentamicin. 
Lentiviral particle production and infection were performed according to standard protocol.  
Briefly, human CXCR7 shRNA pLKO1 vectors (UNC Viral Core) were co-transfected into 
HEK293T cells with lentiviral packaging vectors psPAX2 and MD2.G (Addgene) using 
Lipofectamine 2000 (Invitrogen).  Viral supernatants were filtered, supplemented with 
6ug/mL polybrene, and used to infect LECs for 48 hours before functional assays were 
performed.  
Gene Expression Analysis 
Agilent human gene expression microarrays were performed on three independent 
plates of hLECs treated with 10nM AM (American Peptide Company). Analysis was 
performed using the Significance Analysis of Microarrays (SAM) software (Stanford 
University). For embryonic endothelial cells, CD31 positive cells were isolated using 
magnetic beads. Quantitative RT-PCR was performed using primers and probes or hCXCR7 
Assays on Demand (Life Technology) after reverse transcription of 2 µg of total RNA. For 
AM22-52 treatment, cells were incubated with 1µM AM22-52 (American Peptide Company) for 
30 minutes prior to treatment with 10nM AM and 1µM AM22-52. 
Scavenger assay 
HEK293T cells were transfected with CXCR7 or pcDNA3.1 (negative control) using 
standard calcium phosphate transfection. Cells were treated with biotinylated-AM (Phoenix 
Pharmaceuticals), and aliquots of media were collected over 8 hours. Biotinylated-AM was 
detected with IRDye Streptavidin (1:2500, Li-COR).  
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ERK phosphorylation  
HEK293T cells were transfected with expression plasmids, serum starved for 20 
hours, and treated with vehicle or 10nM AM for 1 minute. Blots were blocked in 5% BSA, 
probed overnight with monoclonal rabbit anti-mouse pERK and tERK (1:1000, Cell 
Signaling) and monoclonal mouse anti-GAPDH (1:2000, Novus Biologicals), incubated in 
appropriate secondary antibody, and imaged on the Odyssey scanner (Li-COR). A blot with 
3 independent experiments run on the same gel was used to perform statistical analysis. 
Immunohistochemistry 
Embryo sections and whole mount tissue were permeabilized, blocked with 5% 
normal donkey serum, and incubated overnight at room temperature with primary 
antibodies, and then probed with appropriate secondary antibodies. Antibodies are 
described in the supplemental experimental procedures.  
Quantitation of LS:JV ratio and Blood and Protein Accumulation in LS 
Transverse sections of jugular lymph sacs of wildtype and mutant mice were H&E 
stained. The area of the LS and JV were measured using ImageJ software (NIH), and 
sections were graded for blood and protein accumulation in the LS using a scoring rubric. 
Blood and protein were graded as follows: 0 = no red blood cells (RBC); 1 = 3-10 RBC; 2 = 
3-50 RBCs; 3 = >50 RBCs; 0 = no protein; 1 = minimal protein accumulation; 2 = moderate 
protein accumulation; 3 = extensive protein accumulation. Brightfield images were taken on 
a Leitz Dialux 20 Micrscope. 
In vitro Migration and Proliferation Assays  
Scratch assay. CXCR7 knockdown (and negative control) LECs were grown to 
confluence and then scratched with a pipette tip.  LECs were rinsed with PBS to remove 
non-adherent cells and then treated in 0.5% FBS RPMI with vehicle or 10nM AM.  Four 
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fields per well were imaged at T=0 hrs and at T=18hrs post-scratch using an Olympus IX-81 
inverted microscope equipped with a QImaging Retiga 4000R camera at 4X magnification.  
The percent change in migration was calculated by measuring the open area of the scratch 
(ImageJ).  Results shown are representative of three independent experiments.  
 
Transwell migration assay. HEK293T cells transfected with expression plasmids and 
LECs with lentiviral induced CXCR7 knockdown were labeled with 5µM Cell Tracker Green 
(CTG) CMFDA (Life Technologies).  Cells (1x105) were treated with 10nM AM for 5 min and 
then seeded onto 8µm transwell inserts (BD Biosciences).  After 4 hour incubation, inserts 
were fixed with 4% PFA, and filters were mounted for analysis.  Quantification of 
transmigrated cells was done by measuring the threshold of CTG-labeled cell fluorescence 
using ImageJ (NIH). 
 
Proliferation. CXCR7 knockdown and scramble LECs were plated, serum starved for 
4 hours, then treated with 10nM AM for 24 hours. Cells counts were assessed using a 
Countess Automated Cell counter (Life Technology). 
Statistical Analysis 
Student’s two-tailed t test was used for all comparisons unless otherwise noted in the 
figure legend.  
Supplemental Experimental Procedures 
qRT-PCR of thoracic duct and vena cava 
RNA was isolated from the thoracic duct and vena cava of adult wildtype mice 
(Qiagen RNeasy Micro kit and Qiashredder). Quantitative RT-PCR was performed after 
reverse transcription of 2 µg of total RNA. Primer sequences for mCxcr7 amplication were 
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5’-GTCAGGAAGGCAAACCACAGC-3’ and 5’-AGGCTCTGCATAGTCAAACAAGTG-3’, and 
the probe sequence was 5’-FAM-GAAGCCCTGAGGTCACTTGGTCGCTC-TAMRA-3’. 
Gene Expression Analysis 
Quantitative RT-PCR was performed using primers and probes or hCXCR7 Assays 
on Demand (Life Technology) after reverse transcription of 2 µg of total RNA. . Primer 
sequences for hCXCR7 amplication were 5’-GCAGAGCTCACAGTTGTTGC-3’ and 
5’GCTGATGTCCGAGAAGTTCC-3’, and the probe sequence was 5’-FAM-
AGGTCATTTGATTGCCCGCCTCAGAA-TAMRA-3’. 
Immunohistochemistry 
Embryo sections and whole mount tissue were permeabilized, blocked with 5% 
normal donkey serum, and incubated overnight at room temperature with primary antibodies 
and incubated with appropriate secondary antibodies (1:200; Jackson ImmunoResearch 
Laboratories) and DAPI (1:1000; Sigma-Aldrich). Antibodies included rabbit anti-mouse 
adrenomedullin (1:100; Novus Biological); chicken anti-GFP (1:500, Aves Lab); rabbit anti-
mouse LYVE1 (1:600, Fitzgerald); Syrian hamster anti-mouse podoplanin (1:50; 
Developmental Studies Hybridoma Bank); rabbit anti-mouse pERK (1:1000, Cell Signaling); 
mouse anti-BrdU (1:200; Zymed Laboratories); rabbit anti-mouse Ki67 (1:200; Vector 
Laboratories), and rabbit anti-mouse Prox1 (1:100; Angiobio). For Ki67 and Prox1 staining, 
antigen retrieval with citrate buffer was performed prior to beginning staining protocol. 
Images were acquired on a Nikon E800 microscope (Nikon) with a Hamamatsu camera 
(Hamamatsu Photonics) with Metamorph software (Molecular Devices, Inc.). H&E staining 
was performed by UNC Histopathology Core.  
Bioluminescence Resonance Energy Transfer (BRET) 
BRET studies to test cAMP accumulation were carried out as described previously. 
Briefly, the calcium phosphate precipitation method was used to transfect HEK293 cells with 
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hCxcr7/hRAMP2, hCLR/hRAMP2 (positive control), and EPAC, a biosensor for cAMP 
accumulation. Cells were treated with the luciferase substrate coelenterazine H (Promega) 
for 10 min. Five minutes into coelentrazine H treatment, increasing doses of AM (American 
Peptide Company) were added. At 10 minutes post-coelentrazine H treatment, BRET signal 
was read using a Berthold Technologies Mithras LB940 plate reader. BRET signal was 
calculated as the ratio of light emitted from YFP (530 nm) to light emitted from RLuc 
(485 nm). YFP/RLuc ratios of PBS-treated cells were used to control for baseline cAMP 
accumulation. Results were analyzed using GraphPad Prism. Results shown are 
representative of at least 3 replicate BRET experiments. 
Whole mount immunohistochemistry 
Whole mount heart. Cardiac tissue was carefully removed from fixed embryos and 
fixed again in 4% PFA for 4 hours at RT. Hearts were permeabilized in PBST (0.1% Triton in 
PBS) at 4oC overnight, washed (5’ in PBST, 5’ in H2O, 7’ in acetone at -20oC, 5’ H2O, and 5’ 
in PBST) and were blocked in 5% normal donkey serum at 4oC overnight. Samples were 
then incubated in primary antibody (LYVE1 - 1:200) for 5 days. Hearts were washed and 
blocked in 5% normal donkey serum (1.5 hours) and incubated in secondary antibody for 48 
hours at 4oC.  
 
Whole mount skin – P1. Skin was removed from the back of P1 pups, submerged in 
20 mM EDTA, and heated in a 37oC oven for 3 hours to remove epidermis. Skin was fixed 
overnight, incubated with LYVE1 and pERK antibodies, and analyzed for ERK 
phosphorylation and vessel morphology. A branch point is defined as a vessel with 3 
vessels branching away. A lacuna is defined as a space where 3 or more branch points 
coallesced. 
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Whole mount skin – e13.5. Skin was removed from e13.5 embryos as previously 
described (James et al., 2013). Briefly, dorsal skin was carefully removed from fixed e13.5 
embryos and blocked in 10% NDS for 2 hours at RT. Samples were then incubated in 
primary antibody overnight at 4oC. Samples were washed, incubated in secondary antibody 
at RT for 1 hour, and whole mounted on glass slides with ProLong Gold (Life Technologies). 
Images were acquired on a Nikon E800 microscope (Nikon) with a Hammamatsu camera 
(Hamamatsu Photonics) with Metamorph software (Molecular Devices, Inc.). 
Scavenger assay and ERK phosphorylation in LECs 
Scavenger Assay. Control LECs and LECs with lentiviral induced CXCR7 knock-
down were treated with biotinylated-AM (Phoenix Pharmaceuticals), and aliquots of media 
were collected over 8 hours. Biotinylated-AM was detected with IRDye Streptavidin (1:2500, 
Li-COR, Lincoln, Nebraska USA). Results shown are representative of at least three 
separate experiments. 
 
ERK phosphorylation in LECs. Control LECs and LECs with lentiviral induced 
CXCR7 knock-down were serum starved in 0.5% FBS for 16 hours with or without 10nM 
AM. Cells were then treated with vehicle or 10nM AM for 15 minutes. Blots were blocked in 
5% BSA, probed overnight with monoclonal rabbit anti-mouse pERK and tERK (1:1000, Cell 
Signaling), and monoclonal mouse anti-GAPDH (1:2000, Novus Biological), incubated in 
appropriate secondary antibody, and then imaged on the Odyssey scanner (Li-COR). A blot 
with 3 independent experiments run on the same gel was used to perform statistical 
analysis. 
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In vivo proliferation  
Lymphatic endothelial cell proliferation. Paraffin sections of e13.5 embryos were 
stained for Ki67 and podoplanin. Podoplanin+ and Ki67+ cells were counted and normalized 
to total number of DAPI cells in the lymph sac to determine percent proliferation. 
Cardiac proliferation. Two hours prior to dissection, pregnant females were injected 
intraperitoneally with BrdU (1 mg/g of BW, Sigma-Aldrich). At e11.5, embryos were carefully 
dissected and genotypes were determined from DNA extracted from the tail. Paraffin 
sections of the heart were stained for BrdU, and percent proliferation was determined by 
quantitation of BrdU+ cells normalized to total number of cells.  
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FIGURES 
 
 
Figure 2-A1. Graphical Abstract 
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Figure 2-1. CXCR7 scavenges AM, dampens AM-mediated ERK phosphorylation in 
vitro, and reduces AM peptide levels in vivo. 
(A) Cxcr7 expression in cardiac tissue of Adm+/+ and Admh/hi mice (n=6) and isolated 
endothelial cells of Adm+/+ and Adm-/- mice (n=3) 
(B) The nine most significantly upregulated and four most significantly downregulated genes 
in human LECs (hLECs) treated with 10nM AM for 1 hour. 
(C) CXCR7 expression in vehicle and 10nM AM treated hLECs at 15m, 1h and 24h, and 
AM22-52, AM, and (AM22-52+AM) for 4 hr. 
(D) Representative western blots probed for biotin and (E) quantitation of biotinylated-AM1-52 
depletion over 8 hours by either CXCR7 or EV expressing cells in three independent 
experiments.  
(F,G) Cxcr7 and AM staining in e13.5 Cxcr7-/- cardiac tissue with epicardial colocalization 
(white arrows). 
(H,I) AM staining of e13.5 Cxcr7+/+ and Cxcr7-/- cardiac tissue. White arrows highlight 
epicardium, CZ identifies the compact zone, and white arrowheads highlight the cardiac 
trabeculae. Images were obtained at the same exposure and the amount of AM expressed 
in the three regions of the heart was assessed by measuring the integrated density of 
staining using Image J software (n=3-5). Scale bars, 100 µM.  
(J-L) Quantitation of AM staining intensity in Cxcr7+/+ (n=3) vs. Cxcr7-/- (n=5) animals in 3 
regions of the heart, trabeculae, epicardium, and compact zone. Staining intensity is 
expressed as arbitrary units of integrated density measured by ImageJ.   
(M) Representative western blot and (N) quantitation of change in pERK:tERK between 
vehicle and 10nM AM treated CXCR7-, CLR/R2-, and CLR/R2+CXCR7-expressing 
HEK293T. Quantitation was calculated using 3 independent experiments run on the same 
gel.  
In (A-L), data are represented as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001.  
See also Figures 2-S1, 2-S2, and Table 2-S1. 
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Figure 2-2. Cxcr7 is dynamically expressed in lymphatic endothelium during 
development. 
(A-C) Cxcr7 and LYVE1 colocalize in the JV of e11.5 Cxcr7+/-  animals. 
(D-F) Higher magnification of the LYVE1 positive portion of the JV. White arrows highlight 
areas of Cxcr7 and LYVE1 colocalization. Asterisk highlights migrating LYVE1 positive, 
Cxcr7 negative cells. 
(G-I) Cxcr7 and Prox1 colocalize in the JV of e11.5 Cxcr7+/- animals. Asterisks highlight 
migrating Prox1 positive, Cxcr7 negative cells LECs. 
(J-O) Cxcr7 and lymphatic markers (J, podoplanin; M, LYVE1) colocalize in the LS (white 
arrows) of e11.5 (J-L) and e13.5 (M-O) Cxcr7+/- animals.  
(P-R) Cxcr7 is also expressed in cells of the JV directly adjacent to the LS. White 
arrowheads highlight Cxcr7 expression in the JV. Scale bars, 50 µM.  
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Figure 2-3. Cxcr7-/- embryos have enlarged blood filled lymphatic sacs and interstitial 
edema.  
(A-C) Some Cxcr7-/- embryos exhibit interstitial edema at e13.5 (white (A) and black (C) 
arrows).  
(D-F) Cxcr7-/- embryos exhibit enlarged lymph sacs filled with blood (asterisks) and 
proteinaceous deposits (arrowheads) at e13.5.  
(F) In some Cxcr7-/- embryos, the LS fails to separate from the JV properly. Platelet thrombi 
are highlighted by arrowheads.  
(G-I) Quantitation of the LS:JV ratio (t test) and blood and protein accumulation (Mann-
Whitney U test) in the LS of Cxcr7-/- embryos (n=10) compared to wildtype controls (n=5). A 
detailed description of the scoring rubric is provided in the methods section. Data are 
represented as mean ± SEM. *p<0.05, **p<0.01.  
See also Figure 2-S3. 
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Figure 2-4. Loss of CXCR7 enhances cardiac lymphangiogenesis by promoting AM-
mediated cellular migration.  
(A) View of ventral side of whole mount hearts of e18.5 embryos stained with the lymphatic 
marker LYVE1.  
(B,C) Quantitation of LYVE1 staining normalized to surface area (B) and LEC migration 
down the apex of the hearts (C) (n=3).  
(D) CXCR7 knockdown in LECs by two shRNA lentiviral constructs.  
(E-H) Control or CXCR7 knockdown LECs treated with vehicle (E,F) or 10nM AM at 18 hrs 
(G,H). Migration from the time of scratch (T=0) was measured. Scale bars,100 µM.  
(I) Quantitation of LEC migration in CXCR7 knockdown and control LECs.  
(J,K) Quantitation of transwell migration of CXCR7 knockdown LECs treated with vehicle or 
10nM AM (J), and empty vector (EV), CXCR7-, CLR/R2-, and CLR/R2+CXCR7-expressing 
HEK293T cells treated with 10nM AM.  
Data are represented as mean ± SEM. *p<0.05, **p<0.01. 
See also Figure 2-S4 and 2-S5. 
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Figure 2-5. Loss of CXCR7 causes enlarged dermal lymphatics with decreased 
branching complexity in vivo and enhances LEC proliferation in vitro.  
 (A,B) Cxcr7-/- P1 skin (n=5) exhibit dysmorphic dermal lymphangiogenesis compared to 
controls (n=4). White asterisks identify a lacuna; yellow dots highlight branch points.  Scale 
bars, 50 µM.  
(C,D) Quantitation of the number of lacunae and branch points respectively. Fewer lacunae 
and decreased branching complexity were observed in Cxcr7-/- animals. A branch point is 
defined as a vessel with 3 vessels branching away. A lacuna is defined as a space where 3 
or more branch points coallesce.  
(E-H) Skin of e13.5 Cxcr7-/- embryos. Scale bars, 50 µM. 
(I-J) Lymphatic vessels of P1 Cxcr7-/- embryos are dilated, with increased junctional area 
where vessels coalesce to form a branch point. Yellow dashed and straight line in (G,H) 
represent the vessel diameter and junctional area, respectively, measured in P1 skin. 
(K) Quantitation of LEC proliferation after a 24h treatment with 10nM AM.  
In (A-K), data are represented as mean ± SEM. *p<0.05, **p<0.01. See also Figure 2-S6. 
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 Figure 2-6. Genetic titration of Adm influences Cxcr7-/- phenotypes. 
(A-B) Schematic of Adm genetic reduction experiment with expected and observed 
Mendelian ratios. Cxcr7+/-;Adm+/- mice were bred with Cxcr+/-;Adm+/+ mice, resulting in the 
following expected distribution: 25% Cxcr7+/+, 50% Cxcr7+/-, and 25% Cxcr7-/- with 50% of 
each Cxcr7 genotype being AM heterozygous. Observed number of animals was statistically 
different from expected as judged by a chi-squared test (p=0.02). 
(C-D) Schematic of Adm genetic increase experiment with expected and observed 
percentage of survival of animals, n = 85. Observed number of animals (including 
resorptions) was statistically different from expected as judged by a chi-squared test 
(p=0.001). 
(E-H) Representative images of JV and LS of e13.5 embryos from the gene reduction 
experiment stained for podoplanin and Ki67. Scale bars, 100 µM. 
(I) Quantitation of the LS:JV ratio in e13.5 embryos (n= 4-8 for each genotype)..  
(J) Percent proliferating cells in the LS (n= 4-8 for each genotype). 
Data are represented as mean ± SEM. *p<0.05, **p<0.01 (One-way ANOVA).  
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Figure 2-7. Genetic reduction of AM normalizes Cxcr7-/-  cardiac proliferation and size.  
(A-G) (A,C,E,G): BrdU staining of cardiac tissue of e11.5 embryos from the gene titration 
experiment. Exposure, 750 ms. Scale bars, 100 µM. (B,D,F,H): Arrows highlight proliferating 
epicardium, and arrowheads highlight proliferating endocardium. Exposure, 250 ms. Scale 
bars, 100 µM. 
(I) Percent proliferating cardiac cells in embryos from genetic reduction experiment. (n=3-5 
for each genotype). Data are represented as mean ± SEM. *p<0.05 (One-way ANOVA). 
(J-L) H&E-stained cardiac tissue of e13.5 animals from the genetic reduction experiment. 
(n=3-5 for each genotype). Scale bars, 100 µM. 
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 Figure 2-S1. Supplemental data related to Figure 2-1  
(A) Cxcr7 expression has been established in normal and pathologic blood vasculature 
[54,55]. To assess whether Cxcr7 is expressed in adult lymphatic tissue, we compared 
mRNA expression in the vena cava and the thoracic duct. Although we observed a trend for 
increased expression in the thoracic duct compared to vena cava, this did not reach 
statistical significance. Data are represented as mean ± SEM. (B) CXCR7-expressing cells 
do not elicit canonical AM-mediated signal. CLR/R2 expressing HEK293T cells exhibit a 
robust accumulation of cAMP with increasing concentrations of AM treatment. CXCR7-
expressing cells, however, do not elicit the same upregulation of cAMP. (C) Quantitation of 
pERK blot in Figure 2-1M. This graph represents the integrated density of the 
representative blot, whereas Figure 2-1N represents quantitation of the change in pERK 
from baseline levels of each condition in three independent experiments. 
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Figure 2-S2. LYVE1 and pERK colocalize in lymphatic vessels from Cxcr7-/- mice 
(related to figure 2-1).  
(A, B) Minimal colocalization of LYVE1 (red) and pERK (green) was observed in lymphatic 
vessels (white arrows) from the skin of Cxcr7+/+ mice. (C, D) LYVE1 (red) and pERK (green) 
staining of skin from Cxcr7-/- mice showed colocalization of pERK in lymphatic vessels (white 
arrows). Average integrated density of pERK in LYVE1 positive vessels of Cxcr7+/+ and 
Cxcr7-/- tails was 102762 and 181768, respectively. (E-J) Podoplanin and pERK staining in 
the JV and LS of Cxcr7+/+ mice (E-G) and Cxcr7-/- mice (H-J). Average integrated density of 
pERK in LYVE1 positive vessels of Cxcr7+/+ and Cxcr7-/- tails was 87231 and 95660, 
respectively. The increase of pERK in the LS of Cxcr7-/- embryos was statistically significant, 
p<0.05 (n=3). 
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Figure 2-S3. Cxcr7-/- mice have normal lymphovenous valves and precocious 
lymphatic development (related to figure 2-3). (A, B) e13.5 Cxcr7+/+ and Cxcr7-/- embryos 
were frontally sectioned and stained with Prox1 and podoplanin. Prox1 highlights the 
lymphovenous valves (LVV) (white arrows). Cxcr7-/- embryos exhibit structurally normal LVV. 
Abbreviations: Internal Jugular Vein (IJV), Subclavian Vein (SCV). (C, D, E) JV and LS of 
Cxcr7+/+, Cxcr7-/-, and Cxcr7-/-;Admhi/hi  at e11.5 stained with lymphatic markers. Sections 
from (C, D) were stained with LYVE1 and (E) was stained with Prox1 and podoplanin. 
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Figure 2-S4. Cxcr7-/- embryos have more cardiac lymphatics with decreased 
branching complexity (related to figure 2-4). (A) Dorsal side of whole mount heart of 
Cxcr7+/+ embryos. (B) Higher magnification of cardiac lymphatic vessels shows the classical 
honeycomb patterning of lymphatic vessels in Cxcr7+/+ embryos. (C) Dorsal side of whole 
mount heart of Cxcr7-/- embryos. White arrows emphasize an extensive network of vessels 
on the outflow tract of the dorsal side of the heart that is not present in wildtype littermates. 
(D) Higher magnification of Cxcr7-/- embryos highlights the decreased lymphatic vessel 
branching complexity. (E, F) Quantitation of the number of branch points and lacunae in the 
cardiac lymphatics. Data are represented as mean ± SEM. *p<0.05. 
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Figure 2-S5.  Loss of CXCR7 affects AM-signaling in LECs (related to figure 2-5). (A, B) 
Western blot probed for biotin (A) and (B) quantitation of biotinylated-AM depletion over 6 
hours by either control or CXCR7 shRNA infected LECs. (C) Western blot analysis for pERK 
and total ERK of control or CXCR7 shRNA LECs treated with or without 10nM AM. 
Integrated density of the pERK/tERK ratio normalized to vehicle treated control cells is 
included below each blot. 
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Figure 2-S6.  Cxcr7 is stochastically expressed in dermal lymphatic vessels (related 
to figure 2-5). LECs in the skin of P1 Cxcr7-/- pups reveal stochastic Cxcr7 expression, with 
high expression in dermal LECs and low expression in valve associated LECs. Gray arrows 
highlight the dermal lymphatic endothelial cells that express Cxcr7. 
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TABLES 
 
Table 2-S1. List of genes significantly changed following 1-hour AM treatment as 
identified by SAM plot (related to figure 1). 
(A)  List of genes up-regulated by 1-hour AM treatment 
 (B) List of genes down-regulated by 1-hour AM treatment 
   (A) List of up-regulated genes 
  
Gene name 
Fold 
change 
p-value 
NR4A1, Homo sapiens nuclear receptor subfamily 4, group 
A, member 1 2.6424 1.94E-07 
[NM_002135] 
RGS2, Homo sapiens regulator of G-protein signaling 2, 
24kDa [NM_002923] 
2.1247 4.23E-06 
NR4A3, Homo sapiens nuclear receptor subfamily 4, group 
A, member 3 2.6826 1.32E-06 
[NM_173198] 
NR4A2, Homo sapiens nuclear receptor subfamily 4, group 
A, member 2 [NM_006186] 
2.9876 2.12E-05 
PDE4B, Homo sapiens phosphodiesterase 4B, cAMP-
specific [NM_001037341] 
1.3623 7.27E-09 
CMKOR1, Homo sapiens chemokine orphan receptor 1  
1.4342 2.50E-07 
[NM_020311] 
DUSP2, Homo sapiens dual specificity phosphatase 2 
1.4347 8.57E-05 
[NM_004418] 
APOLD1, Homo sapiens apolipoprotein L domain containing 
1 1.4654 1.71E-06 
[NM_030817] 
DUSP1, Homo sapiens dual specificity phosphatase 1 
1.3383 4.33E-05 
[NM_004417] 
ENST00000339446, Homo sapiens hypothetical 
LOC387763 1.255 2.22E-05 
[BC052560] 
KLF4, Homo sapiens Kruppel-like factor 4 (gut)  
1.2567 5.44E-06 
[NM_004235] 
SNF1LK, Homo sapiens SNF1-like kinase 
1.2964 3.50E-05 
[NM_173354] 
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ARRDC2, Homo sapiens arrestin domain containing 2  
1.2455 3.35E-04 
[NM_015683] 
SNF1LK, Homo sapiens SNF1-like kinase  
1.3703 3.50E-05 
[NM_173354] 
SOCS3, Homo sapiens suppressor of cytokine signaling 3 
1.2624 8.57E-05 
[NM_003955] 
ENST00000382611, Homo sapiens homeodomain protein 
IRXA2  [AY335940] 
1.9381 8.47E-04 
ZNF331, Homo sapiens zinc finger protein 331 
1.3533 4.47E-05 
[NM_018555] 
PDE4B, Homo sapiens phosphodiesterase 4B, cAMP-specific 
(phosphodiesterase E4 dunce homolog, Drosophila)  1.4349 8.40E-05 
[NM_002600] 
CHMP1B, Homo sapiens chromatin modifying protein 1B 
1.2214 5.64E-05 
[NM_020412] 
ARRDC2, Homo sapiens arrestin domain containing 2  
1.2606 3.35E-04 
[NM_015683] 
A_23_P170719, Unknown 1.198 1.25E-05 
CEBPB, Homo sapiens CCAAT/enhancer binding protein 
1.2139 1.57E-04 
[NM_005194] 
ANKRD37, Homo sapiens ankyrin repeat domain 37  
1.2633 8.84E-04 
[NM_181726] 
ZNF336, Homo sapiens zinc finger protein 3d36  
  
[NM_022482] 1.3356 1.48E-04 
FGF18, Homo sapiens fibroblast growth factor 18 
1.3489 6.46E-04 
[NM_003862] 
LOC388796, Homo sapiens hypothetical LOC388796  
1.3243 1.36E-04 
[BC012894] 
CA2, Homo sapiens carbonic anhydrase II  
1.3348 3.77E-04 
[NM_000067] 
CXCR4, Homo sapiens chemokine (C-X-C motif) receptor 4 
1.151 1.15E-05 
[NM_001008540] 
DLL1, Homo sapiens delta-like 1 (Drosophila) 
1.4976 8.51E-04 
[NM_005618] 
ZNF336, Homo sapiens zinc finger protein 336  
1.2056 1.48E-04 
[NM_022482] 
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HLX1, Homo sapiens H2.0-like homeobox 1  
1.2093 3.27E-04 
[NM_021958] 
CREM, Homo sapiens cAMP responsive element modulator 
1.1368 1.23E-05 
[NM_183013] 
KIAA1754, Homo sapiens KIAA1754  
1.1962 2.20E-04 
[NM_033397] 
CH25H, Homo sapiens cholesterol 25-hydroxylase 
1.2775 3.60E-03 
[NM_003956] 
CEBPD, Homo sapiens CCAAT/enhancer binding protein 
(C/EBP) 1.184 3.73E-04 
[NM_005195] 
TLR5, Homo sapiens toll-like receptor 5 (TLR5) 
1.3429 3.46E-04 
 [NM_003268] 
DUSP2, Homo sapiens dual specificity phosphatase 2 
1.2846 2.97E-03 
[NM_004418] 
ANGPTL4, Homo sapiens angiopoietin-like 4 
1.2242 9.94E-04 
[NM_139314] 
NPTX1, Homo sapiens neuronal pentraxin I 
1.3154 6.86E-03 
[NM_002522] 
IER5L, Homo sapiens immediate early response 5-like 
1.1414 7.92E-05 
[NM_203434] 
PPEF1, Homo sapiens protein phosphatase, EF-hand calcium 
binding domain 1 1.2762 5.19E-04 
[NM_006240] 
GRPEL2, Homo sapiens GrpE-like 2, mitochondrial  
(E. coli) 1.133 1.51E-04 
[NM_152407] 
THC2279735, Unknown 1.2208 1.00E-03 
ZNF331, Homo sapiens zinc finger protein 331 
1.278 4.47E-05 
[NM_018555] 
KIAA0423, Homo sapiens KIAA0423 
1.5619 6.46E-03 
[NM_015091] 
NXT1, Homo sapiens NTF2-like export factor 1 
1.0935 7.95E-06 
[NM_013248] 
F2RL3, Homo sapiens coagulation factor II (thrombin) 
receptor-like 3 [NM_003950] 
1.2219 1.32E-03 
INHBB, Homo sapiens inhibin, beta B (activin AB beta 
polypeptide) [NM_002193] 
1.1954 3.68E-03 
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LOC645294, PREDICTED: Homo sapiens similar to 
RIKEN cDNA 0610013E23 
1.3022 1.53E-03 
[XM_928339]     
MYOG, Homo sapiens myogenin (myogenic factor 4) 1.5228 1.67E-03 
[NM_002479]     
EFNA1, Homo sapiens ephrin-A1  
  
[NM_004428] 1.1123 1.91E-04 
IL8, Homo sapiens interleukin 8  1.1918 1.00E-03 
[NM_000584]     
CBX4, Homo sapiens chromobox homolog 4 (Pc class 
homolog, Drosophila) [NM_003655] 
1.1702 3.77E-03 
DCP_20_3 1.1493 1.31E-03 
XYLT1, Homo sapiens xylosyltransferase I  1.7128 6.21E-03 
[NM_022166]     
C8orf4, Homo sapiens chromosome 8 open reading frame 
4 
1.1377 2.06E-04 
[NM_020130]     
DERL3, Homo sapiens Der1-like domain family, member 
3 
1.2285 1.04E-03 
[NM_198440]     
KIAA1833, Homo sapiens cDNA FLJ42560 fis, clone 
BRACE3006462. [AK124551] 
1.4009 4.04E-03 
GRASP, Homo sapiens GRP1 (general receptor for 
phosphoinositides 1)-associated scaffold protein 
1.1128 1.33E-04 
[NM_181711]     
DTNA, Homo sapiens dystrobrevin, alpha 1.3919 2.30E-03 
[NM_001390]     
KBTBD11, Homo sapiens kelch repeat and BTB (POZ) 
domain containing 11 [NM_014867] 
1.1259 1.55E-03 
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(B) List of Downregulated Genes     
Gene name 
Fold 
change 
p-value 
C10orf10, Homo sapiens chromosome 10 open 
reading frame 10 0.5952 3.69E-07 
[NM_007021] 
RGS16, Homo sapiens regulator of G-protein 
signalling 16 0.5665 1.41E-05 
[NM_002928] 
BC069781, Homo sapiens cDNA clone 
IMAGE:7262583, with apparent retained intron.  0.60333 1.16E-04 
[BC069781] 
RGS16, Homo sapiens regulator of G-protein 
signaling 16 0.58789 7.88E-05 
[NM_002928] 
ADM, Homo sapiens adrenomedullin 
0.85697 8.66E-06 
[NM_001124] 
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Chapter 3: Conclusions and Future Directions 
 
Summary of Results  
We have demonstrated that the decoy receptor CXCR7 (ACKR3) is required as a 
molecular rheostat for controlling the concentration of AM ligand during cardiac and 
lymphatic vascular development. Classical scavenging assays and western blot revealed 
that CXCR7-expressing cells are capable of binding and decreasing AM-mediated 
downstream signaling. Consistently, immunohistochemical staining of Cxcr7-/- mouse tissue 
indicated increased AM and pERK staining compared to wildtype controls, suggesting that, 
in the absence of CXCR7, AM scavenging is disrupted in vivo. 
 Immunohistochemistry of developing lymph sacs established that CXCR7 is 
dynamically expressed in the lymphatic progenitors and early lymphatic vessels during 
embryonic lymphangiogenesis. Importantly, the spatiotemporal expression of Cxcr7 
coincided with AM activity. In contrast to Adm-/- animals, which exhibit small, hypoplastic 
lymph sacs, Cxcr7-/- mice displayed the reciprocal phenotype of enlarged, hyperplastic, 
blood and protein filled lymph sacs. Enhanced cardiac and dermal lymphangiogenesis was 
also observed. Though lymphatic vessel expression of Cxcr7 was stochastic, blood vessel 
expression was consistent. We therefore concluded that CXCR7 affects lymphangionesis in 
both a cell autonomous and non-cell autonomous fashion. 
Finally, we have shown that the cardiac hyperplasia and lymphatic phenotypes 
observed in Cxcr7-/- animals were causally associated with AM ligand concentration. Using a 
genetic approach, we generated gene-targeted mice onto a titrated background of AM 
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ligand that ranged from 50% to 300% of wildtype levels. Haploinsufficiency of Adm improved 
survival of Cxcr7-/- mice, whereas Adm overexpression resulted in significantly decreased 
survival. Additionally, while Adm overexpression exacerbated lymphatic phenotypes, 
haploinsufficiency of Adm was fully sufficient to rescue the cardiac and lymphatic 
hyperplasia. 
Collectively, the findings presented in Chapter 2 clarify the interaction between 
CXCR7 and AM and identify a novel role for the decoy receptor during lymphangiogenesis. 
To our knowledge, these data are the first to identify an atypical chemokine receptor as a 
modulator of lymphatic vascular development. As such, they offer a new conceptual 
paradigm about how growth factors gradients can be controlled during cardiovascular 
development. 
Current State of the Field – AM, decoy receptors, and lymphangiogenesis 
 Our studies have identified a role for the decoy receptor CXCR7 during 
developmental lymphangiogenesis. However, much remains to be learned about how this 
and other atypical chemokine receptors affect lymphatic vasculature during normal and 
disease states. Additionally, the study of the contribution of the lymphatic system to human 
pathophysiology is a relatively nascent field [1]. However, data are emerging that implicate 
the lymphatic vasculature in common diseases, and consequently, the field is expanding. A 
few relevant and interesting areas of research are highlighted below. 
AM and developmental lymphangiogenesis 
The importance of AM during developmental lymphangiogenesis has been 
appreciated for nearly a decade, and our results emphasized that precise dosage of this 
peptide hormone is essential. Our study also suggests that atypical chemokine receptors 
play a prominent role in the development of the lymphatic vasculature.  
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Current dogma indicates that lymphatic vessels originate exclusively from venous 
sprouts [2]. However, recent data has demonstrated that a significant portion of the dermal 
lymphatic vasculature forms from a non-venous origin [3]. The identity of the progenitors that 
give rise to dermal LECs is unknown, and the molecular mechanisms and lymphangiogenic 
factors that dictate their migration and proliferation have not been elucidated. Interestingly, a 
significant portion of the dermal lymphatic vessels of mice lacking Ramp2, an essential 
component of the AM-signaling complex, was observed to be normal, suggesting that the 
early development of these vessels does not require AM-signaling [4]. These data indicate 
that non-venous dermal LECs may behave differently than their venous-derived counterpart. 
Future research is necessary to characterize these LECs and help determine if known 
lymphangiogenic factors, like AM and CXCR7, participate in such ‘lymphvasculogenesis’ [3]. 
AM and lymphatics in the clinical setting 
Roles also exist for AM outside of embryogenesis. A detailed discussion of current 
knowledge regarding the role of AM in lymphatic vasculature is presented in Chapter 1. 
Recently, our group has discovered that AM is important for maintenance of adult lymphatic 
vessels [5]. Loss of AM-signaling during adulthood disrupts fat metabolism, results in ocular 
edema, and recapitulates the clinical symptoms of multi-organ lymphangiectasia. Whether 
this phenomenon depends on precise dosage of AM ligand is unknown. Future studies will 
aim to determine whether loss of the decoy receptor CXCR7 in adulthood affects lymphatic 
homeostasis in adulthood. These and future research are significant as the AM signaling 
system is among the most pharmacologically-tractable molecular players that regulate 
lymphangiogenesis and have potential for use in the clinic. 
 Lymphatics and Lipid Metabolism. In the past decade and a half, we have learned 
that the lymphatic vasculature plays critical roles not only in fluid homeostasis, but also in 
lipid metabolism and immune defense [6].  The lymphatic vasculature within the intestinal 
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villi (lacteals) absorbs and delivers chylomicrons to the bloodstream [7,8]. Several groups 
have demonstrated that disruption of the lacteals results in dysregulated fat metabolism. 
Mice heterozygous for Prox1, a transcription factor that is considered the master-regulator of 
lymphatic fate, exhibit leaky lymphatic vessels and develop adult-onset obesity and 
inflammation [9]. In contrast, while they also develop leaky lymphatic vessels, conditional 
Calcrl-/- mice fail to match weight gain of their wildtype controls [5]. Whereas Prox1+/- mice 
absorb fat but have dysregulated fat deposition, conditional Calcrl-/- mice exhibit lipid 
malabsorption. As both of these phenotypes are attributed to the permeability of vessels, 
these data suggest that additional mechanisms contribute to lipid absorption by the intestinal 
lymphatics. As such, several research groups are actively trying to understand the interplay 
between the lymphatic vasculature and lipid metabolism [7,10]. It will be interesting to 
determine whether polymorphisms in lymphatic associated genes are associated with either 
leanness or obesity. Moreover, as obesity continues to be a major health issue, there will be 
much interest in determining whether targeting the intestinal lymphatics for the treatment of 
weight disorders is feasible. The AM-system, which contains two pharmacologically tractable 
GPCRs in CLR and CXCR7 may prove to be a promising drug target. 
AM, CXCR7, and lymphangiogenesis in cancer. Tumor lymphangiogenesis has also 
received significant attention as it has become clear that lymphatic vessels and 
lymphangiogenic growth factors contribute to promoting cancer metastasis [11].  Several 
studies in the early 2000s revealed vascular endothelial growth factor C and D (VEGF-C 
and VEGF-D) increased tumor lymphangiogenesis and facilitated lymph node metastasis 
[12-14]. Examination of human cancers confirmed a positive correlation between tumor-
induced lymphangiogenesis, lymphangiogenic factors, and the poor prognosis associated 
with lymph node metastasis [11,15]. As such, a major focus of the lymphatic field is to 
identify the molecular players and mechanisms by which metastases utilize lymphatic 
transport.  
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VEGF-C, its receptors, and additional molecules including AM have been shown to 
promote lymphatic associated metastasis [16]. Gene-titration studies in Lewis lung 
carcinoma (LLC) cells revealed that AM leads to distant metastasis by stimulating 
lymphangiogenesis [16]. LLCs that overexpress AM increase lymphatic proliferation, dilation 
and result in increases in metastasis to the lung compared to wildtype LLCs. Karpinich and 
colleagues have further established that AM enhances gap junction coupling, which 
facilitates transendothelial migration of tumor cells [17]. Inhibition of intracellular gap junction 
communication prevented tumor cell migration through LECs. The impact of CXCR7 on AM-
mediated tumor cell migration remains to be addressed.  
Several groups have shown that CXCR7 promotes tumor growth and metastasis [18-
20]. These reports are perhaps counter to what would be expected from the described role 
of CXCR7 as an AM-decoy receptor. In its role as AM scavenger, one might speculate that 
overexpression of CXCR7 would decrease AM-signaling, thereby decreasing metastasis. 
However, it has become clear that the cellular milieu impacts CXCR7 behavior dramatically. 
For example, while CXCR7 is generally thought not to stimulate intracellular signaling, 
recent reports demonstrate that it does couple to G proteins in astrocytes [21]. It is possible 
that in tumor cells CXCR7 functions as a signaling AM receptor (a potential mechanism for 
this will be addressed extensively in Part II of the dissertation), or that its interaction with 
other peptides overwhelms its ability to modulate AM signaling. Additionally, as AM is often 
highly expressed in tumors, the capacity of CXCR7 to downregulate AM-signaling may be 
diminished.  
Decoy Receptors, Macrophages, and Lymphangiogenesis 
Shortly after our work was published, a second atypical chemokine receptor was 
identified to modulate lymphangiogenesis. Mice lacking ACKR2, a CCL2 chemokine 
receptor primarily expressed on the lymphatic endothelilum [22], exhibit increased lymphatic 
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density [23]. Conversely, mice deficient for the CCL2 signaling receptor CCR2 exhibit 
increased lymphatic density. Misregulation of prolymphangiogenic macrophages in the 
absence of these receptors is responsible for these reciprocal phenotypes. Loss of the 
scavenging receptor ACKR2 results in increased macrophage recruitment to the developing 
vessel network, whereas CCL2-deficient mice have decreased pro-lymphangiogenic 
macrophages and a lower concentration of lymphangiogenic factors.  These findings nicely 
complement our studies as they identify a second GPCR that regulates pro-
lymphangiogenic factor gradients. Here, rather than controlling the ligand concentrations, 
ACKR2 controls macrophage recruitment.  
Two potential mechanisms may explain how macrophages contribute to post-natal 
lymphangiogenesis: (1) they can serve as a source of VEGF-C, which stimulates LEC 
proliferation and migration and (2), macrophages can transdifferentiate into LECs and 
integrate into developing lymphatic capillaries [24]. First discovered in association with 
tumors, pro-lymphangiogenic macrophages, once stimulated, release VEGF-C and VEGF-D 
to facilitate tumor lymphangiogenesis and lymph node metastasis [25]. During inflammation-
induced lymphangiogenesis, circulating macrophages start to express lymphatic markers 
and are incorporated into lymphatic vessels [26]. In a corneal wounding model, 
lymphangiogenesis was abrogated with pharmacological depletion of macrophages, 
suggesting that macrophages play a central role in neolymphangiogenesis [27].  
As such, it is possible that modulation of the lymphangiogenic activity of 
machrophages may prove useful in disease states. Inhibition of pro-lymphangiogenic 
macrophages may offer potential to prevent tumor-associated lymphangiogenesis and 
subsequent metastasis. Additionally, autoimmune disorders, such as inflammatory bowel 
disease and diabetes, where aberrant lymphangiogenesis contributes to excessive 
inflammation, may improve with inhibition of neolymphangiogenesis. As many studies have 
indicated that macrophages migrate towards and express AM, pharmacological inhibition of 
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AM may have potential as a therapeutic target [25,28-30]. Further research in this arena is 
warranted. 
Novel Roles for the Lymphatic Vasculature 
 Lymphatic vasculature has newly recognized regulatory roles in physiology. The 
discovery that dermal neolymphangiogenesis is required for electrolyte and blood pressure 
homeostasis has challenged the long-held notion that renal electrolyte elimination is 
sufficient for control of systemic pressure [31]. Interestingly, macrophages attracted to the 
dermis respond to high salt load by expressing the transcription factor TonEBP, a specific 
membrane “osmomemeter”, which activates the VEGF-C promoter in macrophages [1,32]. 
Macrophage stimulated neolymphangiogenesis enhanced electrolyte clearance. Inhibition of 
macrophage recruitment or VEGF-C trapping inhibited this novel lymphatic vessel formation 
and increased sensitivity to dietary sodium, resulting in increased salt loading and 
hypertension [1,31].  
 Recent publications indicate a role for lymphatics in the eye, previously thought to be 
free of lymphatic vessels [33]. Two groups showed that the cells of Schlemm’s canal, a 
specialized vascular structure that drains aqueous humor, achieve a lymphatic-like 
phenotype [34,35]. This lymphatic reprogramming is necessary to maintain drainage through 
Schlemm’s canal. Suppressing these “lymphatic-fated” or “lymphatic-like” cells can lead to 
increased intraocular pressure and potentially glaucoma. These newly identified lymphatic-
like cells not only provide a potential clinical target for the treatment of glaucoma, but also 
suggest that vessels can adopt a hybrid fate.  
Ongoing work in our lab supports this concept, as we have begun to identify 
lymphatic-fated cells in the spiral arteries of the placenta – a tissue where both AM and 
CXCR7 are highly expressed. Here, the spiral arteries remodel to ensure proper blood flow 
to the developing fetus [36]. In accordance with our preliminary data that cells of the spiral 
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arteries turn on LEC markers such as Prox1 and Vegfr3, we hypothesize that, like the cells 
of Schlemm’s canal, these cells become lymphatic-fated. Future work will aim to address 
whether the AM-signaling system governs this lymphatic reprogramming.  
Future Directions  
 The data presented in Part I identify a role for decoy receptors as modulators of the 
timing and extent of GPCR-mediated signaling during cardiovascular development and 
identified a means for the mechanism to achieve control of AM-signaling. Future studies 
should expand our understanding of the role of AM and CXCR7 in cardiovascular tissues 
and continue to emphasize the clinical importance of lymphatic vascular system. 
Future studies: role of AM, CXCR7, in cardiac development 
As discussed in Chapter 2, our excitement about Cxcr7 began with a similar 
phenotype of cardiac hyperplasia observed in both Cxcr7-/- and Admhi/hi mice. Remarkably, 
haploinsuffiency of AM was sufficient to rescue the cardiac hyperproliferation in Cxcr7-/- 
mice, demonstrating excessive AM-signaling is responsible for the hyperplastic phenotype. 
Moreover, while our work suggested that cardiac expression of Cxcr7 paralleled Adm 
expression, we hypothesized that non-cell autonomous CXCR7 expression can affect 
cardiovascular development. Future studies will be aimed at further elucidation of the 
mechanisms of CXCR7 modulation of AM-signaling, with a particular focus on characterizing 
the cell types responsible for scavenging AM.   
Recent work from our lab has identified epicardial-derived AM as the primary driver 
of cardiac proliferation. Immunohistochemistry of AM peptide in Admhi/hi animals showed 
increased staining in the epicardium and the trabeculae in developing mouse hearts (Figure 
3-1).  As shown in Figure 2-1F, H, this increase in expression closely paralleled the 
expression of CXCR7. Additionally, loss of CXCR7 in these regions resulted in increased 
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AM-staining intensity, suggesting that local levels of CXCR7 are responsible for AM 
scavenging (Figure 2-1G, I). In support, Cre-mediated depletion of the Admhi gene from the 
epicardium of Admhi/hi animals completely abolished cardiac hyperplasia, definitively 
demonstrating that local AM secretion from the epicardium is responsible for the cardiac 
hyperplasia [37]. Similar conditional and cell-specific expression and deletion of Cxcr7 will 
help determine whether expression of the decoy receptor in specific cell types modulates 
AM ligand concentrations. 
To address this question, Cxcr7fl/fl mice can be intercrossed with Cre lines to 
generate cell-type specific deletion of Cxcr7. Interestingly, previously reported endothelial 
specific deletion of Cxcr7 via Tie2-Cre resulted in a similar, but less severe cardiac 
phenotype compared to global Cxcr7-/- mice [38]. These data suggest that endocardial 
expressed CXCR7 plays a significant role in AM scavenging. This finding is consistent with 
our observed increase in AM staining in the trabeculae. However, Tie2-Cre causes 
recombination in many other cell types, including all cells stemming from venous 
progenitors. Therefore, vascular expression of Cxcr7 may also contribute to AM scavenging 
in this model.  
Use of additional Cre lines will help parse out which cell types are responsible. 
Intercross of Cxcr7fl/fl mice with the epicardial specific WT1-Cre will be of particular interest. 
Based on the Tie2-Cre model, which identifies the endocardium as a major player in the 
Cxcr7-/- phenotype, loss of CXCR7 exclusively in the epicardium would not be expected to 
fully recapitulate the cardiac phenotypes. However, because AM expression from the 
epicardium is essential to cardiac proliferation, if AM production from these cells remains 
unchecked, it is possible that Cxcr7fl/fl;WT1-Cre+ could result in a phenotype similar to 
Admhi/hi and Cxcr7-/- mice. As we have hypothesized that both cell autonomous and non-cell 
autonomous mechanisms of AM scavenging, it is also possible that loss of Cxcr7 in any 
given cell type may not cause a complete phenocopy. As such, regardless of the outcome, 
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these studies have potential to build upon our studies and extend our understanding of the 
molecular mechanisms that control AM dosage. Understanding whether Cxcr7 works in a 
cell-autonomous or non-cell autonomous fashion (or both) will guide future drug 
development for the treatment of cardiovascular and other diseases. 
Future studies: AM, decoy receptors, and cardiac lymphatics 
 Cardiac lymphatics, which drain the subendocardial, myocardial, and subepicardial 
areas, have recently been shown to modify heart pathologies [39]. As the function of cardiac 
lymphatic vessels is dependent on cardiac contraction, many diseases associated with poor 
myocardial function are also associated with poor lymphatic drainage and myocardial 
edema. Interstitial edema around the myocardium can lead to poor oxygenation, 
inflammation, and fibrosis, exacerbating cardiac injury. Yet, despite their association with 
this significant clinical problem, little is known about how lymphatic vessels might contribute 
to or resolve cardiac edema.  
 Many labs have demonstrated that AM exerts cardioprotective effects in mouse and 
human [40-43]. Our data in Chapter 2 contribute to a growing literature describing the role 
of AM in lymphangiogenesis. Whether the cardioprotective effects of AM are exerted 
through modulation of cardiac lymphatics has yet to be studied.  Preliminary data generated 
by a fellow graduate student in the Caron lab suggest that Admhi/hi mice subjected to left 
anterior descending (LAD) artery ligation to cause myocardial infarction have increased 
survival and significantly improved cardiac function compared to wildtype littermates. 
Immunohistochemical staining of post-infarct cardiac tissues shows increased and more 
patent LYVE1 (an LEC marker)-positive vessels compared to wildtype controls subjected to 
the same surgery. These observations suggest that Admhi/hi mice exhibit more abundant and 
dilated lymphatic vessels following cardiac infarction.  
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While we have not yet evaluated whether the abundance of lymphatic vessels is due 
to increased cardiac lymphangiogenesis during development, analysis of 
lymphangiogenesis in an ear-wounding model suggests that Admhi/hi mice do not have 
enhanced lymphangiogenesis, indicating that Admhi/hi likely do not have increased lymphatic 
density. This absence of increased lymphatic density may be due to an ability to increase 
Cxcr7 expression to compensate for excessive AM-signaling. Instead, as data suggest that 
ADM is potently induced during a variety of cardiovascular disease conditions, we expect 
that the increased lymphatic staining and lymphatic vessel dilatation seen in post-infarct 
cardiac tissue are due to Adm upregulation following injury [44]. Therefore, these data 
suggest the cardioprotective effects of AM are at least partially mediated through the 
increased function and novel formation of cardiac lymphatics in the setting of myocardial 
ischemia.  
To understand the role of AM and CXCR7 during this lymphatic remodeling, careful 
characterization of the post-injury hearts is essential in order to determine whether the 
increased cardiac lymphatic vessels resolves myocardial edema. Measurement of 
myocardial water content 10 days post-surgery will allow for the evaluation of myocardial 
edema. Here, a portion of the ventricular tissue will be weighed and then dried and 
reweighed. If overexpression of Adm contributes to the resolution of myocardial edema, the 
wet:dry ratios will be less than that of their wildtype controls.  
Additionally, evaluation of Cxcr7 expression in post-ischemic wildtype and Admhi/hi 
cardiac tissue may prove interesting. Previous characterization of Admhi/hi hearts revealed an 
upregulation of Cxcr7, which we hypothesized was to homeostatically compensate for 
excessive AM peptide. During myocardial edema, however, where Adm expression is 
hypothesized to be cardioprotective, expression of the molecular rheostat might be expected 
to decrease. qRT-PCR of post-ischemic cardiac tissue will elucidate whether regulation of 
Cxcr7 expression plays a role in cardioprotection.  
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LAD ligation in Cxcr7-/- mice that survive into adulthood will also allow us to 
determine if increased lymphatic density can ameliorate myocardial edema following cardiac 
injury. As we have shown in Chapter 2, Cxcr7-/- mice exhibit increased lymphangiogenesis 
during development. We hypothesize that this increased lymphatic density will protect from 
post-injury cardiac edema and therefore improve survival and cardiac function. Additionally, 
these mice exhibit increased AM-signaling. Determining whether increased lymphatic 
density coupled with increased AM ligand allows for survival benefits above Admhi/hi mice will 
be interesting. Collectively, these data will enhance our understanding of AM-mediated 
cardioprotection. Perhaps more importantly, this work will also elucidate a novel mechanism 
that may lead to a treatment for myocardial edema, which often accompanies and worsens 
chronic heart diseases. 
Future directions: Role of AM and CXCR7 in chemokine signaling 
Part II of my dissertation will address an additional future direction of this body of 
work. The signaling mechanisms that govern chemokine receptors are complex and poorly 
understood. The association of CXCR7 with the AM-signaling system has provided a clue 
into how these receptors might be regulated – via the interaction with Receptor Activity 
Modifying Proteins. Chapter 4 discusses the biology of RAMPs at length, and Chapter 5 
focuses on current studies trying to understand the complexities of chemokine signaling.  
Concluding Remarks  
 Taken together, the data presented in Part I support an important role for AM and 
CXCR7 during lymphangiogenesis and contribute to the expanding field of lymphatic 
vascular development. Research over the past decade has created a strong argument for 
pursuing the lymphatic system for the treatment of many conditions. The next decade will 
see advances in understanding of the molecular mechanisms that govern 
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lymphangiogenesis in development and adulthood and likely will identify a plethora of 
conditions to which dysregulation of lymphatic vasculature contributes. Hopefully, research 
will also identify small molecules to modulate these vessels toward the ultimate goal of 
treating human disease.  
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FIGURES 
Figure 3-1. AM expression is localized to the developing epicardium and up-regulated 
in Admhi/hi mice.1,2 Immunofluorescence of AM peptide in heart sections of E13.5 embryos. 
A,C. Adm+/+ control mice. B,D. Admhi/hi mice. Images A,B were obtained with a 300 ms 
exposure, while images C and D were obtained with a 75 ms exposure. Boxes in A and B 
represent fields shown in panels C and D, respectively. E. The amount of AM expressed in 
the epicardium was assessed from panels C and D by measuring the integrated density of 
staining using Image J software. Data are expressed as arbitrary units (AU) of integrated 
density. Colocalization of AM peptide and the epicardial marker, cytokeratin. F,H. 
Adrenomedullin staining. G,I: Cytokeratin staining. The white boxes on panels F and G 
indicate the fields presented in panels H and I, respectively. Filled arrow heads on panels F 
and H indicate areas of AM staining, while open arrow heads in panels G and I highlight 
areas positive for cytokeratin staining. TR = trabecular zone; CZ = compact zone. Scale bars 
= 50 µM. All values are means ± SEM. **p< 0.01  
                                               
1 Authors: Sarah E. Wetzel-Strong, Manyu Li, Klara R. Klein, Toshio Nishikimi, and Kathleen Caron 
 
2 Reprinted in part with permission from 37. Wetzel-Strong SE, Li M, Klein KR, Nishikimi T, Caron KM 
(2013) Epicardial-derived adrenomedullin drives cardiac hyperplasia during embryogenesis. Dev Dyn 
243: 243-256. 
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Chapter 4: From the dish to the mouse: A glance at receptor activity modifying 
protein biology1,2 
 
Introduction 
Receptor activity modifying proteins (RAMPs) are single-pass transmembrane 
proteins that heterodimerize with seven-transmembrane (7-TM) G protein-coupled receptors 
(GPCRs) to modulate GPCR function. GPCRs constitute ~2% of the human genome and 
activate major signaling pathways in cells [1]. Due to their physiological importance and their 
cell surface expression, the GPCR family is the most pharmacologically tractable class of 
proteins known. Approximately 40% of drugs marketed for the clinic target GPCRs [2]. Only 
a small fraction of GPCRs has been selected for drug development thus far, while the 
complex biology of the remainder are under intense study [3]. GPCR pharmacology is 
further complicated by the ability of these receptors to form homodimers and to 
heterodimerize with different GPCRs and with other proteins, including RAMPs, to form 
GPCR oligomers. How GPCR oligomers affect signaling and function is of particular interest, 
as protein-protein interactions may allow for novel drug development with more specific 
effects. While their interaction with Family B receptors has received the most attention, 
RAMPs have been shown to oligomerize with GPCRs from Family A (Rhodopsin-like) and C 
as well. Thus, the RAMP family extends the targets available for modifying clinical disease. 
                                               
1 Authors: Klein, K.R. and Caron, K.M. 
2 This chapter is an invited review in preparation for Molecular Endocrinology 
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The association of RAMPs with GCPRs affects ligand specificity, receptor trafficking, 
signaling capabilities, and receptor desensitization. Since their discovery over fifteen years 
ago, much has been learned about the effects of RAMPs on their GPCR partners. However, 
a dearth of knowledge still exists regarding additional GPCR-RAMP pairs, and more 
importantly, the biological significance of both known and unknown GPCR-RAMP partners. 
This review will discuss what is currently known about how RAMPs modulate GPCR 
pharmacology, will focus on how RAMPs regulate physiology in vivo, and, finally, will 
address what important questions remain. 
The discovery of RAMPs 
 RAMPs were first identified during an effort to understand the regulation of calcitonin 
gene-related peptide (CGRP) signaling. CGRP belongs to the calcitonin peptide family, 
which consists of five peptide hormones: CGRP, calcitonin (CT), amylin (AMY), 
adrenomedullin (AM), and intermedin (IMD). These peptides have significant structural 
homology, and their often overlapping biological activities include gastric emptying (AMY, 
IMD), vasodilation (AM, CGRP, IMD), angiogenesis (AM, CGRP), and pain sensation 
(CGRP, CT) [4,5]. Despite sharing multiple functional targets, the calcitonin family of 
peptides also mediates unique biological events. This suggests that although the peptide 
group shares affinity for GPCRs, they also must target specific and distinct receptors [5].  
Following the cloning of calcitonin receptor-like receptor (CLR), conflicting data 
emerged regarding whether the orphan receptor was able to bind CGRP. CLR exhibits 58% 
homology to the human CT receptor and was predicted to bind one of the CGRP peptides 
[6]. Previous data suggested that CGRP acted through a Gαs-coupled GPCR to elicit cyclic 
AMP (cAMP) production [7]. Transfection of human CLR or the rat homologue into COS-7 
cells, however, did not result in cAMP accumulation following CGRP treatment [6,8]. In 
contrast, when CLR was transfected into HEK293 cells, CGRP treatment produced a 60-fold 
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increase in cAMP production [9,10]. These data led to the speculation that HEK293 cells 
endogenously expressed an additional factor that was required to activate the CGRP 
receptor, while COS-7 cells did not express this factor.  
Using an expression cloning approach, McLatchie and colleagues demonstrated that 
the CGRP receptor is formed from a GPCR heterodimer: CLR and the 148 amino acid 
protein RAMP1 [11]. Co-transfection of CLR and RAMP1 followed by CGRP treatment 
resulted in significant upregulation of cAMP, compared to transfection of either protein alone 
[11]. Further study showed that cells expressing endogenous RAMPs are able to generate 
cAMP response when transfected with CLR, whereas cell lines without endogenous RAMP1 
cannot [6,8,9]. Clearly, the RAMP1-CLR complex alters the affinity of the CLR for CGRP.   
Interestingly, two additional RAMPs were identified and found to modify ligand 
specificity of CLR. While the RAMP1-CLR complex binds CGRP, when RAMP2 or -3 is 
bound to the GPCR, CLR becomes a high-affinity AM receptor (Figure 4-1A) [11]. These 
data provided a novel mechanism for altering ligand specificity of GPCRs [7]. As such, the 
interaction of the RAMP family of proteins with GPCRs illustrated the complexity of CGRP 
signaling, yielding a paradigm shift in the understanding of GPCR pharmacology [12]. 
Studies over the past 15 years have identified GPCR-RAMP interactions in three GPCR 
classes (Table 4-1). Moreover, the three known RAMPs have been shown to play a broader 
role in the regulation of GPCRs than simply modifying ligand affinity.  
A multitude of effects: RAMP pharmacology 
 The three identified RAMPs share a common structure, yet the proteins only have 
30% sequence homology, which allows unique effects on their GPCR partners. RAMP1 and 
-3 are 148 amino acids long, while RAMP2 is considerably larger at 175 amino acids [11]. 
Each RAMP has a large extracellular N-terminal domain, a single transmembrane domain, 
and a cytoplasmic C-terminus [11]. These domains are critical in dictating how the RAMP 
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modulates the GPCR. For example, studies using chimeras that exchange the domains 
between RAMPs revealed that the N-terminus helps in determining ligand specificity, 
whereas the C-terminus appears to modify downstream signaling [13,14]. The recently 
solved crystal structures of the extracellular domains of RAMP1 and -2 confirmed that 
several intermolecular interactions in the amino terminus of RAMP2 are required for AM 
binding. These are not conserved in RAMP1, indicating that the N-terminus serves to define 
the specificity for ligand binding [15,16]. 
 Ligand Binding and plasma membrane expression. As discussed above, the ability of 
RAMPs to modify CLR was essential to their discovery. As such, RAMP interaction with CLR 
and with the calcitonin receptor (CTR) has been particularly well characterized. In the case 
of CLR, RAMP1 is required for CGRP binding, and RAMP2 or -3 confer the ability to bind 
AM [11].  Additionally, RAMPs act as chaperones for CLR, as co-expression of a RAMP is 
required for cell surface trafficking of CLR. Studies have shown that RAMPs have an 
endoplasmic reticulum retention signal within the C-terminus [17]. RAMP association with 
CLR overrides this retention signal, allowing translocation of the CLR-RAMP complex from 
the endoplasmic reticulum (ER) to the plasma membrane. RAMPs are therefore critical for 
plasma membrane localization of some GPCRs.  
RAMPs, however, can affect binding specificity of GPCRs that successfully express 
at the plasma membrane independent of RAMP association. Similar to the receptors for 
CGRP, the receptors for AMY proved challenging to isolate [7]. While AMY appeared to 
associate with CTR, CTR transfection into cell lines did not consistently reveal convincing 
AMY ligand binding [7,18]. After the discovery of RAMPs, several groups suspected that 
these inconsistencies were due to cell endogenous expression of RAMPs, and subsequently 
demonstrated that CTR interaction with all three RAMPs results in an AMY receptor [19-21]. 
In contrast to CLR, CTR does not require a RAMP for cell surface localization (Figure 4-1B) 
[5]. However, the CTR-RAMP interaction in the ER allows for formation of a functional AMY 
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receptor at the cell surface. CTR interactions with RAMPs 1-3 have been classified as 
AMY1-3, which display varying affinities for AMY [5]. However, the physiological relevance of 
the specific AMY receptors took several years to understand and demonstrated another 
important biological effect of RAMPs: the ability to affect post-receptor signal. 
 Cellular signaling. Because the discovery of RAMPs caused a major shift in the 
understanding of how GPCRs are regulated, there was significant interest in which other 
receptors interacted with RAMPs. CLR and CT are both family B GPCRs. Given the 
structural similarities of family B GPCRs and their affinity for peptide ligands, it stood to 
reason that other members of family B could interact with RAMPs. Using epitope-tagged 
constructs and immunofluorescence confocal microscopy, the Sexton laboratory discovered 
four novel RAMP-GPCR interactions [22]. Co-transfection of the glucagon, parathyroid 1 
receptor (PTH1R), parathyroid 2 receptor (PTH2R), or vasoactive intestinal peptide 1 
receptor (VPAC1R) with RAMPs resulted in cell surface expression of RAMPs, where 
RAMP-only transfection did not. Interestingly, not all of these receptors interacted with all of 
the members of the RAMP family. While VPAC1R associated with all three RAMPs, 
glucagon and PTH1R associated only with RAMP2, and PTH2R only with RAMP3, 
highlighting the specificity of the RAMP-receptor interaction [22].  
Further analysis of VPAC1R revealed that the interaction of a single GPCR with 
different RAMPs could elicit different downstream signals. VPAC1R is able to couple to 
multiple G-proteins and thus able to stimulate cAMP accumulation and phosphoinositide 
hydrolysis [22]. While treatment of cells cotransfected with VPAC1R and RAMP1 or -3 did 
not alter baseline cAMP accumulation, cotransfection of VPAC1R with RAMP2 caused 
significant increase in phosphoinositide hydrolysis, suggesting that RAMP2 could modify G-
protein coupling [22]. Whether this change in signaling is due to direct modification in G-
protein coupling or due to changes in RAMP-receptor localization remains to be determined 
[23].  
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Studies of AMY1-3 offer evidence that RAMPs can indeed alter G-protein coupling. 
Morfis et al. observed that AMY treatment of cells co-transfected with CTR and RAMP1 or -3 
(AMY1 and AMY3 respectively) resulted in a 20- to 30-fold increase in cAMP production 
compared to transfection of CTR alone [24]. Conversely, only a 2- to 5-fold induction of 
intracellular Ca2+ was observed, suggesting that AMY1 and AMY3 preferentially couple to Gαs 
versus Gαq relative to CTR without a RAMP. Interestingly, while no G proteins altered AMY 
binding in cells expressing CTR or CTR-RAMP1, overexpression of Gαs significantly 
increased AMY binding in CTR-RAMP2-expressing cells, and overexpression of Gαs and Gαq 
increased binding in CTR-RAMP3-expressing cells [24].  These data suggest that individual 
RAMPs have the capacity to dictate G-protein coupling compared to RAMP-independent 
GPCRs.  
Finally, a recent study demonstrated that RAMPs associate with vasoactive intestinal 
peptide 2 receptor (VPAC2R) and corticotrophin releasing factor receptor (CRF) and alter G-
protein coupling of both receptors [25]. Here, co-expression of RAMP1 and RAMP2 with 
VPAC2R in HEK293T and CHO-K1 cells significantly increased basal coupling to Gi/o/t/z, 
compared with VPAC2R alone [25]. Similarly, co-expression of RAMP2 with CRF 
significantly enhanced Gi/o/t/z and Gq/11 coupling, leading to enhanced Ca2+ elevation in 
response to agonists [25]. Taken together, these data demonstrate the potential of RAMPs 
to alter downstream signaling, suggesting that an evaluation of the signaling profile is 
important to understanding the physiology of GPCR-RAMP interactions.  
Receptor Trafficking. Finally, as mentioned briefly above, heterodimerization of 
RAMPs with CLR is required for cell surface expression of the GPCR. RAMPs have been 
identified for the first time to play a similar role for a family C receptor, calcium sensing 
receptor (CaSR). When transfected alone into COS-7 cells, CaSR is retained in the ER [26]. 
Co-expression of RAMP1 and RAMP3 with CaSR resulted in plasma membrane expression 
of CaSR, indicating that the RAMP-CaSR interaction promotes forward trafficking of CaSR 
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to the membrane [26]. Although this finding elucidated a mechanism for the regulation of 
CaSR, these data in and of themselves were not groundbreaking. However, this was the 
first non-family B receptor identified to associate with RAMPs, opening the door to the 
possibility that RAMP effects are more pervasive than originally thought. A recent study has 
expanded this even further by identifying an association of RAMP3 with a class A receptor, 
GPR30, now known as G protein-coupled estrogen receptor 1 (GPER) [27]. This study will 
be discussed in detail in the following section addressing the biological effects of RAMPs.  
RAMPs also have the capacity to alter receptor internalization. Early studies 
demonstrated that CLR-RAMP2 internalization was β-arrestin- and dynamin-mediated 
[7,28,29]. Later BRET studies indicated that, for CLR, agonist-mediated β-arrestin 
recruitment was dependent on the presence of RAMP1 [30]. Whether this was unique to 
RAMP1 was not investigated.  
More recent studies have suggested unique protein trafficking roles for RAMP3. The 
C-terminal tail of RAMP3 contains a type 1 PSD-95/Discs-large/ZO-1 (PDZ) domain that is 
not present in RAMP-1 or -2. The PDZ domain allows for additional protein-protein 
interactions that alter receptor trafficking following receptor internalization. In contrast to the 
degradative pathway seen with RAMP1 and -2, Bomberger and colleagues showed that 
interaction of N-ethylmaleimide-sensitive factor (NSF) with the PDZ domain of RAMP3 
causes CLR to be recycled back to the cell surface, allowing for rapid receptor 
resensitization [31]. Additionally, interaction of the PDZ domain with the Na+/H+ exchange 
regulatory factor (NHERF) tethers the CLR-RAMP3 complex to the actin cytoskeleton and 
inhibits the internalization of CLR [32]. In contrast, NHERF had no effect on CLR-RAMP1 or 
CLR-RAMP2 complexes that lack this PDZ domain. 
These data not only highlight another important role for RAMPs but also the unique 
effects that RAMPs have on receptor processing. Many GPCRs interact with several 
RAMPs. Therefore, it is important to define the individual ligand affinity, signaling profile, and 
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trafficking pathway of each RAMP-GPCR complex. It is also worth noting that many 
additional RAMP effects remain undefined, so while the breadth of RAMP effects already 
seems widespread, we likely have only begun to uncover the capacity of RAMPs to alter 
GPCR physiology. 
Figure 4-2 summarizes what is currently known about RAMP effects on GPCR 
pharmacology. In vitro biochemical studies have not only enabled the identification of novel 
GPCR-RAMP pairs but also elucidated much about how RAMPs affect GPCR biology. 
GPCRs are pharmacologically tractable themselves, but the unique GPCR-RAMP interface 
may prove to be even more advantageous for the design of highly selective drugs [3]. 
However, in order to harness their potential as drug targets for disease, we must first 
understand how RAMPs affect physiology and what roles they play in physiological 
dysfunction in vivo. 
RAMP function in vivo 
In general, our knowledge of RAMP biochemistry far exceeds our understanding of 
their biological effects. However, over the past decade, utilization of mouse models has 
taught us enormous amounts about RAMP biology in vivo. When evaluating genetic models 
of RAMPs, it is important to keep in mind that the ability of RAMPs to interact with multiple 
receptors is a major caveat; their promiscuous nature complicates the interpretation of 
RAMP knockout models. Therefore, conclusions suggesting any particular RAMP-GPCR 
interaction should be made with caution. Furthermore, the ability of GPCRs to interact with 
several RAMPs may allow for alternate RAMPs to compensate for the loss of another 
RAMP. Nonetheless, knockout and transgenic overexpression models of RAMPs 
demonstrate their importance to normal and disease physiologies. Our lab has previously 
reviewed the RAMP mouse model literature [33]; however, in the short time since its 
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publication, many additional studies utilizing genetically engineered RAMP mouse models 
have been published to enhance our understanding of how RAMPs affect physiology.  
RAMP1 and the cardiovascular system 
CGRP, a 37 amino acid neuropeptide with potent vasodilatory activity, binds the 
CLR-RAMP1 complex. It was therefore expected that RAMP1-null mice would display 
cardiovascular phenotypes. Indeed, since the generation of RAMP1-null mice, several 
groups have shown a variety of cardiovascular defects. In 2007, the first Ramp1-/- model 
was published [34]. Global deletion of Ramp1 resulted in mice that were viable and overtly 
normal but that did not exhibit a decrease in blood pressure in response to CGRP infusion, 
thus confirming loss of the functional CGRP receptor [34]. However, though serum CGRP 
levels remained similar, the basal blood pressure of Ramp1-/- mice was significantly higher 
than their wildtype controls and increased with age, suggesting that CGRP action through 
CLR-RAMP1 helps maintain low basal blood pressure. Interestingly, Ramp1-/- mice exhibited 
a mild but significant suppression of the hypotensive response to AM administration, 
suggesting that AM exhibits some of its vasodilatory effects through CLR-RAMP1 [34]. 
Therefore, while drugs that target the CLR-RAMP1 interface may be effective for treatment 
of cardiovascular disease, they may also interfere with AM-mediated effects.  
Overexpression models have identified a protective role for RAMP1 in vascular 
function [35]. Angiotensin II (Ang-II) is an important mediator of hypertension in humans. 
Chronic exposure to Ang-II in mice increases cardiovascular risk by causing increases in 
sympathetic drive and inhibition of baroreflex-mediated decreases in vessel tone and heart 
rate. Interestingly, overexpression of hRAMP1 abrogated Ang-II-mediated decreases in 
baroreceptor reflex and increases in blood pressure [35]. Pressor response to a CGRP 
antagonist during Ang-II treatment was also enhanced in hRAMP1-expressing mice, 
suggesting that overexpression of RAMP1 induces hypersensitivity to CGRP stimulation. 
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These data indicate that CGRP activity is limited by the availability of RAMP1 and suggest 
that CGRP association with RAMP1 may be cardioprotective.  
 Chrissobolis et al. utilized a global RAMP1 overexpression model to demonstrate 
that RAMP1 is also vasoprotective [36]. Ang-II treatment normally leads to diminished 
endothelial vasodilatory response to acetylcholine. Whereas wildtype mice failed to respond 
to acetylcholine following Ang-II treatment, RAMP1-overexpressing mice maintained 
baseline acetylcholine-induced relaxation responses in carotid arteries, indicating that 
RAMP1 overexpression protects against endothelial dysfunction [36].  Since endothelial 
dysfunction leads to significant increase in cardiovascular risk, these data suggest that 
development of drugs that target RAMP1 interactions with GPCRs may be useful for treating 
vascular disease [36]. 
 Moreover, recent data has emerged that has identified a new role for RAMP1 in 
neovasculogenesis during wound healing. Kurashige et al. noted that healing of skin 
wounds was significantly delayed in Ramp1-null mice [37]. Experimental mice displayed 
significantly decreased microvessel and lymphatic vessel density during wound healing, 
suggesting that RAMP1 has a role in promoting new vessel formation after injury. Notably, 
the authors did not find RAMP1-positive vessels in granulation tissues, suggesting RAMP1 
activation does not play a direct role in neovascularization [37]. Instead, it appears that 
CGRP activation in macrophages causes an increase in pro-angiogenic and pro-
lymphangiogenic factors.  
 CGRP treatment of wildtype macrophages resulted in increased VEGF-A, a pro-
angiogenic glycoprotein, while macrophages of Ramp1-/- mice had no response. VEGF-C, a 
lymphangiogenic factor, was also upregulated by CGRP and along with its receptor, 
VEGFR3, was observed to be decreased in Ramp1-/- animals. Bone marrow transplant from 
Ramp1-/- to wildtype mice recapitulated this phenotype, suggesting that CGRP activity in 
macrophages recruited from the bone marrow is critical for normal wound healing. These 
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data suggest that in the absence of RAMP1, proper angiogenesis does not occur, resulting 
in delayed wound healing. While AM and the CLR-RAMP2 complex are well known to 
participate in lymphangiogenesis (Klein and Caron, unpublished), particularly during 
embryogenesis [38], these data provide some of the first in vivo evidence that CGRP and 
RAMP1 also play an important role during wound healing. Further, that this effect of RAMP1 
may be mediated through macrophages is particularly interesting, as RAMP1 has been 
found to have important roles in the immune system. 
RAMP1 and inflammation 
 Outside of the cardiovascular system, CGRP and RAMP1 also participate in the 
regulation of inflammation. When the first Ramp1-/- mouse model was generated, 
lipopolysaccharide (LPS) induced inflammation was examined. Again, basal CGRP levels 
were normal, but LPS administration induced a significant increase in serum CGRP levels in 
Ramp1-/- mice compared to controls [34]. Ramp1-/- mice also expressed high serum levels of 
pro-inflammatory cytokines and chemokines. CGRP, which is known to suppress the 
production of cytokines in bone-marrow derived dendritic cells, does not yield this 
suppression in Ramp1-/- mice [34]. These data suggest that CGRP action through CLR-
RAMP1 has anti-inflammatory properties. Recent data from our lab demonstrate the 
converse in the context of the ovalbumin (OVA) induced allergy [39].  
To determine the effect of RAMP1 on allergic asthma, Ramp1-/- mice were OVA 
sensitized. Interestingly, methylcholine treatment of OVA-sensitized Ramp1-/- mice results in 
significantly attenuated airway resistance in comparison to wildtype controls [39]. Similar 
findings are observed in mice that are haploinsufficient for CLR (Calcrl+/-) mice, indicating 
that both of the components of the CGRP receptor complex are involved in airway 
hyperresponsiveness. Mice deficient in either RAMP1 or CLR have better outcomes 
following OVA sensitization. Smooth muscle-specific loss of CLR did not attenuate airway 
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resistance in response to methycholine, indicating that CGRP action on smooth muscle cells 
of the airway is not the primary cause of the airway hyperresponsivity. However, both 
Ramp1-/- and Calcrl-/- mice had significantly reduced IL-4 concentrations from 
bronchoalveolar lavage fluid, suggesting that CGRP, acting through the CLR-RAMP1 
complex, increases inflammatory mediators during allergic asthma and may worsen 
outcomes. In contrast to the previous study discussed, this study suggests that CGRP and 
the CLR-RAMP1 complex also may have a pro-inflammatory role. 
Studies using a neuronal-specific RAMP1 overexpression model also indicate a role 
for RAMP1 during inflammation in neuronal tissue. Injection of CGRP into transgenic mice 
expressing hRAMP1 exhibited increased plasma extravasation and inflammation in 
subcutaneous tissue compared to control mice [40]. Co-treatment with CGRP antagonists 
abrogated this response. Again, overexpression of RAMP1 led to an increased response to 
a given dose of CGRP, suggesting that CGRP action in neurons is also limited by the 
availability of RAMP1. This finding is particularly interesting because many studies have 
suggested that CGRP plays a major role in migraine [41]. This study raises the possibility 
that elevated RAMP1 expression in neurons may predispose individuals to CGRP-induced 
migraines. In fact, several small molecules antagonists of CLR-RAMP1 have been 
developed and tested in clinical trials with reasonable efficacy [42]. Still, the development of 
an orally available small molecule with few off-target effects has been challenging [42]. Drug 
design specifically at the CLR-RAMP1 interface could prove to be the gold standard for 
migraine treatment. 
Though these studies together do not paint a clear picture of whether RAMP1 has 
pro-inflammatory or anti-inflammatory roles, it is likely that the effects differ based upon 
tissue. It is possible that tissue-specific targeting of the CLR-RAMP1 interface has potential 
for relieve symptom of a variety of diseases, including asthma and migraine. Off-target 
effects could be significant given the diverse physiological roles of CLR-RAMP1. 
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Regardless, more work needs to be done to understand the roles of RAMP1 during 
inflammation. Furthermore, the majority of Ramp1 mouse model studies have focused on 
CGRP and the CLR-RAMP1 interaction. As discussed previously, biochemical studies have 
identified several additional GPCR partners for RAMP1. Consequently, future work should 
determine how loss of RAMP1 affects the biology of other peptides.  
RAMP2 in the cardiovascular system 
  The importance of RAMP2 in vascular biology was recognized with the generation of 
the first Ramp2-/- animal. In contrast to RAMP1 and RAMP3, RAMP2 is required during 
embryogenesis [38,43]. Comparative phenotyping of AM (gene = Adm), CLR (gene = 
Calcrl), and RAMP2 knockout mice revealed a conserved phenotype between the three: 
extreme edema and mid-gestational lethality [38]. Our lab suspected that defective 
lymphangiogenesis was the root cause of the edema. Indeed, examination of jugular lymph 
sacs of Ramp2-/-, Adm-/-, Calcrl-/- mice revealed that mutant lymph sac to jugular vein ratios 
were significantly smaller than their wildtype controls [38]. BrdU-incorporation assays 
indicated that the lymphatic endothelial cells of AM-signaling-null mice were 
hypoproliferative, resulting in abnormally small lymphatic sacs. Electron microscopy 
revealed that lymphatic endothelial cells of Ramp2-/- mice were thin and often necrotic, 
though the junctional barrier between the blood and lymphatic endothelium remained intact 
[38]. Together, these data demonstrate that Ramp2 is necessary during embryonic 
lymphangiogenesis, and loss of RAMP2 is incompatible with survival.  
Interestingly, a second, independent Ramp2 knockout model was developed at the 
same time [43]. Ichikawa-Shindo et al. described a similar edematous phenotype and 
embryonic lethality. They also described occasional hemorrhage and defects in the blood 
endothelial barrier in this model of Ramp2-/- mice [43]. The authors concluded that the 
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edema was caused by paracellular leakage from blood vessels. Lymphangiogensis was not 
evaluated.  
These two studies described the first Ramp2-null mice. Though they did not come to 
the same conclusion, they both highlight a critical role for RAMP2 during embryonic 
vasculogenesis and maintenance of endothelial barriers. Moreover, while biochemical and 
more recent in vivo data demonstrate that RAMP2 has many GPCR partners, the work from 
Fritz-six et al. specifically highlight the importance of the CLR-RAMP2 complex during 
development, as neither RAMP1 nor RAMP3 can compensate for the loss of RAMP2.  
In the past five years, the Shindo lab has published numerous papers utilizing tissue-
specific deletion of Ramp2. Several of these models are tamoxifen-inducible in order to 
circumvent embryonic lethality and evaluate the role of RAMP2 during adulthood. 
Yoshizawa and colleagues suggest that tamoxifen-induced cardiomyocyte deletion of 
RAMP2 (C-Ramp2-/- mice) using a myosin heavy chain (MHC)-MerCreMer transgenic mouse 
results in a dilated cardiomyopathy-like heart failure in adult mice with enlargement of 
cardiac ventricles and diminished systolic function [44]. Immunohistochemical analysis of C-
Ramp2-/- hearts indicated higher levels of oxidative stress. Additionally, the authors noted 
changes in mitochondrial structure that were associated with reduced expression of various 
mitochondria-related molecules and increases in reactive oxygen species [44]. While 
reactive oxygen species reduction abrogated increases in cardiomyocyte size in C-Ramp2-/- 
mice, expression of other heart failure genes remained unchanged [44]. Therefore, while 
mitochondrial dysfunction and reactive oxygen species contributes to disease, loss of 
RAMP2 affects additional processes that lead to the heart failure and remain to be 
determined. 
These findings are potentially interesting, however the study is confounded by 
several technical and conceptual inconsistencies. Firstly, several independent publications 
have indicated that the αMHC-MerCreMer transgenic line spontaneously develop 
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cardiomyopathy and heart failure with accompanying reduction in cardiac energy and 
metabolism in the absence of any excised floxed allele [45-47]. Additionally, the 
cardiomyocyte gene expression levels of Ramp2 are reduced to 60% of controls, a level of 
expression that is still higher than Ramp2 heterozygotes. So, it is somewhat surprising that 
the observed phenotype is so dramatic when Ramp2+/- animals fail to develop a similar 
phenotype. Moreover, this study only considered AM as the potential mediator of cardiac 
dysfunction. While AM likely contributes to these phenotypes, the authors fail to address the 
fact that RAMP2 associates with numerous other receptors. 
 This concept becomes apparent in a second paper that investigates an endothelial- 
specific knockout of Ramp2. Utilizing a vascular endothelial-cadherin promoter, the Shindo 
lab generated an endothelial cell-specific knockout of RAMP2 (E-Ramp2-/- mice) during 
embryogenesis, which results in perinatal lethality of 95% of the mice [48]. Five percent of E-
Ramp2-/- mice survive into adulthood, whereas no global Ramp2-/- embryos survive past 
mid-gestation [48]. Interestingly, all mice with endothelial specific knockout of AM (E-Adm-/- 
mice) survive to adulthood. While it is likely that other tissue sources of AM compensate for 
the loss of AM in the endothelium, it is equally likely that RAMP2 interaction with other 
GPCRs and peptides contributes to the severity of the phenotype.  
Despite this caveat, the study of surviving animals proved to be interesting. Surviving 
E-Ramp2-/- mice express 20% of wildtype Ramp2 levels [48]. This incomplete knockout may 
facilitate their survival into adulthood. Phenotypic analysis of long-term survivors revealed 
that adult E-Ramp2-/- mice exhibit significant vascular dysfunction, including aortic thinning 
and increased aortic diameters. Blood pressure was also decreased in E-Ramp2-/- mice [48]. 
This finding is somewhat surprising. As AM is a potent vasodilator, loss of AM signaling 
would be expected to lead to blood pressure increases. It is possible that the disrupted 
vascular structure causes the decrease in blood pressure. The authors also note aortic 
smooth muscle disarray and endothelial cell detachment from the basement membrane [48].  
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E-Ramp2-/- mice also displayed spontaneous vasculitis consistent with endothelial 
damage. Aged mice exhibited significant organ failure and fibrosis and accelerated vascular 
senescence, a purported consequence of vascular damage [48]. Two-year-old global 
Ramp2+/- mice similarly exhibited increased vascular senescence compared to wildtype 
controls, suggesting that even haploinsufficiency for RAMP2 results in vascular damage; 
further reduction of Ramp2 in the endothelium may increase vascular damage, thereby 
accelerating senescence. 
Loss of endothelial RAMP2 during adulthood also leads to significant vascular 
dysfunction. After inducing endothelial-specific Ramp2-/- in adult mice with tamoxifen (drug-
inducible endothelial specific Ramp2-/- = DI-E-Ramp2-/-), the Shindo group noted significant 
edema due to enhanced vascular permeability and plasma leakage, with endothelial cell 
detachment from the basement membrane of aortas. These findings are consistent with the 
expected role of Ramp2 in vascular permeability. Additionally, aged DI-E-Ramp2-/- mice 
displayed vasculitis similar to that seen in E-Ramp2-/- survivors [48]. To examine the 
postnatal angiogenic potency, the authors utilized a hind-limb ischemia model. Interestingly, 
blood flow restoration following hindlimb ischemia was also reduced in DI-E-Ramp2-/-, 
indicating decreased angiogenic potential. Endothelial-specific overexpression of Ramp2 in 
DI-E-Ramp2-/- restored blood flow recovery to the hindlimb, suggesting that Ramp2 is indeed 
responsible for loss of angiogenic potential [48] Collectively, this extensive study portrays a 
critical role for RAMP2 in maintenance of vascular integrity throughout development and into 
adulthood. It is worth mentioning again that GPCR-RAMP2 interactions besides CLR-
RAMP2 likely contribute to these phenotypes. Further work is necessary to establish a 
complete understanding of the role of RAMP2 in vascular dysfunction. 
RAMP2 in the endocrine system 
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 RAMP2 activity in the endocrine system serves as an excellent example of how loss 
of a RAMP can impact several signaling pathways. Recent work from our lab has 
demonstrated that haploinsufficiency of Ramp2 leads to a constellation of endocrine-related 
phenotypes, which are not observed in Calcrl+/- or Adm+/- mice. First, we noticed that the 
Ramp2+/- colony is difficult to maintain due to small litter sizes and fetal demise [49]. 
Extensive evaluation of timed-matings throughout pregnancy and the postpartum period 
revealed peri- and postnatal loss of pups, independent of genotype [50]. Wildtype and 
mutant pups alike exhibited intrauterine growth restriction, suggesting parental, not fetal, 
genotype, contributes to fetal demise. Interestingly, fetal loss was only observed when the 
dam was heterozygous for Ramp2; paternal genotype had no effect on fetal survival, 
indicating that maternal Ramp2 haploinsufficiency causes fetal loss [50]. The true cause of 
fetal demise is not well understood but could be due to the loss of signaling through CLR-
RAMP2, which is critical for normal development of the reproductive tract. In addition, loss of 
glucagon signaling, which is critical for fetal development, through the glucagon receptor-
RAMP2 complex could also contribute. 
We also noticed that pups that died postnatally lacked milk in their stomachs and 
suspected that prolactin production was disrupted in Ramp2 mutant females. Indeed, 
Ramp2+/- females exhibited hyperprolactinemia basally and throughout pregnancy. 
Consistently, pituitary glands, the region of the brain that produces prolactin, of Ramp2+/- 
females were hyperplastic.  Furthermore, examination of the mammary gland of virgin mice 
revealed accelerated mammary gland development in Ramp2+/- mice, which likely 
contributes to lactation dysfunction. These symptoms could be attributed to loss of the 
PTH1R-RAMP2 complex, which fosters signaling of parathyroid hormone-related peptide 
(PTHrP), a peptide important for fetal and placental development, mammary development, 
and bone development. Unpublished work from our lab examining placentas of Ramp2-null 
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mice confirm the PTH1R-RAMP2 interaction in vivo and supports the hypothesis that loss of 
Ramp2 affects PTH1R function (Kadmiel et al. unpublished). 
Ramp2+/- mice also exhibit skeletal abnormalities including delayed bone 
development and decreased bone mineral density from the perinatal period through 
adulthood, suggesting that heterozygosity of Ramp2 affects bone metabolism independent 
of hyperprolactinemia. In fact, these skeletal phenotypes are reminiscent of AMY-deficient 
mice, suggesting that loss of the CTR-AMY receptor complex might cause the bone 
phenotypes.  
Finally, following CRF treatment, adrenocorticotropic hormone (ACTH) response was 
also suppressed in Ramp2+/- mice compared to their wildtype littermates, indicating that 
haploinsufficiency of Ramp2 also affects the CRF receptor-RAMP2 complex and the 
physiologic effects of CRF [25]. Ultimately, these data describe an array of endocrine 
symptoms in Ramp2 heterozygous mice that cannot be attributed to a single RAMP-GPCR 
complex. This complex pattern of dysfunction emphasizes that loss of RAMPs can affect 
many signaling pathways, which often confounds the ability to attribute a given phenotype to 
one GPCR. 
RAMP3 in the cardiovascular and endocrine systems 
 Genetic models of RAMP3 have received the least attention of the three RAMPs. 
However, exciting data is emerging about the role of RAMP3 in vivo. Ramp3-/- mice are 
viable, reproduce normally, and display no obvious defects from birth to 8 months [49]. 
Unlike RAMP1 and RAMP2, loss of RAMP3 had no effect on basal blood pressure or heart 
rate. The only overt phenotype was observed in aged mice. At nine months, Dackor et al. 
noticed that Ramp3-/- mice weighed significantly less than their age-matched controls, 
though no changes in food or water intake were observed. Despite this leanness, Ramp3-/- 
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mice have a similar life expectancy with no obvious decline in health despite their leanness 
[49].   
While no overt phenotypes were observed basally, two recent papers have identified 
a sex-dependent cardioprotective role for RAMP3. Previous data indicated that Ramp3 is 
robustly upregulated in the cardiovascular system during hypertension. Additionally, Ramp3 
is potently induced by estrogen [51-54]. Therefore, Barrick et al. hypothesized that Ramp3 
would be cardioprotective in the setting of hypertension but that the effect would be 
dependent on sex [51]. To examine this hypothesis, the authors intercrossed Ramp3 and 
RenTgMK mice, which have high and constant secretion of renin, elevated circulating levels 
of angiogtensin II, and chronic hypertension [51,55]. Interestingly, male but not female 
RenTgMK;Ramp3-/- mice exhibit significantly greater renal damage than RenTgMK mice. 
Similarly, male but not female RenTgMK;Ramp3-/-  mice exhibit significant pathological 
changes in heart tissue consistent with cardiac hypertrophy. Echocardiography revealed that 
loss of Ramp3 exacerbates the RenTgMK phenotype of concentric cardiac hypertrophy and 
caused left ventricular dilation and progression to systolic failure by 5 months of age. This 
decompensated hypertrophy and transition to heart failure was not evident in RenTgMK or 
female RenTgMK;Ramp3-/- mice even when aged 8 months. Collectively, these data make a 
compelling argument for a sex-dependent role for Ramp3 in the setting of chronic 
hypertension. While the authors argue that AM signaling through CLR-RAMP3 could be 
involved, they hypothesize that other GPCRs are also involved.  
Indeed, a follow-up study identified a novel interaction of GPR30, now known as 
GPER, with RAMP3 that confers sex-dependent cardioprotection in vivo [27]. Studies have 
shown that GPR30 is involved in mediating the effects of estrogen in the heart [56]. 
Synthetic activation of GPR30 with the specific GPR30 agonist G-1 protects cardiac tissue 
from injury in several models of heart disease [57-59]. Despite the substantial functional 
data, controversy regarding the trafficking, subcellular location, and ligand binding of GPR30 
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confounded the field. Based on these questions, the functional role of RAMP3, and the 
cardioprotective nature of both GPR30 and RAMP3, Lenhart et al. hypothesized that GPR30 
and RAMP3 could form a complex that mediates cardioprotection during cardiovascular 
stress [27].  
 After confirming a protein-protein interaction between GPR30 and RAMP3 in vitro, 
investigation of mouse cardiac tissue revealed that GPR30 was mislocalized in the absence 
of RAMP3. In both male and female Ramp3-/- mice, the proportion of GPR30 at the plasma 
membrane was decreased with a concomitant increase in cystolic GPR30 protein relative to 
wild-type controls. Sex differences in GPR30 localization were also observed, as the 
proportion of GPR30 protein at the plasma membrane was increased in females compared 
to males across all genotypes. However, the difference between males and females was 
most significant when Ramp3, an estrogen regulated gene, was present.  
 More importantly, absence of Ramp3 and subsequent mislocalization of GPR30 has 
functional consequences. As expected, G1 treatment, which signals through GPR30 agonist 
and confers cardioprotection, causes a statistically significant decrease in cardiac disease 
pathology in RenTgMK;Ramp3+/+ male mice. Cardiac fibrosis and markers of hypertrophy, 
left ventricle weight to body weight measurements and cardiomyocyte area, were all 
decreased in G1- vs. placebo-treated RenTgMK;Ramp3+/+ male mice. However, G1 had no 
effect RenTgMK;Ramp3-/- mice, suggesting that G1 cardioprotection is due directly to the 
GPR30-RAMP3 function in the heart. G1 treatment of female mice had no effect regardless 
of Ramp3 genotype status, suggesting that because they exhibit higher GPR30 levels at the 
cell membrane basally, female mice remain cardioprotected even in the absence of Ramp3 
[27]. Conversely, male mice only respond to G1 treatment if Ramp3 is present to help 
maintain cell surface localization of GPR30.  
 These data are exciting for several reasons. First, it provides a novel, 
physiologically significant GPCR-RAMP pair. Secondly, the sex-dependent nature of the 
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GPR30-RAMP3 may elucidate important pathways that contribute to the gender differences 
seen in cardiovascular disease and may allow for gender-specific treatment. Finally, this is 
the first identification of a RAMP interacting with a Family A GPCR. With the exception of 
CaSR, the RAMP field has focused exclusively on Family B, the secretin family of receptors. 
These data suggest that RAMPs could have a much broader impact than originally 
suspected.  
Concluding remarks and future questions 
The discovery of RAMPs elucidated a novel mechanism for the regulation of GPCRs 
and transformed our understanding of GPCR pharmacology. Future studies will aim to 
identify additional RAMP-GPCR pairs with a particular focus on their functional 
consequences. If these pairs are found to have roles in normal or disease physiology, 
targeting at the RAMP-GPCR interface could prove to be a very powerful tool.  
Parsing out the exact physiological effect of each RAMP-GPCR pair will be the focus 
of future studies. The ability of RAMPs to bind many receptors confounds the study of 
genetic mouse models. Targeting the GPCR-RAMP interface, therefore, will not only prove 
useful for the treatment of disease, but also in the determination of the functionality of 
specific GPCR-RAMP pairs.  
Additionally, there is much more to understand about the biochemistry of RAMPs. 
For example, the stoichiometry of RAMPs to their GPCR partner has been studied but is still 
debated. Evidence exists for a 1:1, 2:2, and 2:1 ratio of CLR:RAMP; however, whether the 
stoichiometry differs by cellular environment or between GPCRs is not known [15,60,61]. It 
is possible that these questions will become even more convoluted with the identification of 
GPCR heterodimers that interact with RAMPs. So far, studies have only focused on the 
interaction of one GPCR with one RAMP, but it is possible that two different GPCRs could 
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complex with a RAMP, or two different RAMPs could bind to a single GPCR. It is possible 
that we have just begun to discover the breadth of RAMP biology.  
RAMPs provide a beautiful example of the complexity of GPCR pharmacology. 
Though a finite number of GPCRs exist, their ability to heterodimerize with additional 
proteins allows for exponential combinations and diverse cellular signaling. While this makes 
comprehensive understanding of their activity challenging, it may allow for highly specific 
drug targeting. Consequently, further biochemical and genetic studies are warranted in order 
to harness the therapeutic potential of the RAMP-GPCR interface in human disease.  
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TABLES 
Table 4-1. RAMP associating GPCRs 
Receptor Family GPCR Associating RAMPs 
A GPR30 RAMP3 
B CLR 
RAMP1 
RAMP2 
RAMP3 
B CTR 
RAMP1 
RAMP2 
RAMP3 
B CRF RAMP2 
B Glucagon Receptor RAMP2 
B PTH1R RAMP2 
B PTH2R RAMP3 
B Secretin receptor RAMP3 
B VPAC1R 
RAMP1 
RAMP2 
RAMP3 
B VPAC2R 
RAMP1 
RAMP2 
RAMP3 
C CaSR 
RAMP1 
RAMP3 
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FIGURES 
 
Figure 4-1. Effects of RAMP association on CLR and CTR. (A) For cell surface 
expression, calcitonin receptor-like receptor requires the presence of one of the RAMP 
family members. CLR associates with RAMPs in the ER, which facilitates plasma membrane 
expression. Association with RAMP1 yields a high affinity calcitonin gene related peptide 
(CGRP) receptor, whereas CLR association with RAMP2 or -3 results in a potent 
adrenomedullin (AM) receptor. (B) Conversely, calcitonin receptor (CTR) is trafficked to the 
plasma membrane independent of RAMPs. In the absence of a RAMP, CTR binds 
calcitonin. In association with RAMP1, -2, -3, the CTR-RAMP complex binds amylin (AMY).
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2
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Figure 4-2. The effects of RAMP association on GPCR pharmacology. 
 125 
REFERENCES 
1. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein-coupled 
receptors in the human genome form five main families. Phylogenetic analysis, 
paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272. 
2. Rask-Andersen M, Almen MS, Schioth HB (2011) Trends in the exploitation of novel drug 
targets. Nat Rev Drug Discov 10: 579-590. 
3. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2009) Modulating receptor 
function through RAMPs: can they represent drug targets in themselves? Drug 
Discov Today 14: 413-419. 
4. Muff R, Born W, Lutz TA, Fischer JA (2004) Biological importance of the peptides of the 
calcitonin family as revealed by disruption and transfer of corresponding genes. 
Peptides 25: 2027-2038. 
5. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, et al. (2002) International Union 
of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, 
adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 54: 233-246. 
6. Fluhmann B, Muff R, Hunziker W, Fischer JA, Born W (1995) A human orphan calcitonin 
receptor-like structure. Biochem Biophys Res Commun 206: 341-347. 
7. Hay DL, Poyner DR, Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 
109: 173-197. 
8. Njuki F, Nicholl CG, Howard A, Mak JC, Barnes PJ, et al. (1993) A new calcitonin-
receptor-like sequence in rat pulmonary blood vessels. Clin Sci (Lond) 85: 385-388. 
9. Aiyar N, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, et al. (1996) A cDNA encoding 
the calcitonin gene-related peptide type 1 receptor. J Biol Chem 271: 11325-11329. 
10. Han ZQ, Coppock HA, Smith DM, Van Noorden S, Makgoba MW, et al. (1997) The 
interaction of CGRP and adrenomedullin with a receptor expressed in the rat 
pulmonary vascular endothelium. J Mol Endocrinol 18: 267-272. 
11. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, et al. (1998) RAMPs regulate the 
transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 
333-339. 
 126 
12. Parameswaran N, Spielman WS (2006) RAMPs: The past, present and future. Trends 
Biochem Sci 31: 631-638. 
13. Fraser NJ, Wise A, Brown J, McLatchie LM, Main MJ, et al. (1999) The amino terminus 
of receptor activity modifying proteins is a critical determinant of glycosylation state 
and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 55: 1054-1059. 
14. Udawela M, Christopoulos G, Tilakaratne N, Christopoulos A, Albiston A, et al. (2006) 
Distinct receptor activity-modifying protein domains differentially modulate interaction 
with calcitonin receptors. Mol Pharmacol 69: 1984-1989. 
15. Kusano S, Kukimoto-Niino M, Hino N, Ohsawa N, Okuda K, et al. (2012) Structural basis 
for extracellular interactions between calcitonin receptor-like receptor and receptor 
activity-modifying protein 2 for adrenomedullin-specific binding. Protein Sci 21: 199-
210. 
16. Kusano S, Kukimoto-Niino M, Akasaka R, Toyama M, Terada T, et al. (2008) Crystal 
structure of the human receptor activity-modifying protein 1 extracellular domain. 
Protein Sci 17: 1907-1914. 
17. Steiner S, Muff R, Gujer R, Fischer JA, Born W (2002) The transmembrane domain of 
receptor-activity-modifying protein 1 is essential for the functional expression of a 
calcitonin gene-related peptide receptor. Biochemistry 41: 11398-11404. 
18. Perry KJ, Quiza M, Myers DE, Morfis M, Christopoulos G, et al. (1997) Characterization 
of amylin and calcitonin receptor binding in the mouse alpha-thyroid-stimulating 
hormone thyrotroph cell line. Endocrinology 138: 3486-3496. 
19. Armour SL, Foord S, Kenakin T, Chen WJ (1999) Pharmacological characterization of 
receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor. J 
Pharmacol Toxicol Methods 42: 217-224. 
20. Christopoulos G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, et al. (1999) Multiple amylin 
receptors arise from receptor activity-modifying protein interaction with the calcitonin 
receptor gene product. Mol Pharmacol 56: 235-242. 
21. Muff R, Buhlmann N, Fischer JA, Born W (1999) An amylin receptor is revealed following 
co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -
3. Endocrinology 140: 2924-2927. 
 127 
22. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, et al. (2003) Novel 
receptor partners and function of receptor activity-modifying proteins. J Biol Chem 
278: 3293-3297. 
23. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2012) RAMPs as drug 
targets. Adv Exp Med Biol 744: 61-74. 
24. Morfis M, Tilakaratne N, Furness SG, Christopoulos G, Werry TD, et al. (2008) Receptor 
activity-modifying proteins differentially modulate the G protein-coupling efficiency of 
amylin receptors. Endocrinology 149: 5423-5431. 
25. Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, et al. (2013) Receptor 
activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 
receptors and modulate their function. Br J Pharmacol 168: 822-834. 
26. Bouschet T, Martin S, Henley JM (2005) Receptor-activity-modifying proteins are 
required for forward trafficking of the calcium-sensing receptor to the plasma 
membrane. J Cell Sci 118: 4709-4720. 
27. Lenhart PM, Broselid S, Barrick CJ, Leeb-Lundberg LF, Caron KM (2013) GPR30 
Interacts with RAMP3 and Confers Sex-Dependent Cardioprotection. J Mol 
Endocrinol 51:191-202. 
28. Hilairet S, Belanger C, Bertrand J, Laperriere A, Foord SM, et al. (2001) Agonist-
promoted internalization of a ternary complex between calcitonin receptor-like 
receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol 
Chem 276: 42182-42190. 
29. Kuwasako K, Shimekake Y, Masuda M, Nakahara K, Yoshida T, et al. (2000) 
Visualization of the calcitonin receptor-like receptor and its receptor activity-
modifying proteins during internalization and recycling. J Biol Chem 275: 29602-
29609. 
30. Heroux M, Breton B, Hogue M, Bouvier M (2007) Assembly and signaling of CRLR and 
RAMP1 complexes assessed by BRET. Biochemistry 46: 7022-7033. 
31. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS (2005) Novel function 
for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor 
trafficking. J Biol Chem 280: 9297-9307. 
 128 
32. Bomberger JM, Spielman WS, Hall CS, Weinman EJ, Parameswaran N (2005) Receptor 
activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin 
receptor trafficking by NHERF-1. J Biol Chem 280: 23926-23935. 
33. Kadmiel M, Fritz–Six K, Caron K, editors (2011) Understanding RAMPs Through 
Genetically Engineered Mouse Models. Austin: Landes Bioscience. 
34. Tsujikawa K, Yayama K, Hayashi T, Matsushita H, Yamaguchi T, et al. (2007) 
Hypertension and dysregulated proinflammatory cytokine production in receptor 
activity-modifying protein 1-deficient mice. Proc Natl Acad Sci U S A 104: 16702-
16707. 
35. Sabharwal R, Zhang Z, Lu Y, Abboud FM, Russo AF, et al. (2010) Receptor activity-
modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-
induced hypertension. Hypertension 55: 627-635. 
36. Chrissobolis S, Zhang Z, Kinzenbaw DA, Lynch CM, Russo AF, et al. (2010) Receptor 
activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-
related peptide and inhibits angiotensin II-induced vascular dysfunction. Stroke 41: 
2329-2334. 
37. Kurashige C, Hosono K, Matsuda H, Tsujikawa K, Okamoto H, et al. (2014) Roles of 
receptor activity-modifying protein 1 in angiogenesis and lymphangiogenesis during 
skin wound healing in mice. Faseb j 28: 1237-1247. 
38. Fritz-Six KL, Dunworth WP, Li M, Caron KM (2008) Adrenomedullin signaling is 
necessary for murine lymphatic vascular development. J Clin Invest 118: 40-50. 
39. Li M, Wetzel-Strong SE, Hua X, Tilley SL, Oswald E, et al. (2014) Deficiency of RAMP1 
attenuates antigen-induced airway hyperresponsiveness in mice. PLoS One 9: 
e102356. 
40. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF (2007) Sensitization of calcitonin 
gene-related peptide receptors by receptor activity-modifying protein-1 in the 
trigeminal ganglion. J Neurosci 27: 2693-2703. 
41. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine--current understanding and 
treatment. N Engl J Med 346: 257-270. 
42. Bell IM (2014) Calcitonin gene-related peptide receptor antagonists: new therapeutic 
agents for migraine. J Med Chem 57: 7838-7858. 
 129 
43. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, Kawate H, Iinuma N, et al. (2008) The 
GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. 
J Clin Invest 118: 29-39. 
44. Yoshizawa T, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, et al. (2013) Novel 
regulation of cardiac metabolism and homeostasis by the adrenomedullin-receptor 
activity-modifying protein 2 system. Hypertension 61: 341-351. 
45. Hougen K, Aronsen JM, Stokke MK, Enger U, Nygard S, et al. (2010) Cre-loxP DNA 
recombination is possible with only minimal unspecific transcriptional changes and 
without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice. Am J Physiol Heart Circ 
Physiol 299: H1671-1678. 
46. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, et al. (2009) Avoidance of 
transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer 
gene deletion models. Circ Res 105: 12-15. 
47. Buelow B, Scharenberg AM (2008) Characterization of parameters required for effective 
use of tamoxifen-regulated recombination. PLoS One 3: e3264. 
48. Koyama T, Ochoa-Callejero L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, et al. (2013) 
Vascular endothelial adrenomedullin-RAMP2 system is essential for vascular 
integrity and organ homeostasis. Circulation 127: 842-853. 
49. Dackor R, Fritz-Six K, Smithies O, Caron K (2007) Receptor activity-modifying proteins 2 
and 3 have distinct physiological functions from embryogenesis to old age. J Biol 
Chem 282: 18094-18099. 
50. Kadmiel M, Fritz-Six K, Pacharne S, Richards GO, Li M, et al. (2011) Research 
resource: Haploinsufficiency of receptor activity-modifying protein-2 (RAMP2) causes 
reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine 
dysfunction in mice. Mol Endocrinol 25: 1244-1253. 
51. Barrick CJ, Lenhart PM, Dackor RT, Nagle E, Caron KM (2012) Loss of receptor activity-
modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in 
a sex-dependent manner. J Mol Cell Cardiol 52: 165-174. 
52. Hewitt SC, Collins J, Grissom S, Deroo B, Korach KS (2005) Global uterine genomics in 
vivo: microarray evaluation of the estrogen receptor alpha-growth factor cross-talk 
mechanism. Mol Endocrinol 19: 657-668. 
 130 
53. Watanabe H, Takahashi E, Kobayashi M, Goto M, Krust A, et al. (2006) The estrogen-
responsive adrenomedullin and receptor-modifying protein 3 gene identified by DNA 
microarray analysis are directly regulated by estrogen receptor. J Mol Endocrinol 36: 
81-89. 
54. Tadokoro K, Nishikimi T, Mori Y, Wang X, Akimoto K, et al. (2003) Altered gene 
expression of adrenomedullin and its receptor system and molecular forms of tissue 
adrenomedullin in left ventricular hypertrophy induced by malignant hypertension. 
Regul Pept 112: 71-78. 
55. Caron KM, James LR, Kim HS, Morham SG, Sequeira Lopez ML, et al. (2002) A 
genetically clamped renin transgene for the induction of hypertension. Proc Natl 
Acad Sci U S A 99: 8248-8252. 
56. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, et al. (2009) A new 
membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 
17beta-estradiol in the male rat. J Physiol Pharmacol 60: 3-10. 
57. Bopassa JC, Eghbali M, Toro L, Stefani E (2010) A novel estrogen receptor GPER 
inhibits mitochondria permeability transition pore opening and protects the heart 
against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 298: H16-23. 
58. Kang S, Liu Y, Sun D, Zhou C, Liu A, et al. (2012) Chronic activation of the g protein-
coupled receptor 30 with agonist g-1 attenuates heart failure. PLoS One 7: e48185. 
59. Wang H, Jessup JA, Lin MS, Chagas C, Lindsey SH, et al. (2012) Activation of GPR30 
attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized 
mRen2.Lewis rats. Cardiovasc Res 94: 96-104. 
60. Heroux M, Hogue M, Lemieux S, Bouvier M (2007) Functional calcitonin gene-related 
peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-
like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. 
J Biol Chem 282: 31610-31620. 
61. Watkins HA, Au M, Bobby R, Archbold JK, Abdul-Manan N, et al. (2013) Identification of 
key residues involved in adrenomedullin binding to the AM1 receptor. Br J 
Pharmacol 169: 143-155. 
 131 
 
Chapter 5: The Novel Interaction of Receptor Activity Modifying Proteins with the 
Family A Seven Transmembrane Chemokine Receptors 
 
Introduction  
 Receptor activity modifying proteins (RAMPs) are single pass transmembrane 
proteins that complex with certain G protein-coupled receptors (GPCRs) to alter ligand 
binding, receptor trafficking, and downstream signaling [1,2]. First discovered in 1998, 
RAMP modulation of GPCRs added an additional layer of complexity to GPCR 
pharmacology [3]. However, the RAMP-GPCR complex resolved significant debate over the 
ligand specificity and cellular trafficking of certain receptors [4]. For example, the interaction 
of calcitonin receptor-like receptor (CLR) with RAMP2 or RAMP3 constitutes a functional 
receptor for the peptide hormone, adrenomedullin (AM), while CLR association with RAMP1 
changes the ligand affinity to a different peptide, CGRP [4,5]. Additionally, plasma 
membrane expression of CLR is dependent on a RAMP chaperone [4]. While not all GPCRs 
require them, RAMPs offer a unique opportunity for drug discovery, as the RAMP-receptor 
interface could yield specific, high affinity drugs [2,6]. Consequently, there has been great 
interest in discovering alternate RAMP-GPCR pairs.  
Chemokine receptors (CKRs) are seven transmembrane receptors that belong to the 
largest family of GPCRs, Rhodopsin-like or Family A receptors. CKRs and their ligands have 
critical roles in immune defense – mediating attraction, migration, proliferation, and 
activation of immune cells [7]. Roles also exist for these receptors outside of the immune 
system during normal and disease physiology [8-12]. While RAMP research has largely 
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focused on the Family B G protein-coupled secretin receptors, the association of RAMPs 
with the Family A receptor G protein-coupled estrogen receptor 1 (GPER), formerly known 
as GPR30, has recently been appreciated and broadened the scope of RAMP-GPCR 
interactions [13].  
Increasing evidence suggests a potential interaction of RAMPs with the CKRs. 
Firstly, many CKRs have promiscuous ligand binding, displaying the ability to bind a broad 
spectrum of molecules. Interestingly, their promiscuity extends beyond typical chemokines, 
as two recently published papers establish that peptide hormones bind the chemokine 
receptor CXCR7 [10,14]. This diverse binding profile is reminiscent of RAMP modulation of 
CLR ligand specificity. 
Furthermore, several CKRs belong to a small family of atypical chemokine receptors 
(ACKR) or non-signaling decoy receptors, which act as molecular sinks for ligands, and 
whose pharmacology resonates with RAMP modulation of GPCRs. In order to promote the 
rapid sequestration of ligand, a decoy receptor must be quickly recycled. Indeed, several 
studies have noted rapid shuttling of these receptors to and from the cell surface and the 
endosome [15,16]. RAMP3 is unique among the RAMP family as it contains a PDZ domain 
in the C-terminus that allows for the interaction of RAMP3 with N-ethylmaleimide-sensitive 
factor (NSF), a trafficking protein that facilitates the rapid recycling of receptors [17]. 
Association of the RAMP3-GPCR complex with NSF converts the receptor lifecycle from a 
degradative to a recycling pathway. Whether RAMP3 could participate in CKR recycling has 
not yet been investigated.  
Finally, the intracellular environment of a particular ACKR, CXCR7, dramatically 
alters the downstream signaling of the receptor. Consistent with its function as a ligand sink, 
initial studies demonstrated that CXCR7 fails to elicit downstream signaling upon ligand 
binding [18]. However, more recent studies indicate that CXCR7 can induce beta-arrestin 
mediated signal [19]. Moreover, while CXCR7 does not typically couple to a G protein, data 
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suggests that, in astrocytes, CXCR7 is capable of coupling to Gαi [19-22]. No determinant of 
these functional differences has been identified, however, RAMPs offer a potential 
explanation for these inconsistencies. We thus hypothesized that chemokine receptors 
interact with RAMPs.  
Specifically, based on the Caron laboratory’s interest in CXCR7 (Chapter 2), we 
aimed to determine whether three related members of the chemokine receptor family, 
CXCR7, CXCR4, and CCR5 interact with the RAMP family. These CKRs are capable of 
heterodimerizing with each other – CXCR4 forms stable heterodimers with both CXCR7 and 
CCR5 [21,23,24]  – and they share biological activity. CXCR7 and CXCR4, which both bind 
CXCL12, have been extensively studied for their roles in cancer progression [25]. 
Additionally, CCR5 and CXCR4, and to a smaller degree CXCR7, act as co-receptors for 
human immunodeficiency virus (HIV). RAMP interaction with CKRs, therefore, offers exciting 
potential for drug discovery. Here, we utilize biolumescence resonance energy transfer 
(BRET), confocal imaging, and a fluorogen activating protein (FAP) assay to present 
preliminary data demonstrating novel protein-protein interactions between these three CKRs 
and the RAMP family.   
Experimental procedures 
Bioluminescent Resonance Energy Transfer  
To test the association of the chemokine receptors with the RAMPs, BRET titration 
studies were performed as described previously [13,26]. Briefly, HEK293T cells were 
transfected with the positive control (CLR-Rluc), the negative control (B2ADR-Rluc), or 
experimental plasmids (CXCR7-Rluc, CXCR4-Rluc, CCR5-Rluc), and increasing amounts of 
RAMP1-YFP, RAMP2-YFP, or RAMP3-YFP. Cells were treated with a luciferase substrate, 
coelanterazine H, for 10 minutes, and plates were read on a Berthold Technologies Mithras 
LB940 plate reader. BRET signal was calculated as the ratio of light emitted from YFP (530 
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nm) to the light emitted from Rluc (485 nm) ratio. Total YFP (measured in untreated wells) 
and total luminescence were used to control for the transfection efficiency. BRET data were 
analyzed and evaluated using a non-linear regression equation assuming a single binding 
site (GraphPad Prism). 
Confocal Imaging 
 HEK293T cells were plated on 35 mm MatTek glass bottom culture dishes and co-
transfected with RAMP3-YFP and untagged positive control (CLR), negative control (B2ADR 
or V2R) or experimental plasmids (CXCR7, CXCR4, and CCR5). 24 hours following 
transfection, live cells were imaged. Optical sections were acquired on the confocal 
microscope using the Zeiss LSM Image Browser v4.2. 
FAP assay 
Plasmids. FAP-RAMP3 was generated using multisite gateway cloning following 
manufacturer’s instruction (Life Technologies). Briefly, a RAMP3 entry clone (attL5-RAMP3-
attL2) was constructed by inserting an att-flanked RAMP3 geneblock (element 2, attB5-
RAMP3-attB2; Integrated DNA Technologies) into a P5-P2 pDONR vector using BP clonase 
II. Recombination of the RAMP3 entry clone with a FAP entry clone (element 1, attL1-
RAMP3-attR5) into a destination vector yielded the final FAP-RAMP3 expression clone.  
FAP assay. HEK293T cells were transfected with 0.75 µg FAP-RAMP3 and 0.75 µg 
CLR, V2R, B2ADR, or CCR5. Cells were washed with PBS and treated with a cell 
impermeant malachite green (MG) fluorogen (1:4000) ~5 minutes prior to imaging. Cells 
were imaged on an Odyssey scanner (Li-COR).  
 
 
 
 135 
Results 
In order to investigate whether the CKRs interact with RAMPs, we first performed 
BRET studies, which have been previously used to demonstrate protein-protein interactions 
between RAMPs and GPCRs [13,27]. Here, HEK293T cells were transfected with constant 
amounts of a Renilla luciferase (Rluc)-GPCRs and increasing amounts of YFP-tagged 
RAMP. The well-established interaction of CLR with RAMPs were utilized as a positive 
control, while beta-2 adrenergic receptor (B2ADR) provided a negative control. In cells 
expressing CLR, we observed a robust change in BRET signal with increasing RAMP2-YFP 
(Figure 5-1A, green). Conversely, B2ADR-expressing cells demonstrated a linear 
relationship to increasing concentration of RAMP2-YFP, which is characteristic of a non-
specific interaction (Figure 5-1A, red) [28].  
We then examined the interaction of the CKRs with the RAMP family. Similar to the 
positive control control, we observed an increase in BRET signal in cells cotransfected with 
CXCR7 and increasing amounts of RAMP2-YFP or RAMP3-YFP (Figure 5-1B), indicating a 
potential interaction between CXCR7 and two members of the RAMP family. Conversely, we 
detected a linear, non-specific interaction between CXCR7 and RAMP1-YFP (Figure 5-1B), 
suggesting that CXCR7 and RAMP1 fail to associate. It is possible that the donor (Rluc) and 
acceptor (YFP) molecules are not in the correct orientation for interaction. Therefore, these 
data are considered inconclusive [28]. In cells expressing CXCR4-Rluc, we detected an 
increase in BRET signal with increasing amounts of RAMP2-YFP and RAMP3-YFP (Figure 
5-1C). Cells expressing CCR5-Rluc also demonstrated robust changes in BRET signal with 
increasing doses of RAMP2-YFP and RAMP3-YFP (Figure 5-1D). CCR5-expressing cells 
demonstrated an inconclusive, linear relationship to increasing doses of RAMP1-YFP. 
 Based on our interest in the trafficking potential of RAMP3 and the positive BRET 
signal observed with CXCR4 and CCR5, we sought to confirm the interaction of these CKRs 
with RAMP3 using the classical assay for RAMP association. As RAMPs do not traffic to the 
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plasma membrane without a receptor, the ability of a GPCR to translocate a RAMP to the 
cell surface is the standard in the field for determining RAMP-receptor interactions [13,27]. 
We therefore investigated whether the CKRs were able to transport RAMP3-YFP to the 
plasma membrane. As shown in Figure 5-2A,B, in HEK293T cells transiently expressing 
B2ADR or vasopressin 2 receptor (V2R), RAMP3-YFP does not localize to the plasma 
membrane. Conversely, in CLR-expressing cells RAMP3-YFP is robustly expressed at the 
plasma membrane (Figure 5-2C, white arrows). Interestingly, we observed similar plasma 
membrane expression with all three CKR receptors (Figure 5-2D-F, white arrows). Plasma 
membrane localization of RAMP3-YFP was more obvious in cells expressing CXCR4 and 
CCR5 than with CXCR7. However, plasma membrane localization was particularly well 
visualized at cell-cell contacts in CXCR7-expressing cells, where presence of two plasma 
membranes allowed for clear linear fluorescence (Figure 5-2D, white arrows). Importantly, 
this linear fluorescence is not observed in V2R and RAMP3 expressing cells (Figure 5-2B), 
where multiple cells are imaged.  
 Finally, we utilized a FAP assay to quantitatively determine plasma membrane 
expression of RAMP3. Developed by the Waggoner group in 2007, fluorogen activated 
proteins are protein reporters that generate fluorescence only when bound to a specific 
chemical label (fluorogen) [29]. Exposing N-terminally FAP-tagged proteins to cell-
impermeant fluorogen allows for visualization of plasma membrane localized proteins, while 
intracellular proteins that have not been activated by the fluorogen remain dark [30]. 
Conveniently, the fluorogen has absorption and emission wavelengths such that it can be 
directly imaged on the Odyssey Imaging System (Li-COR). We thus generated and 
expressed an N-terminally tagged RAMP3 in HEK293T cells. While minimal FAP-RAMP3 
was visualized when co-expressed with V2R or B2ADR (Figure 5-3A, second and third 
columns), we observed a statistically significant increase in plasma membrane localization 
of FAP-RAMP3 when cells expressing CLR or CCR5 were treated with cell impermeant 
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fluorogen (Figure 5-3A,B, first and fourth column). These data further support the 
interaction of CKRs with the RAMP family.  
Discussion 
In the current study, we present preliminary evidence suggesting an interaction 
between RAMPs and CXCR7, CXCR4, and CCR5. First, utilizing a well-characterized BRET 
assay for determining protein-protein interactions, we observed robust interactions of 
CXCR7, CXCR4, and CCR5 with members of the RAMP family. Co-expression of CXCR7 
and CCR5 with the RAMP1-YFP constructs resulted in BRET curves similar to those of the 
negative control (B2ADR). Because the placement of the donor and acceptor molecules on 
the proteins is critical to facilitate the interaction, we could not conclude that CXCR7 and 
CCR5 do not interact with RAMP1. However, numerous receptors have been shown to 
complex with some but not all of the members of the RAMP family (Table 4-1); the 
association of CXCR7 and CCR5 with RAMP2 and -3, but not RAMP1, would therefore be 
consistent with previous reports. 
For the remainder of our studies, we focused on CKR association with RAMP3. 
RAMP3 is a particularly attractive candidate for association with CKRs, as the PDZ domain 
of RAMP3 regulates receptor trafficking [17,31]. ACKRs, like CXCR7 (also known as 
ACKR3), must continuously cycle from the plasma membrane and endosomal 
compartments, thus enabling efficient internalization and delivery of ligand for lysosomal 
degradation [32]. ACKR interaction with RAMP3 may facilitate this rapid recycling via NSF 
[17]. Furthermore, typical CKRs may need to remain at the cell surface to perpetuate 
signaling. The interaction of the PDZ domain of RAMP3 with Na+/H+ exchanger regulatory 
factor-1 (NHERF-1), an adaptor protein that prevents receptor internalization, could stabilize 
receptor expression at the plasma membrane [31]. Therefore, RAMP3 association with 
CKRs may result in functional consequences that are both interesting and easily assessed. 
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As RAMPs do not traffic to the cell surface independently, visualization of RAMP 
expression at the plasma membrane by confocal microscopy is considered the standard in 
the field for demonstrating RAMP-GPCR interactions. Consistent with our BRET data, we 
found that co-expression of CXCR4 or CCR5 with RAMP3-YFP allowed for robust 
visualization of RAMP3-YFP at the cell surface, providing further evidence that these CKRs 
associate with RAMPs. We also noted some plasma membrane localization of RAMP3 in 
cells expressing CXCR7, suggesting that CXCR7 does indeed interact with RAMP3.  
In addition to these well-characterized assays, we utilized a newly described FAP 
assay to quantitatively determine RAMP expression at the cell surface [29]. While RAMP 
translocation by GPCRs has been the gold standard for determining RAMP associations, it 
is inherently biased by which cells are imaged. In contrast, the FAP assay allows for 
visualization of plasma membrane expression of entire populations of cells. Again, 
consistent with our previous findings, we found that similar to CLR, FAP-RAMP3 
successfully localizes to the plasma membrane when co-expressed with CCR5, whereas 
minimal plasma membrane expression of FAP-RAMP3 was observed in cells expressing 
B2ADR and V2R. Collectively, these data suggest that CKRs are able to form protein 
complexes with RAMPs. 
Whether these interactions have functional consequences has yet to be determined. 
However, RAMP association could explain some of CKR pharmacology, including 
chemokine promiscuity, receptor recycling, and inconsistencies in downstream signaling. 
Endogenous expression of RAMPs may affect the biological activity of CKRs. The presence 
of a particular CKR-RAMP complex may alter ligand specificity or affinity. Likewise, as it has 
been shown to do for other GPCRs, RAMP association with CKR may affect G protein 
coupling [33,34]. For example, the presence of a RAMP may account for CXCR7 coupling to 
Gαi in astrocytes, whereas in other cell types, where endogenous RAMP expression is low, 
CXCR7 fails to G protein couple [20].  
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Moreover, although these results are preliminary, the CKR-RAMP interaction may 
have pathophysiological roles. CKRs and their ligands play pivotal roles in normal 
physiology. As such, dysregulation of their signaling can result in severe pathologies, 
including autoimmune disorders, pulmonary disease, transplant rejection, cancer, and 
vascular disease [35].  Moreover, viral exploitation of CKRs can facilitate their entry into host 
cells [35].  For example, HIV primarily uses CCR5 and CXCR4 for entry into human CD4+ T 
cells [36]. Consequently, direct antagonism of chemokine receptors offers potential for 
treatment of a wide variety of disease. CXCR4 and CXCR7 have already received 
significant attention from pharmaceutical companies for their roles in cancer metastasis [37]. 
If their association with RAMPs has functional consequences, the RAMP-CKR interface 
could be exploited for anticancer therapies.  
More interestingly, several naturally occurring mutations in the coding region of 
CCR5 have been identified to affect the transport, binding, and signaling of CCR5 [38]. 
CCR5-893(–) is a single-nucleotide deletion observed exclusively in Asians, which results in 
premature termination of translation, a 54 amino acid deletion at the C-terminus, and poor 
cell surface expression of CCR5 [39,40]. While this mutation has not been studied 
extensively, it is possible that this truncation interferes with the association of CCR5 with a 
RAMP, thus preventing cell surface expression. Further research is necessary to evaluate 
whether the CCR5-RAMP association has biological consequences. Nevertheless, drugs 
designed to target the CCR5-RAMP interface could prove to be an exciting prospect for HIV 
therapy.  
In summary, our results demonstrate evidence for the novel interaction of CXCR7, 
CXCR4, and CCR5 with the RAMP family. The RAMP-CKR interaction adds complexity to 
an already complex CKR system. GPCR homo- and heterodimerization is a well-known 
phenomenon. It will be interesting to determine whether CKR heterodimers, like CXCR7-
CXCR4 or CCR5-CXCR4, form complexes with the RAMPs, and if RAMP-heterodimer 
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interactions yield different biological activities. Future studies will aim to address these 
questions.  Furthermore, these data emphasize the breadth of RAMP interaction with 
GPCRs. While they are still mostly considered modifiers of Family B GPCR, we may find 
that RAMPs touch every branch of the GPCR tree. 
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Figure 5-1. BRET analysis of CKR-RAMP protein-protein interaction 
(A) BRET analysis of CLR (green) and B2ADR (red) with RAMP2. CLR+RAMP2 shows a robust increase in BRET signal with 
increasing doses of RAMP2-YFP. B2ADR+RAMP2 displays a linear, non-specific interaction. (B) BRET analysis of CXCR7 with 
RAMP1 (blue), -2 (periwinkle), -3 (purple). CXCR7+RAMP1 displays a linear, nonspecific interaction. However, both 
CXCR7+RAMP2 and CXCR7+RAMP3 show positive changes in BRET signal with increasing RAMP-YFP. (C) BRET analysis of 
CXCR4 with RAMP2 (periwinkle) and -3 (purple). Both CXCR4+RAMP2 and CXCR4+RAMP3 show positive changes in BRET 
signal with increasing RAMP-YFP (D) BRET analysis of CCR5 with RAMP1, -2, and -3. CCR5+RAMP1 demonstrates a linear, 
non-specific interaction with increasing doses of RAMP1-YFP. CCR5-Rluc-expressing cells, however, show robust changes in 
BRET signal with increasing doses of RAMP2-YFP or RAMP3-YFP.  
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Figure 5-2. Localization of the GPCR-RAMP3 complex in vitro 
(A,B) In order to determine RAMP3 localization in the absence of an interacting receptor, 
B2ADR and V2R were co-transfected with RAMP3-YFP and live cells were visualized by 
confocal microscopy. While significant fluorescence was visible in the golgi apparatus, no 
plasma membrane localization of RAMP3 was observed. (C) CLR, a well-established 
RAMP3 partner, clearly enables RAMP3-YFP localization to the plasma membrane (white 
arrows). Plasma membrane localization was also observed when CXCR7 (D), CXCR4 (E), 
or CCR5 (F) were co-transfected with RAMP3-YFP. Plasma membrane localization was 
particularly well visualized at cell-cell contacts, where presence of two plasma membranes 
allowed for clear linear fluorescence (D, white arrows). Note that these are not seen in 
V2R+RAMP3-YFP (B), where multiple cells are imaged. 
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Figure 5-3. FAP assay of CCR5 interaction with RAMP3  
(A) HEK293T cells were transfected with positive (CLR) or negative (V2R and B2ADR) 
controls, or CCR5 and FAP-RAMP3 (FAP-R3). Cells were treated with a membrane 
impermeant fluorogen for 5 minutes and then imaged on an Odyssey scanner (LI-COR). 
Robust fluorogen labeling of cell surface proteins was observed in the positive control (FAP-
R3+CLR, first column) and with FAP-R3+CCR5 (fourth column). The negative controls had 
negligible cell surface labeling following treatment. (B) Quanititation of FAP assay. All wells 
were normalized to the average of the four nontransfected (NT) wells (column five in A). 
While no significant difference was observed between FAP-R3+CLR or FAP-R3+CCR5, a 
significant difference was observed in both conditions over FAP-R3+V2R and FAP-
R3+B2ADR (*p<0.05, **p<0.01, ***p<0.001)
 145 
REFERENCES 
1. Kadmiel M, Fritz–Six K, Caron K, editors (2011) Understanding RAMPs Through 
Genetically Engineered Mouse Models. Austin: Landes Bioscience. 
2. Hay DL, Poyner DR, Sexton PM (2006) GPCR modulation by RAMPs. Pharmacol Ther 
109: 173-197. 
3. Parameswaran N, Spielman WS (2006) RAMPs: The past, present and future. Trends 
Biochem Sci 31: 631-638. 
4. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, et al. (1998) RAMPs regulate the 
transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393: 
333-339. 
5. Husmann K, Born W, Fischer JA, Muff R (2003) Three receptor-activity-modifying proteins 
define calcitonin gene-related peptide or adrenomedullin selectivity of the mouse 
calcitonin-like receptor in COS-7 cells. Biochem Pharmacol 66: 2107-2115. 
6. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL (2012) RAMPs as drug 
targets. Adv Exp Med Biol 744: 61-74. 
7. Viola A, Luster AD (2008) Chemokines and their receptors: drug targets in immunity and 
inflammation. Annu Rev Pharmacol Toxicol 48: 171-197. 
8. Dambly-Chaudiere C, Cubedo N, Ghysen A (2007) Control of cell migration in the 
development of the posterior lateral line: antagonistic interactions between the 
chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev Biol 7: 23. 
9. Dona E, Barry JD, Valentin G, Quirin C, Khmelinskii A, et al. (2013) Directional tissue 
migration through a self-generated chemokine gradient. Nature 503: 285-289. 
10. Klein KR, Karpinich NO, Espenschied ST, Willcockson HH, Dunworth WP, et al. (2014) 
Decoy Receptor CXCR7 Modulates Adrenomedullin-Mediated Cardiac and 
Lymphatic Vascular Development. Dev Cell 30: 528-540. 
11. Valentin G, Haas P, Gilmour D (2007) The chemokine SDF1a coordinates tissue 
migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Curr Biol 
17: 1026-1031. 
 146 
12. Venkiteswaran G, Lewellis SW, Wang J, Reynolds E, Nicholson C, et al. (2013) 
Generation and dynamics of an endogenous, self-generated signaling gradient 
across a migrating tissue. Cell 155: 674-687. 
13. Lenhart PM, Broselid S, Barrick CJ, Leeb-Lundberg LF, Caron KM (2013) GPR30 
Interacts with RAMP3 and Confers Sex-Dependent Cardioprotection. J Mol 
Endocrinol 51:191-202. 
14. Ikeda Y, Kumagai H, Skach A, Sato M, Yanagisawa M (2013) Modulation of circadian 
glucocorticoid oscillation via adrenal opioid-CXCR7 signaling alters emotional 
behavior. Cell 155: 1323-1336. 
15. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD (2010) Constitutive and chemokine-
dependent internalization and recycling of CXCR7 in breast cancer cells to degrade 
chemokine ligands. Oncogene 29: 4599-4610. 
16. Weber M, Blair E, Simpson CV, O'Hara M, Blackburn PE, et al. (2004) The chemokine 
receptor D6 constitutively traffics to and from the cell surface to internalize and 
degrade chemokines. Mol Biol Cell 15: 2492-2508. 
17. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS (2005) Novel function 
for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor 
trafficking. J Biol Chem 280: 9297-9307. 
18. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, et al. (2006) A novel 
chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and 
tumor development. J Exp Med 203: 2201-2213. 
19. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, et al. (2010) Beta-arrestin- but not G 
protein-mediated signaling by the "decoy" receptor CXCR7. Proc Natl Acad Sci U S 
A 107: 628-632. 
20. Odemis V, Lipfert J, Kraft R, Hajek P, Abraham G, et al. (2012) The presumed atypical 
chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent 
astrocytes and human glioma cells. Glia 60: 372-381. 
21. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B (2009) CXCR7 
heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. 
Blood 113: 6085-6093. 
22. Thelen M, Thelen S (2008) CXCR7, CXCR4 and CXCL12: an eccentric trio? J 
Neuroimmunol 198: 9-13. 
 147 
23. Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, et al. (2009) Hetero-oligomerization 
of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J 
Biol Chem 284: 31270-31279. 
24. Contento RL, Molon B, Boularan C, Pozzan T, Manes S, et al. (2008) CXCR4-CCR5: a 
couple modulating T cell functions. Proc Natl Acad Sci U S A 105: 10101-10106. 
25. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C (2013) CXCR7 impact on CXCL12 
biology and disease. Trends Mol Med 19: 12-22. 
26. Heroux M, Breton B, Hogue M, Bouvier M (2007) Assembly and signaling of CRLR and 
RAMP1 complexes assessed by BRET. Biochemistry 46: 7022-7033. 
27. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ (2009) Molecular Basis 
of Association of Receptor Activity-Modifying Protein 3 with the Family B G Protein-
Coupled Secretin Receptor. Biochemistry. 
28. Marullo S, Bouvier M (2007) Resonance energy transfer approaches in molecular 
pharmacology and beyond. Trends Pharmacol Sci 28: 362-365. 
29. Szent-Gyorgyi C, Schmidt BF, Creeger Y, Fisher GW, Zakel KL, et al. (2008) Fluorogen-
activating single-chain antibodies for imaging cell surface proteins. Nat Biotechnol 
26: 235-240. 
30. Holleran J, Brown D, Fuhrman MH, Adler SA, Fisher GW, et al. (2010) Fluorogen-
activating proteins as biosensors of cell-surface proteins in living cells. Cytometry A 
77: 776-782. 
31. Bomberger JM, Spielman WS, Hall CS, Weinman EJ, Parameswaran N (2005) Receptor 
activity-modifying protein (RAMP) isoform-specific regulation of adrenomedullin 
receptor trafficking by NHERF-1. J Biol Chem 280: 23926-23935. 
32. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, et al. (2014) 
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update 
on the extended family of chemokine receptors and introducing a new nomenclature 
for atypical chemokine receptors. Pharmacol Rev 66: 1-79. 
33. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, et al. (2003) Novel 
receptor partners and function of receptor activity-modifying proteins. J Biol Chem 
278: 3293-3297. 
 148 
34. Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, et al. (2013) Receptor 
activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 
receptors and modulate their function. Br J Pharmacol 168: 822-834. 
35. Allen SJ, Crown SE, Handel TM (2007) Chemokine: receptor structure, interactions, and 
antagonism. Annu Rev Immunol 25: 787-820. 
36. Lusso P (2006) HIV and the chemokine system: 10 years later. EMBO J 25: 447-456. 
37. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, et al. (2011) CXCL12 
(SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for 
anticancer therapies? Clin Cancer Res 17: 2074-2080. 
38. Barmania F, Potgieter M, Pepper MS (2013) Mutations in C-C chemokine receptor type 
5 (CCR5) in South African individuals. Int J Infect Dis 17: e1148-1153. 
39. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA (1997) The extent of genetic 
variation in the CCR5 gene. Nat Genet 16: 221-222. 
40. Shioda T, Nakayama EE, Tanaka Y, Xin X, Liu H, et al. (2001) Naturally occurring 
deletional mutation in the C-terminal cytoplasmic tail of CCR5 affects surface 
trafficking of CCR5. J Virol 75: 3462-3468. 
 
 149 
 
Chapter 6: Conclusions and Future Directions 
 
Summary of Results 
We have presented preliminary data indicating that the chemokine receptors, 
CXCR7, CXCR4, and CCR5 form protein-protein interactions with members of the RAMP 
family. BRET studies suggest that CXCR4 and CCR5 interact with RAMP2 and RAMP3 in 
vitro. While BRET studies for CXCR7 were inconclusive, confocal microscopy investigating 
plasma membrane localization of RAMP3 demonstrated that all three chemokine receptors 
are capable of translocating RAMP3 to the cell surface. Finally, a quantitative FAP assay 
showed that CCR5 facilitates cell surface expression of RAMP3 at an equivalent level to the 
well-established RAMP-interacting GPCR, CLR. Plasma membrane expression of RAMP3 in 
CCR5-expressing cells was significantly increased above all negative controls.  
 Collectively, these data identify a novel group of Family A Rhodopsin-like GPCRs 
that interact with RAMPs. While the functional consequences of these interactions have not 
been characterized, the potential for modulating receptor pharmacology during inflammation 
or to alter viral receptivity could prove interesting. Future studies will characterize CKR-
RAMP interactions and aim to delineate their biological roles. 
Future Studies 
 As the current state of the RAMP field is comprehensively addressed in Chapter 4, 
this section will focus on the current and future studies associated with the data presented in 
Part II, where we identify the novel interaction between CKR and RAMPs.  
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Our first aim will focus on completing the trifecta of experiments for CXCR7, CXCR4, 
and CCR5 and all three RAMPs: BRET studies, confocal imaging, and FAP assays.  We are 
confident that CCR5 forms a true protein-protein interaction with RAMP3, as we noted 
positive results for all three experiments. While CXCR4 and CXCR7 exhibited promising 
interactions with RAMPs, we must confirm these data with further assays. Thus, we have 
generated stable cell lines expressing 3xHA-RAMP1, -2, or -3. Additionally, we have 
acquired Flag epitope tagged CKR constructs. If these CKRs truly associate with RAMPs, 
live cell staining of HEK293T cells co-expressing a 3xHA-RAMP and a Flag epitope tagged 
CKRs will allow for visualization of CKR and RAMP co-localization at the plasma membrane. 
 Furthermore, though the live cell imaging of RAMP3-YFP was encouraging, the high 
intercellular fluorescence due to RAMP3-YFP presence in the golgi apparatus made 
discerning the plasma membrane challenging. With HA-tagged constructs, we can perform 
live cell staining on permeabilized and non-permeablized cells. This experiment will allow for 
robust visualization of RAMP expression at the plasma membrane in non-permeabilized 
cells without the interference of intracellular fluorescence. HA-staining in permeabilized cells 
will ensure RAMP-HA expression. We have also generated FAP-tagged RAMP1 and -2 and 
plan to perform FAP assays with all three CKRs. This assay is both quantitative and 
exquisitely sensitive, and together with live cell imaging will provide convincing evidence as 
to which CKRs are capable of RAMP translocation to the cell surface.  
Additionally, the ease of the FAP assay facilitates a much larger experiment. We 
have acquired a library of nearly 350 known druggable GPCRs (also known as the 
druggable “GPCR-ome”) with which we will perform a semi-high throughput screen for 
GPCR interactions with RAMPs [1]. We will test this system first with a pilot study, utilizing 
19 CKRs. Here, we will transfect cells stably expressing FAP-RAMP1, -2, and -3 with CKRs, 
treat with membrane impermeant fluorogen and image the cells to determine which CKRs 
traffic RAMPs to the plasma membrane. 
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If this screen proves reliable and yields interesting results, we can perform this assay 
on the entire druggable GPCR-ome. Remarkably, four percent of the GPCRs in the GPCR-
ome library are not efficiently surface expressed [1]. It will be interesting to determine 
whether co-transfection with a RAMP family member allows for cell surface expression of 
these GPCRs. As all of the receptors are Flag epitope tagged, we can monitor cell-surface 
expression of both the FAP-RAMP and the Flag-GPCR.  
Concluding Remarks  
Collectively, the studies presented in Part II support the interaction of CKRs with the 
RAMP family and contribute additional Family A GPCRs to the growing number of receptors 
that interact with RAMPs. Over the past decade and a half, there has been great interest in 
understanding how RAMPs affect GPCR pharmacology, but determining which receptors 
interact with RAMPs has been a slow process. As discussed in Chapter 4, RAMPs have 
historically been thought to only interact with Family B G protein-coupled secretin receptors. 
However, since their discovery, RAMPs have also been shown to modulate at least one 
member of both family A and family C GPCRs [2,3]. Our preliminary data suggest a much 
wider group of GPCRs interact with RAMPs. The proposed semi-high throughput screen will 
allow us to characterize the breadth of RAMP interactions, facilitating a shift in the focus of 
RAMP research to the design of functional assays to determine whether a given GPCR-
RAMP association affects pharmacology or biological activity. A thorough understanding of 
RAMP effects on biology has the potential to have significant clinical impact, as targeting of 
the RAMP-GPCR interface could yield highly specific, high affinity drugs.  
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